<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy - Riley, P - 2017 | Cochrane Library</title> <meta content="Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy - Riley, P - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012744/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy - Riley, P - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012744/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012744" name="dc.identifier" scheme="DOI"/> <meta content="Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy" name="citation_title"/> <meta content="Philip Riley" name="citation_author"/> <meta content="Division of Dentistry, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester" name="citation_author_institution"/> <meta content="philip.riley@manchester.ac.uk" name="citation_author_email"/> <meta content="Anne‐Marie Glenny" name="citation_author"/> <meta content="The University of Manchester" name="citation_author_institution"/> <meta content="Fang Hua" name="citation_author"/> <meta content="Division of Dentistry, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester" name="citation_author_institution"/> <meta content="Helen V Worthington" name="citation_author"/> <meta content="Division of Dentistry, School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD012744" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/07/31" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012744/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012744/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012744/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amifostine [therapeutic use]; Drugs, Chinese Herbal [therapeutic use]; Fibroblast Growth Factor 7 [therapeutic use]; Pilocarpine [therapeutic use]; Quality of Life; Radiation‐Protective Agents [adverse effects, therapeutic use]; Radiotherapy [*adverse effects]; Randomized Controlled Trials as Topic; Saliva, Artificial; Salivary Gland Diseases [etiology, *prevention &amp; control]; Salivary Glands [radiation effects]; Salivation [drug effects, radiation effects]; Xerostomia [etiology, *prevention &amp; control]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012744&amp;doi=10.1002/14651858.CD012744&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="FKeXZrqu";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012744\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012744\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012744\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012744\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","hr","fr","zh_HANS","fa","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012744",title:"Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy",firstPublishedDate:"Jul 31, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Oral Health Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=FKeXZrqu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012744&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012744';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012744/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012744/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012744%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012744/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012744/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012744/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012744/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012744" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012744/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012744" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012744/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012744/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6007 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012744" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012744/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012744/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-sec-0216"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-sec-0044"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-sec-0045"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-sec-0076"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-sec-0207"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012744/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012744/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012744/appendices#CD012744-sec-0221"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012744/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012744/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/table_n/CD012744StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/table_n/CD012744StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012744/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012744/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012744/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012744/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012744/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012744/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2017 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012744/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012744/information#CD012744-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Philip Riley</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012744/information#CD012744-cr-0003">Anne‐Marie Glenny</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012744/information#CD012744-cr-0004">Fang Hua</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012744/information#CD012744-cr-0005">Helen V Worthington</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012744/information/en#CD012744-sec-0233">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 31 July 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012744/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012744">https://doi.org/10.1002/14651858.CD012744</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012744-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012744-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012744-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012744-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012744-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012744-abs-0009">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012744-abs-0001" lang="en"> <section id="CD012744-sec-0001"> <h3 class="title" id="CD012744-sec-0001">Background</h3> <p>Salivary gland dysfunction is an 'umbrella' term for the presence of either xerostomia (subjective sensation of dryness), or salivary gland hypofunction (reduction in saliva production). It is a predictable side effect of radiotherapy to the head and neck region, and is associated with a significant impairment of quality of life. A wide range of pharmacological interventions, with varying mechanisms of action, have been used for the prevention of radiation‐induced salivary gland dysfunction. </p> </section> <section id="CD012744-sec-0002"> <h3 class="title" id="CD012744-sec-0002">Objectives</h3> <p>To assess the effects of pharmacological interventions for the prevention of radiation‐induced salivary gland dysfunction. </p> </section> <section id="CD012744-sec-0003"> <h3 class="title" id="CD012744-sec-0003">Search methods</h3> <p>Cochrane Oral Health's Information Specialist searched the following databases: Cochrane Oral Health's Trials Register (to 14 September 2016); the Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 8) in the Cochrane Library (searched 14 September 2016); MEDLINE Ovid (1946 to 14 September 2016); Embase Ovid (1980 to 14 September 2016); CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature; 1937 to 14 September 2016); LILACS BIREME Virtual Health Library (Latin American and Caribbean Health Science Information database; 1982 to 14 September 2016); Zetoc Conference Proceedings (1993 to 14 September 2016); and OpenGrey (1997 to 14 September 2016). We searched the US National Institutes of Health Ongoing Trials Register (<a href="http://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a>) and the <a href="http://apps.who.int/trialsearch/" target="_blank">World Health Organization International Clinical Trials Registry Platform</a> for ongoing trials. No restrictions were placed on the language or date of publication when searching the electronic databases. </p> </section> <section id="CD012744-sec-0004"> <h3 class="title" id="CD012744-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials, irrespective of their language of publication or publication status. Trials included participants of all ages, ethnic origin and gender, scheduled to receive radiotherapy on its own or in addition to chemotherapy to the head and neck region. Participants could be outpatients or inpatients. We included trials comparing any pharmacological agent regimen, prescribed prophylactically for salivary gland dysfunction prior to or during radiotherapy, with placebo, no intervention or an alternative pharmacological intervention. Comparisons of radiation techniques were excluded. </p> </section> <section id="CD012744-sec-0005"> <h3 class="title" id="CD012744-sec-0005">Data collection and analysis</h3> <p>We used standard methodological procedures expected by Cochrane.</p> </section> <section id="CD012744-sec-0006"> <h3 class="title" id="CD012744-sec-0006">Main results</h3> <p>We included 39 studies that randomised 3520 participants; the number of participants analysed varied by outcome and time point. The studies were ordered into 14 separate comparisons with meta‐analysis only being possible in three of those. </p> <p>We found low‐quality evidence to show that amifostine, when compared to a placebo or no treatment control, might reduce the risk of moderate to severe xerostomia (grade 2 or higher on a 0 to 4 scale) at the end of radiotherapy (risk ratio (RR) 0.35, 95% confidence interval (CI) 0.19 to 0.67; P = 0.001, 3 studies, 119 participants), and up to three months after radiotherapy (RR 0.66, 95% CI 0.48 to 0.92; P = 0.01, 5 studies, 687 participants), but there is insufficient evidence that the effect is sustained up to 12 months after radiotherapy (RR 0.70, 95% CI 0.40 to 1.23; P = 0.21, 7 studies, 682 participants). We found very low‐quality evidence that amifostine increased unstimulated salivary flow rate up to 12 months after radiotherapy, both in terms of mg of saliva per 5 minutes (mean difference (MD) 0.32, 95% CI 0.09 to 0.55; P = 0.006, 1 study, 27 participants), and incidence of producing greater than 0.1 g of saliva over 5 minutes (RR 1.45, 95% CI 1.13 to 1.86; P = 0.004, 1 study, 175 participants). However, there was insufficient evidence to show a difference when looking at stimulated salivary flow rates. There was insufficient (very low‐quality) evidence to show that amifostine compromised the effects of cancer treatment when looking at survival measures. There was some very low‐quality evidence of a small benefit for amifostine in terms of quality of life (10‐point scale) at 12 months after radiotherapy (MD 0.70, 95% CI 0.20 to 1.20; P = 0.006, 1 study, 180 participants), but insufficient evidence at the end of and up to three months postradiotherapy. A further study showed no evidence of a difference at 6, 12, 18 and 24 months postradiotherapy. There was low‐quality evidence that amifostine is associated with increases in: vomiting (RR 4.90, 95% CI 2.87 to 8.38; P &lt; 0.00001, 5 studies, 601 participants); hypotension (RR 9.20, 95% CI 2.84 to 29.83; P = 0.0002, 3 studies, 376 participants); nausea (RR 2.60, 95% CI 1.81 to 3.74; P &lt; 0.00001, 4 studies, 556 participants); and allergic response (RR 7.51, 95% CI 1.40 to 40.39; P = 0.02, 3 studies, 524 participants). </p> <p>We found insufficient evidence (that was of very low quality) to determine whether or not pilocarpine performed better or worse than a placebo or no treatment control for the outcomes: xerostomia, salivary flow rate, survival, and quality of life. There was some low‐quality evidence that pilocarpine was associated with an increase in sweating (RR 2.98, 95% CI 1.43 to 6.22; P = 0.004, 5 studies, 389 participants). </p> <p>We found insufficient evidence to determine whether or not palifermin performed better or worse than placebo for: xerostomia (low quality); survival (moderate quality); and any adverse effects. </p> <p>There was also insufficient evidence to determine the effects of the following interventions: biperiden plus pilocarpine, Chinese medicines, bethanechol, artificial saliva, selenium, antiseptic mouthrinse, antimicrobial lozenge, polaprezinc, azulene rinse, and Venalot Depot (coumarin plus troxerutin). </p> </section> <section id="CD012744-sec-0007"> <h3 class="title" id="CD012744-sec-0007">Authors' conclusions</h3> <p>There is some low‐quality evidence to suggest that amifostine prevents the feeling of dry mouth in people receiving radiotherapy to the head and neck (with or without chemotherapy) in the short‐ (end of radiotherapy) to medium‐term (three months postradiotherapy). However, it is less clear whether or not this effect is sustained to 12 months postradiotherapy. The benefits of amifostine should be weighed against its high cost and side effects. There was insufficient evidence to show that any other intervention is beneficial. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012744-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012744-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012744-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012744-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012744-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012744-abs-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012744-abs-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012744-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012744-abs-0010">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012744-abs-0004" lang="en"> <h3>Drugs for preventing dry mouth and problems with saliva after radiotherapy</h3> <p><b>Review question</b> </p> <p>To assess the effects of treatment with drugs in order to prevent damage to salivary glands following radiotherapy to the head and neck </p> <p><b>Background</b> </p> <p>Problems with saliva production and salivary glands are a significant and mostly permanent side effect for people after radiotherapy treatment to the head and neck. When this occurs the condition is known as dry mouth or xerostomia. Dry mouth is not measurable and is a subjective or personal expression of how the mouth feels. It can have other causes and is a consequence of the production of less saliva or by the consistency of saliva. The rate of flow of saliva in an individual's mouth however can be measured. People who have dry mouth have a reduced quality of life. They can experience issues with taste and general discomfort, difficulties chewing, swallowing and speaking as well as tooth decay, thrush and other infections of the mouth. A wide range of drugs that work in different ways have been used to try and prevent problems with salivary glands caused by radiotherapy. Unfortunately there is currently not enough evidence to show which drugs or which type of drugs are most effective. </p> <p><b>Study characteristics</b> </p> <p>The evidence in this review is current up to 14 September 2016. 39 studies were included with a total of 3520 participants. Participants were male and female, all ages and ethnic origins, out patients or in patients, who were scheduled to have radiation therapy with or without chemotherapy to the head and neck. </p> <p>Drugs included were any prescribed to prevent salivary gland problems and given before or during radiotherapy. Information was collected from the end of radiotherapy except for that about adverse effects. Different techniques for giving radiation treatment that might reduce damage were not included. </p> <p>The main outcomes measured were participant's own assessment of dry mouth and the measurement of salivary flow. Secondary outcomes measured included adverse or unwanted effects such as sweating, crying, watery discharge from the nose, diarrhoea and nausea. </p> <p><b>Key results</b> </p> <p>There is some low‐quality evidence to suggest that the drug amifostine prevents the feeling of dry mouth in people receiving radiotherapy to the head and neck (with or without chemotherapy) in the short‐ (end of radiotherapy) to medium‐term (three months after radiotherapy). However it is less clear whether or not this effect is sustained to 12 months after radiotherapy. The benefits of amifostine should be weighed against its high costs and side effects. Adverse effects of vomiting, low blood pressure, feeling of sickness and allergic response were all more frequent in those receiving amifostine. There was insufficient evidence to show that any other treatment is beneficial. </p> <p><b>Quality of the evidence</b> </p> <p>The quality of evidence for amifostine was found to be low because of risk of bias, inconsistency and imprecision caused by the small number of studies in the comparison or sample size. A standardized scale for measuring participant's experience of dry mouth would in future allow comparison and pooling together of results. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012744-sec-0216" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012744-sec-0216"></div> <h3 class="title" id="CD012744-sec-0217">Implications for practice</h3> <section id="CD012744-sec-0217"> <p>There is some low‐quality evidence to suggest that amifostine prevents the feeling of dry mouth in people receiving radiotherapy to the head and neck (with or without chemotherapy) in the short‐ (end of radiotherapy) to medium‐term (three months postradiotherapy). However, it is less clear whether or not this effect is sustained to 12 months postradiotherapy. The benefits of amifostine should be weighed against its high cost and side effects. There was insufficient evidence to show that any other intervention is beneficial. </p> </section> <h3 class="title" id="CD012744-sec-0218">Implications for research</h3> <section id="CD012744-sec-0218"> <p>Further well conducted, well reported and adequately powered randomised controlled trials are needed to add to the evidence base for the interventions assessed in the single‐study comparisons of this systematic review. Amifostine should be assessed with longer term follow‐up to establish whether the promising shorter term effects are sustained. Palifermin should also be studied further and with longer follow‐up. </p> <p>Trialists should endeavour to use similar scales to measure xerostomia i.e. one that can be dichotomised to report the incidence of moderate to severe or severe xerostomia or both. Buglione et al recommend several established standardised scales such as NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events), RTOG (Radiation Therapy Oncology Group), and LENT‐SOMA (Late Effects Normal Tissue Task Force ‐ Subjective, Objective, Management, Analytic scale) (<a href="./references#CD012744-bbs2-0092" title="BuglioneM , CavagniniR , DiRosarioF , MaddaloM , VassalliL , GrisantiS , et al. Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. Critical Reviews in Oncology/Hematology2016;102:47‐54. ">Buglione 2016</a>). This should be reported alongside a more objective measure such as salivary flow rate. Adverse effects should also be clearly reported and quality of life would be a useful patient‐important outcome. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012744-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012744-sec-0036"></div> <div class="table" id="CD012744-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Pilocarpine compared to no treatment/placebo for preventing salivary gland dysfunction following radiotherapy</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b> Pilocarpine compared to no treatment/placebo for preventing salivary gland dysfunction following radiotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region<br/> <b>Intervention:</b> pilocarpine<br/> <b>Comparison:</b> no treatment/placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment/placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with pilocarpine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xerostomia ‐ Up to and including 6 months postRT</p> <p>Studies used different ways of measuring the outcome and therefore we combined the studies using SMD </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.35 lower<br/> (1.04 lower to 0.33 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence of a difference at this time point and also at the end of RT and 3 months postRT </p> <p>1 of the 2 studies in this assessment showed inconsistent results when using an alternative way of measuring this outcome at the 6‐month time point. 2 further studies showed insufficient evidence of a difference, 1 at the end of RT and the other at 3 months postRT </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salivary flow rate (unstimulated) ‐ Up to and including 3 months postRT</p> <p>Studies used different ways of measuring the outcome and therefore we combined the studies using SMD </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.06 lower (0.23 lower to 0.11 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence of a difference at this time point and also at the end of RT</p> <p>Same results for stimulated salivary flow rates at end of RT, and 3, 6 and 12 months postRT </p> <p>Same results for a further study at the end of RT and 3 months postRT looking at whether or not stimulated and unstimulated salivary flow was &gt; 0 g </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival ‐ Up to and including 6 months postRT</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>724 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>775 per 1000<br/> (579 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07<br/> (0.80 to 1.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence of a difference</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ Up to and including 6 months postRT</p> <p>McMaster University Head and Neck Questionnaire (HNRQ). Score 1‐7, lower score = poorer quality of life </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Control group mean was 5.3</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.20 higher<br/> (0.19 lower to 0.59 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence of a difference at this time point and also at the end of RT and 3 months postRT </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Insufficient evidence of a difference between groups for any reported adverse event, apart from for sweating where data from 5 studies showed an increased risk associated with pilocarpine (RR 2.98, 95% CI 1.43 to 6.22; P = 0.004; I<sup>2</sup> = 0%; 389 participants; ⊕⊕⊝⊝ LOW<sup>4</sup>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)<br/> <br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference; <b>RT:</b> radiotherapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 level for risk of bias, 1 level for imprecision (small sample size and 95% CIs include both possibility of benefit and harm), and 1 level for inconsistency (I<sup>2</sup> = 68%).<br/> <sup>2</sup>Downgraded by 1 level for risk of bias, and 2 levels for imprecision (single study with 12 participants per group and 95% CIs include both possibility of benefit and harm).<br/> <sup>3</sup>Downgraded by 1 level for risk of bias, and 2 levels for imprecision (single study and 95% CIs include both possibility of benefit and harm).<br/> <sup>4</sup>Downgraded by 1 level for risk of bias, and 1 level for imprecision (very wide 95% CIs). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012744-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Amifostine compared to no treatment/placebo for preventing salivary gland dysfunction following radiotherapy</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b> Amifostine compared to no treatment/placebo for preventing salivary gland dysfunction following radiotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region<br/> <b>Intervention:</b> amifostine<br/> <b>Comparison:</b> no treatment/placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment/placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with amifostine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xerostomia (0‐4 scale ‐ grade 2 or above) ‐ 12 months postRT</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>418 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>292 per 1000<br/> (167 to 514) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70<br/> (0.40 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>682<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence of a difference at this time point. However, both at the end of RT (RR 0.35, 95% CI 0.19 to 0.67; 3 studies, 119 participants) and up to 3 months postRT (RR 0.66, 95% CI 0.48 to 0.92; 5 studies, 687 participants), amifostine reduced the risk of developing grade ≥ 2 xerostomia </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salivary flow rate (mg/5 min) (unstimulated) ‐ 12 months postRT</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Control group mean was 0.16</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.32 higher<br/> (0.09 higher to 0.55 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amifostine led to increased unstimulated saliva flow both at 12 months postRT and at the end of RT, but there was insufficient evidence of a difference at 3 months postRT. This evidence was supported by a further study showing a benefit for amifostine at 12 months postRT when looking at incidence of producing &gt; 0.1 g of saliva over 5 minutes (RR 1.45, 95% CI 1.13 to 1.86; 175 participants). A further study narratively reported no difference </p> <p>Insufficient evidence of a difference in stimulated saliva flow at any time point</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival at 12 to 24 months postRT</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450 per 1000**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>531 per 1000<br/> (383 to 747) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.18<br/> (0.85 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to determine whether or not amifostine reduces overall survival, progression‐free survival, disease‐free survival or locoregional tumour control up to 24 months postRT </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (Patient Benefit Questionnaire) ‐ 12 months postRT</p> <p>8 items each on a 10‐point scale where higher = better QoL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Control group mean was 6.66</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.7 higher<br/> (0.2 higher to 1.2 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amifostine led to a small improvement in quality of life at 12 months postRT, but there was insufficient evidence of a difference at the end of RT and 3 months postRT </p> <p>A further study narratively reported no difference at end of RT and 6, 12, 18, and 24 months postRT </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p> <ul id="CD012744-list-0001"> <li> <p>Data from 5 studies showed an increased risk of vomiting associated with amifostine (RR 4.90, 95% CI 2.87 to 8.38; 601 participants; ⊕⊕⊝⊝ LOW<sup>4</sup>) </p> </li> <li> <p>Data from 3 studies showed an increased risk of hypotension associated with amifostine (RR 9.20, 95% CI 2.84 to 29.83; 376 participants; ⊕⊕⊝⊝ LOW<sup>4</sup>) </p> </li> <li> <p>Data from 4 studies showed an increased risk of nausea associated with amifostine (RR 2.60, 95% CI 1.81 to 3.74; 556 participants; ⊕⊕⊝⊝ LOW<sup>4</sup>) </p> </li> <li> <p>Data from 3 studies showed an increased risk of allergic response associated with amifostine (RR 7.51, 95% CI 1.40 to 40.39; 524 participants; ⊕⊕⊝⊝ LOW<sup>4</sup>) </p> </li> </ul> </p> <p>There was insufficient evidence of a difference between groups for any other adverse events </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)<br/> **2014 5‐year overall survival rate of patients with head and neck squamous cell carcinoma (<a href="http://www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf" target="_blank">www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf</a>)<br/> <br/> <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>MD:</b> mean difference; <b>QoL:</b> quality of life; <b>RR:</b> risk ratio; <b>RT:</b> radiotherapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 level for risk of bias, and 1 level for inconsistency (I<sup>2</sup> = 83%).<br/> <sup>2</sup>Downgraded by 1 level for risk of bias, and 2 levels for imprecision (single study and small sample size).<br/> <sup>3</sup>Downgraded by 1 level for risk of bias, and 2 levels for imprecision (small sample size and 95% CIs include both possibility of benefit and harm).<br/> <sup>4</sup>Downgraded by 1 level for risk of bias, and 1 level for imprecision (very wide 95% CIs). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012744-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Palifermin compared to placebo for preventing salivary gland dysfunction following radiotherapy</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b> Palifermin compared to placebo for preventing salivary gland dysfunction following radiotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region<br/> <b>Intervention:</b> palifermin<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with palifermin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xerostomia (0‐4 scale ‐ grade 2 or above) ‐ Up to and including 3 months postRT</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>727 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>705 per 1000<br/> (560 to 887) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/> (0.77 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>471<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence of a difference at this time point</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival at 42 to 72 months from baseline</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450 per 1000**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>450 per 1000<br/> (324 to 626) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.00<br/> (0.72 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to determine whether or not amifostine reduces overall survival and progression‐free survival up to 72 months </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>There was insufficient evidence of patients in either group experiencing more or less adverse events </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI) </p> <p>**2014 5‐year overall survival rate of patients with head and neck squamous cell carcinoma (<a href="http://www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf" target="_blank">www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf</a>)<br/> <br/> <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RR:</b> risk ratio; <b>RT:</b> radiotherapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 level for imprecision (95% CIs include both possibility of benefit and harm), and 1 level for inconsistency (I<sup>2</sup> = 76%).<br/> <sup>2</sup>Downgraded by 1 level for imprecision (95% CIs include both possibility of benefit and harm). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012744-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012744-sec-0037"></div> <section id="CD012744-sec-0038"> <h3 class="title" id="CD012744-sec-0038">Description of the condition</h3> <p>Xerostomia (dry mouth) has been defined as the "subjective sensation of dryness" (<a href="./references#CD012744-bbs2-0110" title="SreebnyLM . Xerostomia: diagnosis, management and clinical complications. In: EdgarWM , O'MullaneDM editor(s). Saliva and Oral Health. 2nd Edition. London: British Dental Association, 1996:43‐66. ">Sreebny 1996</a>), whilst salivary gland hypofunction has been defined as "any objectively demonstrable reduction in either whole and/or individual salivary gland flow rates" (<a href="./references#CD012744-bbs2-0104" title="NavazeshM , ChristensenC , BrightmanV . Clinical criteria for the diagnosis of salivary gland hypofunction. Journal of Dental Research1992;71(7):1363‐9. ">Navazesh 1992</a>). Xerostomia is usually the result of a decrease in the volume of saliva secreted. Indeed, healthy individuals complain of a dry mouth when their unstimulated whole salivary flow rate falls below 50% of their normal level (<a href="./references#CD012744-bbs2-0095" title="DawesC . Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. Journal of Dental Research1987;66 Spec No:648‐53. ">Dawes 1987</a>). However, xerostomia may also occur without a reduction in salivary flow (<a href="./references#CD012744-bbs2-0106" title="PorterSR , ScullyC , HegartyAM . An update of the etiology and management of xerostomia. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;97(1):28‐46. ">Porter 2004</a>), possibly resulting from a change in composition of saliva secreted (<a href="./references#CD012744-bbs2-0105" title="PankhurstCL , SmithEC , RogersJO , DunneSM , JacksonSH , ProctorG . Diagnosis and management of the dry mouth: Part 1. Dental Update1996;23(2):56‐62. ">Pankhurst 1996</a>). Thus, xerostomia may, or may not be associated with salivary gland hypofunction. Salivary gland dysfunction is an 'umbrella' term for the presence of either xerostomia, or salivary gland hypofunction. </p> <p>Salivary gland dysfunction is an extremely common side effect of radiotherapy to the head and neck region (<a href="./references#CD012744-bbs2-0099" title="GuchelaarHJ , VermesA , MeerwaldtJH . Radiation‐induced xerostomia: pathophysiology, clinical course and supportive treatment. Supportive Care in Cancer1997;5(4):281‐8. ">Guchelaar 1997</a>). The total dose for a course of radiotherapy for head and neck cancer is 50 Gy (gray) to 70 Gy (<a href="./references#CD012744-bbs2-0109" title="ShiboskiCH , HodgsonTA , ShipJA , SchiodtM . Management of salivary hypofunction during and after radiotherapy. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2007;103 Suppl(S66):e1‐19. ">Shiboski 2007</a>). However, doses over 52 Gy will cause severe salivary gland dysfunction (<a href="./references#CD012744-bbs2-0106" title="PorterSR , ScullyC , HegartyAM . An update of the etiology and management of xerostomia. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;97(1):28‐46. ">Porter 2004</a>). A major decrease in saliva flow develops within one week of starting radiotherapy, and continues to deteriorate throughout treatment, culminating in permanent salivary gland dysfunction (<a href="./references#CD012744-bbs2-0109" title="ShiboskiCH , HodgsonTA , ShipJA , SchiodtM . Management of salivary hypofunction during and after radiotherapy. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2007;103 Suppl(S66):e1‐19. ">Shiboski 2007</a>). Indeed, even a dose of 20 Gy is enough to permanently damage salivary flow if it is given as a single dose (<a href="./references#CD012744-bbs2-0106" title="PorterSR , ScullyC , HegartyAM . An update of the etiology and management of xerostomia. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;97(1):28‐46. ">Porter 2004</a>). Salivary gland hypofunction is associated with a variety of oral problems in this group of people (e.g. oral discomfort, taste disturbance, difficulty chewing, difficulty swallowing, speech problems, dental caries, oral candidiasis, and other oral infections). Certainly salivary gland dysfunction is associated with a significant impairment of quality of life in this group of patients. </p> </section> <section id="CD012744-sec-0039"> <h3 class="title" id="CD012744-sec-0039">Description of the intervention</h3> <p>The literature discusses a wide range of pharmacological interventions for preventing radiation‐induced salivary gland dysfunction. Examples of these include. </p> <section id="CD012744-sec-0040"> <h4 class="title">Parasympathomimetic drugs (choline esters, cholinesterase inhibitors)</h4> <p>Parasympathomimetic drugs stimulate salivary secretion by stimulating the parasympathetic nervous system. The parasympathetic nervous system increases bodily secretions such as tears, gastric juices, mucus and saliva to defend the body and help digestion. The most widely used parasympathomimetic drug in this clinical situation is pilocarpine hydrochloride (a choline ester) and has been licensed in many countries for the treatment of radiation‐induced salivary gland dysfunction (<a href="./references#CD012744-bbs2-0112" title="WisemanLR , FauldsD . Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs1995;49(1):143‐55. ">Wiseman 1995</a>). Other indirectly acting parasympathomimetics, for example bethanecol, are much more widely used in other contexts, but have also been used 'off‐licence' to treat this condition (<a href="./references#CD012744-bbs2-0097" title="EpsteinJB , BurchellJL , EmertonS , LeND , SilvermanSJr . A clinical trial of bethanechol in patients with xerostomia after radiation therapy. A pilot study. Oral Surgery, Oral Medicine, and Oral Pathology1994;77(6):610‐4. ">Epstein 1994</a>). </p> </section> <section id="CD012744-sec-0041"> <h4 class="title">Parasympatholytic drugs</h4> <p>Parasympatholytic drugs have the opposite effect to parasympathomimetic drugs, their action is anticholinergic, i.e. they inhibit the secretion of saliva. Results from animal tests (<a href="./references#CD012744-bbs2-0088" title="AhlnerBH , HagelqvistE , LindMG . Influence on rabbit submandibular gland injury by stimulation or inhibition of gland function during irradiation. Histology and morphometry after 15 gray. Annals of Otology, Rhinology, and Laryngology1994;103(2):125‐34. ">Ahlner 1994</a>) and a study by Rode et al (<a href="./references#CD012744-bbs2-0032" title="RodeM , SmidL , BudihnaM , SobaE , RodeM , GaspersicD . The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics1999;45(2):373‐8. ">Rode 1999</a>; <a href="./references#CD012744-bbs2-0108" title="RodeM , SmidL , BudihnaM , GassperssicD , RodeM , SobaE . The influence of pilocarpine and biperiden on pH value and calcium, phosphate, and bicarbonate concentrations in saliva during and after radiotherapy for head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2001;92(5):509‐14. ">Rode 2001</a>) suggest that the inhibition of salivary secretion during radiotherapy might actually protect later damage of the salivary glands and improve salivation following the treatment. </p> </section> <section id="CD012744-sec-0042"> <h4 class="title">Cytoprotective agents</h4> <p>Cytoprotective agents can be administered before, with, or after cancer therapy to reduce or prevent damage or toxicity to the normal cells and tissues without compromising therapeutic efficacy. Amifostine is a cytoprotective agent and has been shown to accumulate in the salivary glands (<a href="./references#CD012744-bbs2-0081" title="TakahashiI , NagaiT , MiyaishiK , MaeharaY , NiibeH . Clinical study of the radioprotective effects of amifostine (YM‐08310, WR‐2721) on chronic radiation injury. International Journal of Radiation Oncology, Biology, Physics1986;12(6):935‐8. ">Takahashi 1986</a>); there are reports that this might lead to a reduction in parotid parenchymal damage due to radiotherapy (<a href="./references#CD012744-bbs2-0044" title="BohuslavizkiKH , KlutmannS , BleckmannC , BrennerW , LassmannS , MesterJ , et al. Salivary gland protection by amifostine in high‐dose radioiodine therapy of differentiated thyroid cancer. Strahlentherapie und Onkologie1999;175(2):57‐61. BohuslavizkiKH , KlutmannS , BrennerW , KrögerS , BuchertR , BleckmannC , et al. Radioprotection of salivary glands by amifostine in high‐dose radioiodine treatment. Results of a double‐blinded, placebo‐controlled study in patients with differentiated thyroid cancer. Strahlentherapie und Onkologie1999;175(Suppl 4):6‐12. BohuslavizkiKH , KlutmannS , BrennerW , MesterJ , HenzeE , ClausenM . Salivary gland protection by amifostine in high‐dose radioiodine treatment: results of a double‐blind placebo‐controlled study. Journal of Clinical Oncology1998;16(11):3542‐9. BohuslavizkiKH , KlutmannS , JenickeL , KrögerS , BuchertR , MesterJ , et al. Salivary gland protection by S‐2‐(3‐amino‐propylamino)‐ethylphosphorothioic acid (amifostine) in high‐dose radioiodine treatment: results obtained in a rabbit animal model and in a double‐blind multi‐arm trial. Cancer Biotherapy &amp; Radiopharmaceuticals1999;14(5):337‐47. ">Bohuslavizki 1998</a>), and reduce the incidence of radiation‐induced xerostomia (<a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>). </p> </section> </section> <section id="CD012744-sec-0043"> <h3 class="title" id="CD012744-sec-0043">Why it is important to do this review</h3> <p>Salivary gland dysfunction is a significant and mostly permanent side effect of radiotherapy to the head and neck region that has numerous knock‐on effects, negatively affecting quality of life. Unfortunately, the evidence for prevention using pharmacological agents is weak and some guideline statements do not currently recommend any (<a href="./references#CD012744-bbs2-0092" title="BuglioneM , CavagniniR , DiRosarioF , MaddaloM , VassalliL , GrisantiS , et al. Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. Critical Reviews in Oncology/Hematology2016;102:47‐54. ">Buglione 2016</a>). Although there is a recently published Cochrane Review looking at parasympathomimetic drugs for treating radiation‐induced salivary gland dysfunction (<a href="./references#CD012744-bbs2-0094" title="DaviesAN , ThompsonJ . Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy. Cochrane Database of Systematic Reviews2015, Issue 10. [DOI: 10.1002/14651858.CD003782.pub3] ">Davies 2015</a>), other drugs with different modes of action have the potential to be effective in this situation, and a broader review of prophylactic measures was needed. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012744-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012744-sec-0044"></div> <p>To assess the effects of pharmacological interventions for the prevention of radiation‐induced salivary gland dysfunction. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012744-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012744-sec-0045"></div> <section id="CD012744-sec-0046"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012744-sec-0047"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials of parallel design. Trials were included irrespective of language of publication or publication status. </p> </section> <section id="CD012744-sec-0048"> <h4 class="title">Types of participants</h4> <p>We included participants of all ages, ethnic origin and gender scheduled to receive radiotherapy on its own or in addition to chemotherapy to the head and neck region. Participants could be outpatients or inpatients. </p> </section> <section id="CD012744-sec-0049"> <h4 class="title">Types of interventions</h4> <section id="CD012744-sec-0050"> <h5 class="title">Active agents</h5> <p>Any pharmacological agent prescribed prophylactically for salivary gland dysfunction prior to or during radiotherapy, by any route, any dose, and for any length of time. Radiation techniques were excluded. </p> </section> <section id="CD012744-sec-0051"> <h5 class="title">Control groups</h5> <p>No preventative intervention, placebo, or another pharmacological preventative measure for salivary gland dysfunction. </p> </section> </section> <section id="CD012744-sec-0052"> <h4 class="title">Types of outcome measures</h4> <p>As radiotherapy‐induced salivary gland dysfunction is considered to be permanent, we were interested in long‐term treatment effects and only collected data starting from the end of radiotherapy, except in the case of adverse effects. </p> <section id="CD012744-sec-0053"> <h5 class="title">Primary outcomes</h5> <p>The primary outcome measure for the review is salivary gland dysfunction as indicated by either: </p> <p> <ul id="CD012744-list-0002"> <li> <p>xerostomia, i.e. the subjective sensation of dryness of the mouth. It was anticipated that different investigators would use different scales to assess xerostomia, e.g. visual analogue scales, verbal rating scales; </p> </li> <li> <p>salivary flow rates (stimulated or unstimulated).</p> </li> </ul> </p> </section> <section id="CD012744-sec-0054"> <h5 class="title">Secondary outcomes</h5> <p>The secondary outcome measures of the review are:</p> <p> <ul id="CD012744-list-0003"> <li> <p>adverse effects, e.g. sweating, lacrimation (excess tears, crying), rhinorrhoea (watery discharge from the nose), diarrhoea, nausea; </p> </li> <li> <p>survival data (overall, disease‐free, progression‐free, locoregional control);</p> </li> <li> <p>other oral signs/symptoms, e.g. oral discomfort/pain, dysgeusia (taste disturbance), dysmasesia (difficulty in chewing), dysphagia (difficulty in swallowing), dysphonia (difficulty in speaking); </p> </li> <li> <p>quality of life, e.g. ability to sleep, work, speak;</p> </li> <li> <p>patient satisfaction;</p> </li> <li> <p>cost data.</p> </li> </ul> </p> </section> </section> </section> <section id="CD012744-sec-0055"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012744-sec-0056"> <h4 class="title">Electronic searches</h4> <p>Cochrane Oral Health's Information Specialist conducted systematic searches in the following databases for randomised controlled trials and controlled clinical trials. There were no publication year or publication status restrictions: </p> <p> <ul id="CD012744-list-0004"> <li> <p>Cochrane Oral Health's Trials Register (searched 14 September 2016) (<a href="./appendices#CD012744-sec-0222">Appendix 1</a>); </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2016, Issue 8) in the Cochrane Library (searched 14 September 2016) (<a href="./appendices#CD012744-sec-0223">Appendix 2</a>); </p> </li> <li> <p>MEDLINE Ovid (1946 to 14 September 2016) (<a href="./appendices#CD012744-sec-0224">Appendix 3</a>); </p> </li> <li> <p>Embase Ovid (1980 to 14 September 2016) (<a href="./appendices#CD012744-sec-0225">Appendix 4</a>); </p> </li> <li> <p>CINAHL EBSCO (Cumulative Index to Nursing and Allied Health Literature; 1937 to 14 September 2016) (<a href="./appendices#CD012744-sec-0226">Appendix 5</a>); </p> </li> <li> <p>LILACS BIREME Virtual Health Library (Latin American and Caribbean Health Science Information database; 1982 to 14 September 2016) (<a href="./appendices#CD012744-sec-0227">Appendix 6</a>); </p> </li> <li> <p>Zetoc Conference Proceedings (1993 to 14 September 2016) (<a href="./appendices#CD012744-sec-0228">Appendix 7</a>); </p> </li> <li> <p>OpenGrey (1997 to 14 September 2016) (<a href="./appendices#CD012744-sec-0229">Appendix 8</a>). </p> </li> </ul> </p> <p>Subject strategies were modelled on the search strategy designed for MEDLINE Ovid. Where appropriate, they were combined with subject strategy adaptations of the highly sensitive search strategy designed by Cochrane for identifying randomised controlled trials and controlled clinical trials as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Chapter 6 (<a href="./references#CD012744-bbs2-0102" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Lefebvre 2011</a>). The Embase subject search was linked to an adapted version of the Cochrane Crowd Project filter for identifying randomised controlled trials in Embase Ovid (see <a href="http://www.cochranelibrary.com/help/central-creation-details.html" target="_blank">www.cochranelibrary.com/help/central‐creation‐details.html</a> for information). </p> <section id="CD012744-sec-0057"> <h5 class="title">Language</h5> <p>The search attempted to identify all relevant studies irrespective of language. Articles in Chinese (<a href="./references#CD012744-bbs2-0016" title="HanF , ZhangJD , ShaoZY , LiuFJ . Effects of concurrent chemoradiotherapy combined with Jinlong capsules for patients with advanced nasopharyngeal squamous carcinoma. Chinese Journal of Cancer Prevention and Treatment2010;(2):138‐9. ">Han 2010</a>; <a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a>; <a href="./references#CD012744-bbs2-0019" title="HuYR , WuCQ , LiuYJ , WangY , LiX , ZhongH , et al. Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumour. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):623‐5. ">Hu 2005</a>; <a href="./references#CD012744-bbs2-0037" title="WangQ , LiuH , QiaoN . Effects of traditional Chinese medicine on salivary glands in the patients with head and neck cancer during radiotherapy. Zhongguo Zhong Xi Yi Jie He Za Zhi1998;18(11):662‐4. ">Wang 1998</a>) were translated and included in the review. An article in Spanish (<a href="./references#CD012744-bbs2-0054" title="Fuertes CaberoS , Setoain PeregoX , Rovirosa CasinoA , Mateos FernándezJJ , Fuster PelfortD , Ferre JorgeJ , et al. Usefulness of pilocarpine in the prevention of xerostomia in patients with head and neck cancer treated with radiotherapy. Assessment with gammagraphy and salivary flow [Utilidad de la pilocarpina como profiláctico de xerostomia en pacientes con cáncer de cabeza y cuello tratados con radioterapia. Valoración mediante gammagrafía y flujo salivar]. Revista Española de Medicina Nuclear2004;23(4):259‐66. ">Fuertes 2004</a>) was translated and subsequently excluded. </p> </section> </section> <section id="CD012744-sec-0058"> <h4 class="title">Searching other resources</h4> <section id="CD012744-sec-0059"> <h5 class="title">Ongoing studies</h5> <p>We searched the following trial registries for ongoing studies:</p> <p> <ul id="CD012744-list-0005"> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov</a>; searched 14 September 2016) (<a href="./appendices#CD012744-sec-0230">Appendix 9</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>; searched 14 September 2016) (<a href="./appendices#CD012744-sec-0231">Appendix 10</a>). </p> </li> </ul> </p> </section> <section id="CD012744-sec-0060"> <h5 class="title">Reference list searching</h5> <p>The reference lists of review articles and standard clinical oncology textbooks were checked for additional studies. The reference lists of included studies were also checked for additional studies. </p> </section> <section id="CD012744-sec-0061"> <h5 class="title">Handsearching</h5> <p>Only handsearching done as part of the Cochrane Worldwide Handsearching Programme and uploaded to CENTRAL was included. </p> </section> <section id="CD012744-sec-0062"> <h5 class="title">Unpublished studies</h5> <p>Requests for information about unpublished studies/studies published in the 'grey literature' were sent to relevant pharmaceutical companies, relevant investigators, editors of radiotherapy journals, and relevant professional organisations. </p> </section> </section> </section> <section id="CD012744-sec-0063"> <h3 class="title" id="CD012744-sec-0063">Data collection and analysis</h3> <section id="CD012744-sec-0064"> <h4 class="title">Selection of studies</h4> <p>The titles and abstracts of all records identified by the search strategy were scanned independently and in duplicate by two review authors. For both studies that appeared to meet the inclusion criteria, and studies that contained insufficient information in the title and abstract to determine eligibility, we obtained the full‐text report and two review authors independently assessed them to establish whether they met the inclusion criteria. Studies excluded at this or subsequent stages were entered in the table of excluded studies with the reasons for exclusion recorded. All disagreements were resolved by discussion. </p> </section> <section id="CD012744-sec-0065"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently and in duplicate extracted data using specially designed data extraction forms. The data extraction forms were piloted on several papers and modified as required before use. The data extracted included. </p> <p> <ul id="CD012744-list-0006"> <li> <p>Citation details: including year of publication, country of origin, setting and source of funding. </p> </li> <li> <p>Details of participants: including demographic characteristics, cancer details (type, stage, location), radiation therapy and criteria for inclusion. </p> </li> <li> <p>Details of intervention: including type, duration and method of administration.</p> </li> <li> <p>Details of outcomes reported: including method of assessment (if measurement scales were used, details of whether the scale was validated were recorded). </p> </li> <li> <p>Sample size calculation and trial registration.</p> </li> </ul> </p> <p>Authors were contacted where possible for clarification and missing information.</p> </section> <section id="CD012744-sec-0066"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors independently assessed the risk of bias of each included study using the Cochrane domain‐based, two‐part tool as described in Chapter 8 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012744-bbs2-0100" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). We contacted study authors for clarification or missing information where necessary and feasible. Disagreements were resolved through discussion, consulting a third review author to achieve consensus when necessary. </p> <p>We completed a 'Risk of bias' table for each included study. For each domain of risk of bias, we described what was reported to have happened in the study. This information provided the rationale for our judgement of whether that domain was at low, high, or unclear risk of bias. </p> <p>We assessed the following domains:</p> <p> <ul id="CD012744-list-0007"> <li> <p>sequence generation (selection bias);</p> </li> <li> <p>allocation concealment (selection bias);</p> </li> <li> <p>blinding of participants and personnel (performance bias);</p> </li> <li> <p>blinding of outcome assessment (detection bias);</p> </li> <li> <p>incomplete outcome data (attrition bias);</p> </li> <li> <p>selective outcome reporting (reporting bias);</p> </li> <li> <p>other bias.</p> </li> </ul> </p> <p>We categorised the overall risk of bias of individual studies as being at low, high, or unclear risk of bias according to the following criteria: </p> <p> <ul id="CD012744-list-0008"> <li> <p>low risk of bias (plausible bias unlikely to seriously alter the results) if all domains were at low risk of bias; </p> </li> <li> <p>high risk of bias (plausible bias that seriously weakens confidence in the results) if one or more domains were at high risk of bias; or </p> </li> <li> <p>unclear risk of bias (plausible bias that raises some doubt about the results) if one or more domains were at unclear risk of bias. </p> </li> </ul> </p> <p>We also presented the 'Risk of bias' summary graphically.</p> </section> <section id="CD012744-sec-0067"> <h4 class="title">Measures of treatment effect</h4> <p>For continuous outcomes (e.g. xerostomia on a visual analogue scale) where studies use the same scale, we used the mean values and standard deviations (SDs) reported in the studies in order to express the estimate of effect as mean difference (MD) with 95% confidence interval (CI). Where different scales were used to measure the same outcome, we expressed the treatment effect as standardised mean difference (SMD) with 95% CI. </p> <p>For dichotomous outcomes, the estimate of effect of an intervention is expressed as risk ratios (RR) together with 95% CIs. </p> </section> <section id="CD012744-sec-0068"> <h4 class="title">Unit of analysis issues</h4> <p>The participant is the unit of analysis.</p> </section> <section id="CD012744-sec-0069"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the author(s) of included studies, where feasible, to identify missing data and details of any other outcomes that may have been measured but not reported. We would have used the methods described in Section 7.7.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> to estimate missing SDs (<a href="./references#CD012744-bbs2-0100" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>) if appropriate. We did not use any other statistical methods or perform any further imputation to account for missing data. </p> </section> <section id="CD012744-sec-0070"> <h4 class="title">Assessment of heterogeneity</h4> <p>Before any pooling of data was conducted, for comparisons with two or more studies, clinical heterogeneity was assessed by examining the types of participants (e.g. cancer types), interventions (e.g. control group used, dose and mode of administration), and outcomes (e.g. stimulated salivary flow rates or quality of life questionnaires). Statistical heterogeneity was also assessed using a Chi<sup>2</sup> test, where a P value &lt; 0.1 indicated statistically significant heterogeneity. We also quantified the heterogeneity using the I<sup>2</sup> statistic. </p> </section> <section id="CD012744-sec-0071"> <h4 class="title">Assessment of reporting biases</h4> <p>Publication bias was to have been assessed for comparisons where at least 10 studies were included in a meta‐analysis. We would have used the recommendations on testing for funnel plot asymmetry (<a href="./references#CD012744-bbs2-0096" title="EggerM , Davey SmithG , SchneiderM , MinderC . Bias in meta‐analysis detected by a simple, graphical test. BMJ1997;315(7109):629‐34. ">Egger 1997</a>), as described in Section 10.4 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012744-bbs2-0100" title="HigginsJP , GreenS , editor(s) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). </p> </section> <section id="CD012744-sec-0072"> <h4 class="title">Data synthesis</h4> <p>Meta‐analyses were only undertaken where there were studies of similar comparisons reporting the same outcomes. We combined MDs for continuous data, and RRs for dichotomous data. Our general approach was to use a random‐effects model. Our preference for the more conservative random‐effects model is because statistical assessments can miss potentially important between‐study heterogeneity in small samples (<a href="./references#CD012744-bbs2-0101" title="KontopantelisE , ReevesD . Performance of statistical methods for meta‐analysis when true study effects are non‐normally distributed: A simulation study. Statistical Methods in Medical Research2012;21(4):409‐26. ">Kontopantelis 2012</a>). </p> <p>We presented data not suitable for meta‐analysis in additional tables.</p> </section> <section id="CD012744-sec-0073"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Where possible, subgroup analyses would have been performed according to cancer type and treatment plans for cancer, and age of participants (i.e. children under the age of 18 years). </p> </section> <section id="CD012744-sec-0074"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analysis was to be undertaken on the primary outcomes by excluding studies at unclear and high risk of bias from the analyses and also excluding unpublished literature. </p> <p>If any meta‐analyses had included studies with a large variation in sample size (for example several small studies and a single very large study), we would have undertaken a sensitivity analysis comparing the effect estimates from both random‐effects and fixed‐effect models. If these were different we would have reported on both analyses as part of the results section, and we would have considered possible interpretation. </p> <section id="CD012744-sec-0075"> <h5 class="title">Presentation of main results</h5> <p>We produced a 'Summary of findings' table for each comparison that included more than one study. We included data on: xerostomia, salivary flow rate, survival, quality of life and adverse events. We used GRADE methods (<a href="./references#CD012744-bbs2-0098" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490. ">GRADE 2004</a>), and the GRADEpro online tool for developing 'Summary of findings' tables (<a href="http://www.guidelinedevelopment.org" target="_blank">www.guidelinedevelopment.org</a>). We assessed the quality of the body of evidence for each comparison and outcome by considering the overall risk of bias of the included studies, the directness of the evidence, the inconsistency of the results, the precision of the estimates, and the risk of publication bias. We described our level of certainty in the overall findings for each comparison/outcome in terms of high, moderate, low, very low. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012744-sec-0076" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012744-sec-0076"></div> <section id="CD012744-sec-0077"> <h3 class="title">Description of studies</h3> <section id="CD012744-sec-0078"> <h4 class="title">Results of the search</h4> <p>Electronic searches identified a total of 3536 titles and abstracts. A further study was identified by one of the review authors' knowledge of the topic area. After removal of duplicates, 2284 records were identified for screening. Following screening of these titles and abstracts by two review authors, 87 were identified as potentially relevant. Full papers were retrieved and authors of abstracts were written to in order to gain the full papers. Following a second screening of these studies, 46 were excluded for reasons described in the <a href="#CD012744-sec-0084">Excluded studies</a> section and in the table of <a href="./references#CD012744-sec-0241" title="">Characteristics of excluded studies</a>. One study is ongoing and a further study is awaiting classification. Therefore, 39 studies met our eligibility criteria and were included in this review. This process is presented graphically in <a href="#CD012744-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD012744-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012744-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012744-sec-0079"> <h4 class="title">Included studies</h4> <section id="CD012744-sec-0080"> <h5 class="title">Characteristics of trial setting, publication status and funding</h5> <p>Thirty‐nine trials were included; five were multinational (<a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a>; <a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>; <a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a>; <a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a>), six were conducted in China (<a href="./references#CD012744-bbs2-0016" title="HanF , ZhangJD , ShaoZY , LiuFJ . Effects of concurrent chemoradiotherapy combined with Jinlong capsules for patients with advanced nasopharyngeal squamous carcinoma. Chinese Journal of Cancer Prevention and Treatment2010;(2):138‐9. ">Han 2010</a>; <a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a>; <a href="./references#CD012744-bbs2-0019" title="HuYR , WuCQ , LiuYJ , WangY , LiX , ZhongH , et al. Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumour. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):623‐5. ">Hu 2005</a>; <a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin 2014</a>; <a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a>; <a href="./references#CD012744-bbs2-0037" title="WangQ , LiuH , QiaoN . Effects of traditional Chinese medicine on salivary glands in the patients with head and neck cancer during radiotherapy. Zhongguo Zhong Xi Yi Jie He Za Zhi1998;18(11):662‐4. ">Wang 1998</a>), four were conducted in Germany (<a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a>; <a href="./references#CD012744-bbs2-0008" title="BuentzelJ , MickeO , GlatzelM , BrunsF , KistersK , MueckeR . Evaluation of the effect of selenium on radiation‐induced toxicities in head neck cancer patients. Journal of Clinical Oncology2009;27(15 Suppl):e20698. BüntzelJ , MickeO , GlatzelM , SchäferU , RiesenbeckD , KistersK , et al. Selenium substitution during radiotherapy in head and neck cancer. Trace Elements and Electrolytes2010;27:235‐9. BüntzelJ , RiesenbeckD , GlatzelM , Berndt‐SkorkaR , RiedelT , MückeR , et al. Limited effects of selenium substitution in the prevention of radiation‐associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Research2010;30(5):1829‐32. ">Büntzel 2010</a>; <a href="./references#CD012744-bbs2-0013" title="GrötzKA , Henneicke‐Von ZepelinHH , KohnenR , KutznerJ , BelzGG . Prophylaxis of mucositis and dry mouth after head and neck radiotherapy. A new treatment. Krankenhauspharmazie2002;23(5):193‐8. GrötzKA , Henneicke‐von ZepelinHH , KohnenR , al‐NawasB , BockischA , KutznerJ , et al. Prospective double‐blind study of prophylaxis of radioxerostomia with Coumarin/Troxerutine in patients with head and neck cancer [Prospektive, doppelblinde Therapiestudie zur Prophylaxe der Radioxerostomie durch Cumarin/Troxerutin bei Patienten mit Kopf‐Hals‐Karzinomen]. Strahlentherapie und Onkologie1999;175(8):397‐404. GrötzKA , WüstenbergP , KohnenR , Al‐NawasB , Henneicke‐von ZepelinH , BockischA , et al. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer ‐ a prospective, randomized, placebo‐controlled, double‐blind study. British Journal of Oral and Maxillofacial Surgery2001;39(1):34‐9. ">Grötz 2001</a>; <a href="./references#CD012744-bbs2-0034" title="VachaP , FehlauerF , MahlmannB , MarxM , HinkeA , SommerK , et al. Randomized phase III trial of postoperative radiochemotherapy +/‐ amifostine in head and neck cancer. Is there evidence for radioprotection?. Strahlentherapie und Onkologie2003;179(6):385‐9. VachaP , MarxM , EngelA , RichterE , FeyerabendT . Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlentherapie und Onkologie1999;175 Suppl 4:18‐22. ">Vacha 2003</a>), four in the USA (<a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a>; <a href="./references#CD012744-bbs2-0015" title="HaddadR , SonisS , PosnerM , WirthL , CostelloR , BraschaykoP , et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer2009;115(19):4514‐23. ">Haddad 2009</a>; <a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a>; <a href="./references#CD012744-bbs2-0035" title="ValdezIH , WolffA , AtkinsonJC , MacynskiAA , FoxPC . Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer1993;71(5):1848‐51. WolffA , AtkinsonJC , MacynskiAA , FoxPC . Oral complications of cancer therapies. Pretherapy interventions to modify salivary dysfunction. NCI Monographs1990;(9):87‐90. ">Valdez 1993</a>), three in Canada (<a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a>; <a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a>; <a href="./references#CD012744-bbs2-0038" title="WardeP , O'SullivanB , AslanidisJ , KrollB , LockwoodG , MathM , et al. A phase III placebo‐controlled trial of oral pilocarpine in patients undergoing radiotherapy for head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;54(1):9‐13. ">Warde 2002</a>), three in Brazil (<a href="./references#CD012744-bbs2-0020" title="JaguarGC . A Prospective Study of Bethanechol in the Salivary Glands Physiology in Patients Following Head and Neck Radiotherapy [Estudo Prospectivo do Uso do Betanecol na Fisiologia de Glândulas Salivares em Pacientes Irradiados em Região de Cabeça e Pescoço] [Dissertation]. Sao Paulo (Brazil): Fundaçao Antonio Prudente, 2010. JaguarGC , CamposL , PellizzonAC , LimaEN , KowalskiLP , AlvesFA . Double‐blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in cancer patients. Supportive Care in Cancer2012;20(1 Suppl):S252. JaguarGC , LimaEN , KowalskiLP , PellizzonAC , CarvalhoAL , BoccalettiKW , et al. Double blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in head and neck cancer patients. Radiotherapy and Oncology2015;115(2):253‐6. ">Jaguar 2015</a>; <a href="./references#CD012744-bbs2-0022" title="JhamBC , ChenH , CarvalhoAL , FreireAR . A randomized phase III prospective trial of bethanechol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis. Journal of Oral Science2009;51(4):565‐72. JhamBC , TeixeiraIV , AboudCG , CarvalhoAL , Coelho MdeM , FreireAR . A randomized phase III prospective trial of bethanechol to prevent radiotherapy‐induced salivary gland damage in patients with head and neck cancer. Oral Oncology2007;43(2):137‐42. ">Jham 2007</a>; <a href="./references#CD012744-bbs2-0030" title="PimentelMJ , FilhoMM , AraújoM , GomesDQ , DaCostaLJ . Evaluation of radioprotective effect of pilocarpine ingestion on salivary glands. Anticancer Research2014;34(4):1993‐9. ">Pimentel 2014</a>), two in Thailand (<a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>), two in India (<a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a>; <a href="./references#CD012744-bbs2-0031" title="ReshmaK , KamalakshS , BinduYS , PramodK , AsfaA , AmrithaD , et al. Tulasi (Ocimum Sanctum) as radioprotector in head and neck cancer patients undergoing radiation therapy. Biomedicine2012;32:39‐44. ">Reshma 2012</a>), two in the Netherlands (<a href="./references#CD012744-bbs2-0009" title="BurlageFR , RoesinkJM , KampingaHH , CoppesRP , TerhaardC , LangendijkJA , et al. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double‐blind, randomized, placebo‐controlled study. International Journal of Radiation Oncology, Biology, Physics2008;70(1):14‐22. ">Burlage 2008</a>; <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>), one in Croatia (<a href="./references#CD012744-bbs2-0023" title="LajtmanZ , KrajinaZ , KrpanD , VinceljJ , BorcicV , Popovic‐KovacicJ . Pilocarpine in the prevention of postirradiation xerostomia. Acta Medica Croatica2000;54(2):65‐7. ">Lajtman 2000</a>), one in Turkey (<a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a>), one in Greece (<a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a>), one in Iran (<a href="./references#CD012744-bbs2-0014" title="HaddadP , KarimiM . A randomised, double‐blind, placebo‐controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation‐induced xerostomia. Radiotherapy and Oncology2002;64(1):29‐32. ">Haddad 2002</a>), one in France (<a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a>), one in Spain (<a href="./references#CD012744-bbs2-0024" title="LanzósI , HerreraD , SantosS , O'ConnorA , PeñaC , LanzósE , et al. Mucositis in irradiated cancer patients: effects of an antiseptic mouthrinse. Medicina Oral, Patología Oral y Cirugía Bucal2010;15(5):e732‐8. ">Lanzós 2010</a>), one in Japan (<a href="./references#CD012744-bbs2-0039" title="WatanabeT , IshiharaM , MatsuuraK , MizutaK , ItohY . Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. International Journal of Cancer2010;127(8):1984‐90. ">Watanabe 2010</a>), and one in Slovenia (<a href="./references#CD012744-bbs2-0032" title="RodeM , SmidL , BudihnaM , SobaE , RodeM , GaspersicD . The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics1999;45(2):373‐8. ">Rode 1999</a>). </p> <p>All trials had a parallel‐group design. Ten trials had more than one published paper, with <a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a> publishing seven papers relating to the one trial. <a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a> is an unpublished dissertation and data were gained from the authors of two trials following publication of their results as conference abstracts (<a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a>; <a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a>). Eighteen of the trials received external funding, six trials received internal or no funding and the funding source was not stated in 15 trials. </p> <p>One trial is ongoing (<a href="./references#CD012744-bbs2-0087" title="NCT02430298 . Topical/oral melatonin for preventing concurrent radiochemotherapy induced oral mucositis/xerostomia cancer patients [Topical and oral melatonin for preventing concurrent radiochemotherapy induced oral mucositis and xerostomia in head and neck cancer patients]. clinicaltrials.gov/show/NCT02430298 (first received 28 January 2014). ">NCT02430298</a>) and will be considered for future updates. </p> </section> <section id="CD012744-sec-0081"> <h5 class="title">Characteristics of the participants</h5> <p>All of the trials recruited adults scheduled to receive radiotherapy to the salivary glands for cancer. The majority of participants were male. The type of cancer was head and neck at different sites in 36 trials and nasopharyngeal in 3 trials (<a href="./references#CD012744-bbs2-0016" title="HanF , ZhangJD , ShaoZY , LiuFJ . Effects of concurrent chemoradiotherapy combined with Jinlong capsules for patients with advanced nasopharyngeal squamous carcinoma. Chinese Journal of Cancer Prevention and Treatment2010;(2):138‐9. ">Han 2010</a>; <a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a>; <a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a>). </p> <p>Ten of the trials explicitly stated that chemotherapy was given as part of the treatment regimen in addition to radiotherapy for all patients (<a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a>; <a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a>; <a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>; <a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a>; <a href="./references#CD012744-bbs2-0016" title="HanF , ZhangJD , ShaoZY , LiuFJ . Effects of concurrent chemoradiotherapy combined with Jinlong capsules for patients with advanced nasopharyngeal squamous carcinoma. Chinese Journal of Cancer Prevention and Treatment2010;(2):138‐9. ">Han 2010</a>; <a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a>; <a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a>; <a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a>; <a href="./references#CD012744-bbs2-0034" title="VachaP , FehlauerF , MahlmannB , MarxM , HinkeA , SommerK , et al. Randomized phase III trial of postoperative radiochemotherapy +/‐ amifostine in head and neck cancer. Is there evidence for radioprotection?. Strahlentherapie und Onkologie2003;179(6):385‐9. VachaP , MarxM , EngelA , RichterE , FeyerabendT . Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlentherapie und Onkologie1999;175 Suppl 4:18‐22. ">Vacha 2003</a>; <a href="./references#CD012744-bbs2-0039" title="WatanabeT , IshiharaM , MatsuuraK , MizutaK , ItohY . Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. International Journal of Cancer2010;127(8):1984‐90. ">Watanabe 2010</a>). Chemotherapy was given to some patients of the following four trials: <a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a>; <a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a>; <a href="./references#CD012744-bbs2-0015" title="HaddadR , SonisS , PosnerM , WirthL , CostelloR , BraschaykoP , et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer2009;115(19):4514‐23. ">Haddad 2009</a>; <a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a>. The other trials either undertook no chemotherapy, or were unclear about whether any chemotherapy was given. </p> <p>Four studies explicitly referred to neck dissection but varied in the clarity of reporting: two clearly reported the proportions in each group that had their submandibular glands removed (<a href="./references#CD012744-bbs2-0009" title="BurlageFR , RoesinkJM , KampingaHH , CoppesRP , TerhaardC , LangendijkJA , et al. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double‐blind, randomized, placebo‐controlled study. International Journal of Radiation Oncology, Biology, Physics2008;70(1):14‐22. ">Burlage 2008</a>; <a href="./references#CD012744-bbs2-0034" title="VachaP , FehlauerF , MahlmannB , MarxM , HinkeA , SommerK , et al. Randomized phase III trial of postoperative radiochemotherapy +/‐ amifostine in head and neck cancer. Is there evidence for radioprotection?. Strahlentherapie und Onkologie2003;179(6):385‐9. VachaP , MarxM , EngelA , RichterE , FeyerabendT . Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlentherapie und Onkologie1999;175 Suppl 4:18‐22. ">Vacha 2003</a>); one only reported the proportion that had neck dissection in each group, but did not refer to salivary gland removal (<a href="./references#CD012744-bbs2-0015" title="HaddadR , SonisS , PosnerM , WirthL , CostelloR , BraschaykoP , et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer2009;115(19):4514‐23. ">Haddad 2009</a>); and one only stated that participants were stratified by submandibular gland removal, but numbers of participants affected were not reported (<a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>). </p> <p>The 39 included studies randomised 3520 participants, ranging from 10 to 291.</p> <p>The percentage of participants lost to follow‐up ranged from 0% to 38%.</p> </section> <section id="CD012744-sec-0082"> <h5 class="title">Characteristics of the intervention</h5> <p>All of the trials provided a detailed description of the intervention including the dose and method of administration for the test and control groups. Twenty‐one trials included a placebo control group and 14 a 'no intervention' control group, the remaining four trials making head‐to‐head comparisons (<a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a>; <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>; <a href="./references#CD012744-bbs2-0022" title="JhamBC , ChenH , CarvalhoAL , FreireAR . A randomized phase III prospective trial of bethanechol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis. Journal of Oral Science2009;51(4):565‐72. JhamBC , TeixeiraIV , AboudCG , CarvalhoAL , Coelho MdeM , FreireAR . A randomized phase III prospective trial of bethanechol to prevent radiotherapy‐induced salivary gland damage in patients with head and neck cancer. Oral Oncology2007;43(2):137‐42. ">Jham 2007</a>; <a href="./references#CD012744-bbs2-0039" title="WatanabeT , IshiharaM , MatsuuraK , MizutaK , ItohY . Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. International Journal of Cancer2010;127(8):1984‐90. ">Watanabe 2010</a>). </p> <p> <ul id="CD012744-list-0009"> <li> <p>Pilocarpine hydrochloride was assessed in 12 trials at various dosages: <a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a>; <a href="./references#CD012744-bbs2-0009" title="BurlageFR , RoesinkJM , KampingaHH , CoppesRP , TerhaardC , LangendijkJA , et al. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double‐blind, randomized, placebo‐controlled study. International Journal of Radiation Oncology, Biology, Physics2008;70(1):14‐22. ">Burlage 2008</a>; <a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a>; <a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a>; <a href="./references#CD012744-bbs2-0014" title="HaddadP , KarimiM . A randomised, double‐blind, placebo‐controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation‐induced xerostomia. Radiotherapy and Oncology2002;64(1):29‐32. ">Haddad 2002</a>; <a href="./references#CD012744-bbs2-0023" title="LajtmanZ , KrajinaZ , KrpanD , VinceljJ , BorcicV , Popovic‐KovacicJ . Pilocarpine in the prevention of postirradiation xerostomia. Acta Medica Croatica2000;54(2):65‐7. ">Lajtman 2000</a>; <a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a>; <a href="./references#CD012744-bbs2-0030" title="PimentelMJ , FilhoMM , AraújoM , GomesDQ , DaCostaLJ . Evaluation of radioprotective effect of pilocarpine ingestion on salivary glands. Anticancer Research2014;34(4):1993‐9. ">Pimentel 2014</a>; <a href="./references#CD012744-bbs2-0032" title="RodeM , SmidL , BudihnaM , SobaE , RodeM , GaspersicD . The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics1999;45(2):373‐8. ">Rode 1999</a>; <a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a>; <a href="./references#CD012744-bbs2-0035" title="ValdezIH , WolffA , AtkinsonJC , MacynskiAA , FoxPC . Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer1993;71(5):1848‐51. WolffA , AtkinsonJC , MacynskiAA , FoxPC . Oral complications of cancer therapies. Pretherapy interventions to modify salivary dysfunction. NCI Monographs1990;(9):87‐90. ">Valdez 1993</a>; <a href="./references#CD012744-bbs2-0038" title="WardeP , O'SullivanB , AslanidisJ , KrollB , LockwoodG , MathM , et al. A phase III placebo‐controlled trial of oral pilocarpine in patients undergoing radiotherapy for head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;54(1):9‐13. ">Warde 2002</a>. </p> </li> <li> <p>Biperiden plus pilocarpine was assessed in one trial: <a href="./references#CD012744-bbs2-0032" title="RodeM , SmidL , BudihnaM , SobaE , RodeM , GaspersicD . The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics1999;45(2):373‐8. ">Rode 1999</a>. </p> </li> <li> <p>Amifostine was assessed in 12 trials at various dosages: <a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a>; <a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a>; <a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>; <a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a>; <a href="./references#CD012744-bbs2-0015" title="HaddadR , SonisS , PosnerM , WirthL , CostelloR , BraschaykoP , et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer2009;115(19):4514‐23. ">Haddad 2009</a>; <a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a>; <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>; <a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a>; <a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a>; <a href="./references#CD012744-bbs2-0034" title="VachaP , FehlauerF , MahlmannB , MarxM , HinkeA , SommerK , et al. Randomized phase III trial of postoperative radiochemotherapy +/‐ amifostine in head and neck cancer. Is there evidence for radioprotection?. Strahlentherapie und Onkologie2003;179(6):385‐9. VachaP , MarxM , EngelA , RichterE , FeyerabendT . Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlentherapie und Onkologie1999;175 Suppl 4:18‐22. ">Vacha 2003</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>. </p> </li> <li> <p>Chinese medicine was assessed in five trials, all comparing different herbs: <a href="./references#CD012744-bbs2-0016" title="HanF , ZhangJD , ShaoZY , LiuFJ . Effects of concurrent chemoradiotherapy combined with Jinlong capsules for patients with advanced nasopharyngeal squamous carcinoma. Chinese Journal of Cancer Prevention and Treatment2010;(2):138‐9. ">Han 2010</a>; <a href="./references#CD012744-bbs2-0019" title="HuYR , WuCQ , LiuYJ , WangY , LiX , ZhongH , et al. Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumour. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):623‐5. ">Hu 2005</a>; <a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin 2014</a>; <a href="./references#CD012744-bbs2-0031" title="ReshmaK , KamalakshS , BinduYS , PramodK , AsfaA , AmrithaD , et al. Tulasi (Ocimum Sanctum) as radioprotector in head and neck cancer patients undergoing radiation therapy. Biomedicine2012;32:39‐44. ">Reshma 2012</a>; <a href="./references#CD012744-bbs2-0037" title="WangQ , LiuH , QiaoN . Effects of traditional Chinese medicine on salivary glands in the patients with head and neck cancer during radiotherapy. Zhongguo Zhong Xi Yi Jie He Za Zhi1998;18(11):662‐4. ">Wang 1998</a>. </p> </li> <li> <p>Palifermin was assessed in three trials: <a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a>; <a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a>; <a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a>. </p> </li> <li> <p>Bethanechol was assessed in two trials: <a href="./references#CD012744-bbs2-0020" title="JaguarGC . A Prospective Study of Bethanechol in the Salivary Glands Physiology in Patients Following Head and Neck Radiotherapy [Estudo Prospectivo do Uso do Betanecol na Fisiologia de Glândulas Salivares em Pacientes Irradiados em Região de Cabeça e Pescoço] [Dissertation]. Sao Paulo (Brazil): Fundaçao Antonio Prudente, 2010. JaguarGC , CamposL , PellizzonAC , LimaEN , KowalskiLP , AlvesFA . Double‐blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in cancer patients. Supportive Care in Cancer2012;20(1 Suppl):S252. JaguarGC , LimaEN , KowalskiLP , PellizzonAC , CarvalhoAL , BoccalettiKW , et al. Double blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in head and neck cancer patients. Radiotherapy and Oncology2015;115(2):253‐6. ">Jaguar 2015</a>; <a href="./references#CD012744-bbs2-0022" title="JhamBC , ChenH , CarvalhoAL , FreireAR . A randomized phase III prospective trial of bethanechol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis. Journal of Oral Science2009;51(4):565‐72. JhamBC , TeixeiraIV , AboudCG , CarvalhoAL , Coelho MdeM , FreireAR . A randomized phase III prospective trial of bethanechol to prevent radiotherapy‐induced salivary gland damage in patients with head and neck cancer. Oral Oncology2007;43(2):137‐42. ">Jham 2007</a>. </p> </li> <li> <p>Artificial saliva was assessed in one trial: <a href="./references#CD012744-bbs2-0022" title="JhamBC , ChenH , CarvalhoAL , FreireAR . A randomized phase III prospective trial of bethanechol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis. Journal of Oral Science2009;51(4):565‐72. JhamBC , TeixeiraIV , AboudCG , CarvalhoAL , Coelho MdeM , FreireAR . A randomized phase III prospective trial of bethanechol to prevent radiotherapy‐induced salivary gland damage in patients with head and neck cancer. Oral Oncology2007;43(2):137‐42. ">Jham 2007</a>. </p> </li> <li> <p>Selenium was assessed in one trial: <a href="./references#CD012744-bbs2-0008" title="BuentzelJ , MickeO , GlatzelM , BrunsF , KistersK , MueckeR . Evaluation of the effect of selenium on radiation‐induced toxicities in head neck cancer patients. Journal of Clinical Oncology2009;27(15 Suppl):e20698. BüntzelJ , MickeO , GlatzelM , SchäferU , RiesenbeckD , KistersK , et al. Selenium substitution during radiotherapy in head and neck cancer. Trace Elements and Electrolytes2010;27:235‐9. BüntzelJ , RiesenbeckD , GlatzelM , Berndt‐SkorkaR , RiedelT , MückeR , et al. Limited effects of selenium substitution in the prevention of radiation‐associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Research2010;30(5):1829‐32. ">Büntzel 2010</a>. </p> </li> <li> <p>Antiseptic mouthrinse was assessed in one trial: <a href="./references#CD012744-bbs2-0024" title="LanzósI , HerreraD , SantosS , O'ConnorA , PeñaC , LanzósE , et al. Mucositis in irradiated cancer patients: effects of an antiseptic mouthrinse. Medicina Oral, Patología Oral y Cirugía Bucal2010;15(5):e732‐8. ">Lanzós 2010</a>. </p> </li> <li> <p>Antimicrobial lozenge was assessed in one trial: <a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a>. </p> </li> <li> <p>Polaprezinc was assessed in one trial: <a href="./references#CD012744-bbs2-0039" title="WatanabeT , IshiharaM , MatsuuraK , MizutaK , ItohY . Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. International Journal of Cancer2010;127(8):1984‐90. ">Watanabe 2010</a>. </p> </li> <li> <p>Azulene oral rinse assessed in one trial: <a href="./references#CD012744-bbs2-0039" title="WatanabeT , IshiharaM , MatsuuraK , MizutaK , ItohY . Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. International Journal of Cancer2010;127(8):1984‐90. ">Watanabe 2010</a>. </p> </li> <li> <p>Venalot Depot (coumarin/ troxerutin) was assessed in one trial: <a href="./references#CD012744-bbs2-0013" title="GrötzKA , Henneicke‐Von ZepelinHH , KohnenR , KutznerJ , BelzGG . Prophylaxis of mucositis and dry mouth after head and neck radiotherapy. A new treatment. Krankenhauspharmazie2002;23(5):193‐8. GrötzKA , Henneicke‐von ZepelinHH , KohnenR , al‐NawasB , BockischA , KutznerJ , et al. Prospective double‐blind study of prophylaxis of radioxerostomia with Coumarin/Troxerutine in patients with head and neck cancer [Prospektive, doppelblinde Therapiestudie zur Prophylaxe der Radioxerostomie durch Cumarin/Troxerutin bei Patienten mit Kopf‐Hals‐Karzinomen]. Strahlentherapie und Onkologie1999;175(8):397‐404. GrötzKA , WüstenbergP , KohnenR , Al‐NawasB , Henneicke‐von ZepelinH , BockischA , et al. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer ‐ a prospective, randomized, placebo‐controlled, double‐blind study. British Journal of Oral and Maxillofacial Surgery2001;39(1):34‐9. ">Grötz 2001</a>. </p> </li> </ul> </p> <p>The length of follow‐up ranged from day 28 of the radiotherapy (RT) to 34 months: day 28/29 of RT (<a href="./references#CD012744-bbs2-0030" title="PimentelMJ , FilhoMM , AraújoM , GomesDQ , DaCostaLJ . Evaluation of radioprotective effect of pilocarpine ingestion on salivary glands. Anticancer Research2014;34(4):1993‐9. ">Pimentel 2014</a>; <a href="./references#CD012744-bbs2-0031" title="ReshmaK , KamalakshS , BinduYS , PramodK , AsfaA , AmrithaD , et al. Tulasi (Ocimum Sanctum) as radioprotector in head and neck cancer patients undergoing radiation therapy. Biomedicine2012;32:39‐44. ">Reshma 2012</a>), end of RT (<a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a>; <a href="./references#CD012744-bbs2-0019" title="HuYR , WuCQ , LiuYJ , WangY , LiX , ZhongH , et al. Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumour. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):623‐5. ">Hu 2005</a>; <a href="./references#CD012744-bbs2-0037" title="WangQ , LiuH , QiaoN . Effects of traditional Chinese medicine on salivary glands in the patients with head and neck cancer during radiotherapy. Zhongguo Zhong Xi Yi Jie He Za Zhi1998;18(11):662‐4. ">Wang 1998</a>), four weeks from start of RT (<a href="./references#CD012744-bbs2-0024" title="LanzósI , HerreraD , SantosS , O'ConnorA , PeñaC , LanzósE , et al. Mucositis in irradiated cancer patients: effects of an antiseptic mouthrinse. Medicina Oral, Patología Oral y Cirugía Bucal2010;15(5):e732‐8. ">Lanzós 2010</a>), four weeks after RT (<a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin 2014</a>; <a href="./references#CD012744-bbs2-0013" title="GrötzKA , Henneicke‐Von ZepelinHH , KohnenR , KutznerJ , BelzGG . Prophylaxis of mucositis and dry mouth after head and neck radiotherapy. A new treatment. Krankenhauspharmazie2002;23(5):193‐8. GrötzKA , Henneicke‐von ZepelinHH , KohnenR , al‐NawasB , BockischA , KutznerJ , et al. Prospective double‐blind study of prophylaxis of radioxerostomia with Coumarin/Troxerutine in patients with head and neck cancer [Prospektive, doppelblinde Therapiestudie zur Prophylaxe der Radioxerostomie durch Cumarin/Troxerutin bei Patienten mit Kopf‐Hals‐Karzinomen]. Strahlentherapie und Onkologie1999;175(8):397‐404. GrötzKA , WüstenbergP , KohnenR , Al‐NawasB , Henneicke‐von ZepelinH , BockischA , et al. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer ‐ a prospective, randomized, placebo‐controlled, double‐blind study. British Journal of Oral and Maxillofacial Surgery2001;39(1):34‐9. ">Grötz 2001</a>), five weeks after RT (<a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a>), six weeks after RT (<a href="./references#CD012744-bbs2-0008" title="BuentzelJ , MickeO , GlatzelM , BrunsF , KistersK , MueckeR . Evaluation of the effect of selenium on radiation‐induced toxicities in head neck cancer patients. Journal of Clinical Oncology2009;27(15 Suppl):e20698. BüntzelJ , MickeO , GlatzelM , SchäferU , RiesenbeckD , KistersK , et al. Selenium substitution during radiotherapy in head and neck cancer. Trace Elements and Electrolytes2010;27:235‐9. BüntzelJ , RiesenbeckD , GlatzelM , Berndt‐SkorkaR , RiedelT , MückeR , et al. Limited effects of selenium substitution in the prevention of radiation‐associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Research2010;30(5):1829‐32. ">Büntzel 2010</a>; <a href="./references#CD012744-bbs2-0034" title="VachaP , FehlauerF , MahlmannB , MarxM , HinkeA , SommerK , et al. Randomized phase III trial of postoperative radiochemotherapy +/‐ amifostine in head and neck cancer. Is there evidence for radioprotection?. Strahlentherapie und Onkologie2003;179(6):385‐9. VachaP , MarxM , EngelA , RichterE , FeyerabendT . Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlentherapie und Onkologie1999;175 Suppl 4:18‐22. ">Vacha 2003</a>), seven weeks after RT (<a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a>), two months after RT (<a href="./references#CD012744-bbs2-0022" title="JhamBC , ChenH , CarvalhoAL , FreireAR . A randomized phase III prospective trial of bethanechol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis. Journal of Oral Science2009;51(4):565‐72. JhamBC , TeixeiraIV , AboudCG , CarvalhoAL , Coelho MdeM , FreireAR . A randomized phase III prospective trial of bethanechol to prevent radiotherapy‐induced salivary gland damage in patients with head and neck cancer. Oral Oncology2007;43(2):137‐42. ">Jham 2007</a>), three months after RT (<a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a>; <a href="./references#CD012744-bbs2-0016" title="HanF , ZhangJD , ShaoZY , LiuFJ . Effects of concurrent chemoradiotherapy combined with Jinlong capsules for patients with advanced nasopharyngeal squamous carcinoma. Chinese Journal of Cancer Prevention and Treatment2010;(2):138‐9. ">Han 2010</a>; <a href="./references#CD012744-bbs2-0020" title="JaguarGC . A Prospective Study of Bethanechol in the Salivary Glands Physiology in Patients Following Head and Neck Radiotherapy [Estudo Prospectivo do Uso do Betanecol na Fisiologia de Glândulas Salivares em Pacientes Irradiados em Região de Cabeça e Pescoço] [Dissertation]. Sao Paulo (Brazil): Fundaçao Antonio Prudente, 2010. JaguarGC , CamposL , PellizzonAC , LimaEN , KowalskiLP , AlvesFA . Double‐blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in cancer patients. Supportive Care in Cancer2012;20(1 Suppl):S252. JaguarGC , LimaEN , KowalskiLP , PellizzonAC , CarvalhoAL , BoccalettiKW , et al. Double blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in head and neck cancer patients. Radiotherapy and Oncology2015;115(2):253‐6. ">Jaguar 2015</a>; <a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a>), six months after RT (<a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a>; <a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a>; <a href="./references#CD012744-bbs2-0014" title="HaddadP , KarimiM . A randomised, double‐blind, placebo‐controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation‐induced xerostomia. Radiotherapy and Oncology2002;64(1):29‐32. ">Haddad 2002</a>; <a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a>; <a href="./references#CD012744-bbs2-0038" title="WardeP , O'SullivanB , AslanidisJ , KrollB , LockwoodG , MathM , et al. A phase III placebo‐controlled trial of oral pilocarpine in patients undergoing radiotherapy for head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;54(1):9‐13. ">Warde 2002</a>), 12 months after RT (<a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a>; <a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>; <a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a>; <a href="./references#CD012744-bbs2-0009" title="BurlageFR , RoesinkJM , KampingaHH , CoppesRP , TerhaardC , LangendijkJA , et al. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double‐blind, randomized, placebo‐controlled study. International Journal of Radiation Oncology, Biology, Physics2008;70(1):14‐22. ">Burlage 2008</a>; <a href="./references#CD012744-bbs2-0023" title="LajtmanZ , KrajinaZ , KrpanD , VinceljJ , BorcicV , Popovic‐KovacicJ . Pilocarpine in the prevention of postirradiation xerostomia. Acta Medica Croatica2000;54(2):65‐7. ">Lajtman 2000</a>; <a href="./references#CD012744-bbs2-0032" title="RodeM , SmidL , BudihnaM , SobaE , RodeM , GaspersicD . The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics1999;45(2):373‐8. ">Rode 1999</a>; <a href="./references#CD012744-bbs2-0035" title="ValdezIH , WolffA , AtkinsonJC , MacynskiAA , FoxPC . Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer1993;71(5):1848‐51. WolffA , AtkinsonJC , MacynskiAA , FoxPC . Oral complications of cancer therapies. Pretherapy interventions to modify salivary dysfunction. NCI Monographs1990;(9):87‐90. ">Valdez 1993</a>), 18 months after RT (<a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a>), 24 months after RT (<a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a>; <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>; <a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a>; <a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>), and 34 months after RT (<a href="./references#CD012744-bbs2-0015" title="HaddadR , SonisS , PosnerM , WirthL , CostelloR , BraschaykoP , et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer2009;115(19):4514‐23. ">Haddad 2009</a>). Duration of follow‐up/timing of assessment was unclear in two studies (<a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a>; <a href="./references#CD012744-bbs2-0039" title="WatanabeT , IshiharaM , MatsuuraK , MizutaK , ItohY . Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. International Journal of Cancer2010;127(8):1984‐90. ">Watanabe 2010</a>). </p> </section> <section id="CD012744-sec-0083"> <h5 class="title">Characteristics of outcome measures</h5> <p>The trials used a variety of assessment measures for salivary gland dysfunction. Ten trials included a subjective measure of salivary gland dysfunction, i.e. the patient was involved in the assessment through visual analogue scales (VAS) (<a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a>; <a href="./references#CD012744-bbs2-0014" title="HaddadP , KarimiM . A randomised, double‐blind, placebo‐controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation‐induced xerostomia. Radiotherapy and Oncology2002;64(1):29‐32. ">Haddad 2002</a>; <a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a>; <a href="./references#CD012744-bbs2-0037" title="WangQ , LiuH , QiaoN . Effects of traditional Chinese medicine on salivary glands in the patients with head and neck cancer during radiotherapy. Zhongguo Zhong Xi Yi Jie He Za Zhi1998;18(11):662‐4. ">Wang 1998</a>), linear analogue scale (LASA) (<a href="./references#CD012744-bbs2-0038" title="WardeP , O'SullivanB , AslanidisJ , KrollB , LockwoodG , MathM , et al. A phase III placebo‐controlled trial of oral pilocarpine in patients undergoing radiotherapy for head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;54(1):9‐13. ">Warde 2002</a>), and modified patient questionnaires (<a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a>; <a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a>; <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>; <a href="./references#CD012744-bbs2-0023" title="LajtmanZ , KrajinaZ , KrpanD , VinceljJ , BorcicV , Popovic‐KovacicJ . Pilocarpine in the prevention of postirradiation xerostomia. Acta Medica Croatica2000;54(2):65‐7. ">Lajtman 2000</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>). One study reported 'acute' or 'chronic' dry mouth only (<a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a>). Fifteen trials reported a clinical assessment of salivary gland dysfunction using various scales: RTOG/EORTC (Radiation Therapy Oncology Group/European Organisation for Research and Treatment of Cancer) scoring (<a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a>; <a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>; <a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a>; <a href="./references#CD012744-bbs2-0013" title="GrötzKA , Henneicke‐Von ZepelinHH , KohnenR , KutznerJ , BelzGG . Prophylaxis of mucositis and dry mouth after head and neck radiotherapy. A new treatment. Krankenhauspharmazie2002;23(5):193‐8. GrötzKA , Henneicke‐von ZepelinHH , KohnenR , al‐NawasB , BockischA , KutznerJ , et al. Prospective double‐blind study of prophylaxis of radioxerostomia with Coumarin/Troxerutine in patients with head and neck cancer [Prospektive, doppelblinde Therapiestudie zur Prophylaxe der Radioxerostomie durch Cumarin/Troxerutin bei Patienten mit Kopf‐Hals‐Karzinomen]. Strahlentherapie und Onkologie1999;175(8):397‐404. GrötzKA , WüstenbergP , KohnenR , Al‐NawasB , Henneicke‐von ZepelinH , BockischA , et al. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer ‐ a prospective, randomized, placebo‐controlled, double‐blind study. British Journal of Oral and Maxillofacial Surgery2001;39(1):34‐9. ">Grötz 2001</a>; <a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a>; <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>; <a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>), NCI CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) (<a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a>; <a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a>; <a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a>), WHO (World Health Organization) grading/classification (<a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a>), and Late Effects Normal Tissue Task Force (LENT)‐Subjective, Objective, Management, Analytic (SOMA) scales (<a href="./references#CD012744-bbs2-0009" title="BurlageFR , RoesinkJM , KampingaHH , CoppesRP , TerhaardC , LangendijkJA , et al. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double‐blind, randomized, placebo‐controlled study. International Journal of Radiation Oncology, Biology, Physics2008;70(1):14‐22. ">Burlage 2008</a>; <a href="./references#CD012744-bbs2-0014" title="HaddadP , KarimiM . A randomised, double‐blind, placebo‐controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation‐induced xerostomia. Radiotherapy and Oncology2002;64(1):29‐32. ">Haddad 2002</a>). Unstimulated or stimulated whole saliva secretion data or both were collected in ten trials (<a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a>; <a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>; <a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a>; <a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a>; <a href="./references#CD012744-bbs2-0023" title="LajtmanZ , KrajinaZ , KrpanD , VinceljJ , BorcicV , Popovic‐KovacicJ . Pilocarpine in the prevention of postirradiation xerostomia. Acta Medica Croatica2000;54(2):65‐7. ">Lajtman 2000</a>; <a href="./references#CD012744-bbs2-0032" title="RodeM , SmidL , BudihnaM , SobaE , RodeM , GaspersicD . The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics1999;45(2):373‐8. ">Rode 1999</a>; <a href="./references#CD012744-bbs2-0035" title="ValdezIH , WolffA , AtkinsonJC , MacynskiAA , FoxPC . Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer1993;71(5):1848‐51. WolffA , AtkinsonJC , MacynskiAA , FoxPC . Oral complications of cancer therapies. Pretherapy interventions to modify salivary dysfunction. NCI Monographs1990;(9):87‐90. ">Valdez 1993</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>; <a href="./references#CD012744-bbs2-0037" title="WangQ , LiuH , QiaoN . Effects of traditional Chinese medicine on salivary glands in the patients with head and neck cancer during radiotherapy. Zhongguo Zhong Xi Yi Jie He Za Zhi1998;18(11):662‐4. ">Wang 1998</a>), and salivary gland scintigraphy was used in five trials (<a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a>; <a href="./references#CD012744-bbs2-0013" title="GrötzKA , Henneicke‐Von ZepelinHH , KohnenR , KutznerJ , BelzGG . Prophylaxis of mucositis and dry mouth after head and neck radiotherapy. A new treatment. Krankenhauspharmazie2002;23(5):193‐8. GrötzKA , Henneicke‐von ZepelinHH , KohnenR , al‐NawasB , BockischA , KutznerJ , et al. Prospective double‐blind study of prophylaxis of radioxerostomia with Coumarin/Troxerutine in patients with head and neck cancer [Prospektive, doppelblinde Therapiestudie zur Prophylaxe der Radioxerostomie durch Cumarin/Troxerutin bei Patienten mit Kopf‐Hals‐Karzinomen]. Strahlentherapie und Onkologie1999;175(8):397‐404. GrötzKA , WüstenbergP , KohnenR , Al‐NawasB , Henneicke‐von ZepelinH , BockischA , et al. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer ‐ a prospective, randomized, placebo‐controlled, double‐blind study. British Journal of Oral and Maxillofacial Surgery2001;39(1):34‐9. ">Grötz 2001</a>; <a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a>; <a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>). </p> <p>Secondary outcomes were sporadically reported, using various scales. However, the majority of studies reported adverse events. </p> </section> </section> <section id="CD012744-sec-0084"> <h4 class="title">Excluded studies</h4> <p>Of the 87 trials that were identified as potentially eligible, 46 were excluded, with the main reason being the publication of an abstract only (17 publications), with insufficient information to allow thorough assessment: <a href="./references#CD012744-bbs2-0041" title="BaggaP , AnandAK , RainaA , ChoudharyPS , ChaudhooryAR . Evaluation of pilocarpine for the prevention of radiation induced xerostomia in head and neck cancers. Annals of Oncology2007;18(Suppl 9):ix177. [Abs No 62] ">Bagga 2007</a>; <a href="./references#CD012744-bbs2-0045" title="BorgM , KrishnanS , OlverL , SteinB , ChattertonB , CoatesE , et al. Randomised double‐blind trial of amifostine vs placebo for radiation‐induced xerostomia in patients with head and neck cancer. ANZ Journal of Surgery2007;77(12):A3. ">Borg 2007</a>; <a href="./references#CD012744-bbs2-0049" title="ChambersMS , PosnerMR , JonesCU , WeberRS , VittiR . Two phase III clinical studies of cevimeline for post‐radiation xerostomia in patients with head and neck cancer. Journal of Clinical Oncology2005;23(16 Suppl):5503. ">Chambers 2005</a>; <a href="./references#CD012744-bbs2-0055" title="GoyalS , SharmaDN , JulkaPK , RathGK . Effect of oral pilocarpine on xerostomia and quality of life in patients receiving curative radiotherapy for head and neck cancers. Journal of Clinical Oncology2007;25(18 Suppl):6088. ">Goyal 2007</a>; <a href="./references#CD012744-bbs2-0056" title="GuJ , ZhuS , LiX , WuH , LiY , HuaF . Effect of amifostine in head and neck cancer patients treated with radiotherapy: a systematic review and meta‐analysis based on randomized controlled trials. PloS One2014;9(5):e95968. ">Gu 2014</a>; <a href="./references#CD012744-bbs2-0060" title="KumarchandraR , ShenoyK , BinduYS , KadabaP , ChandrashekarR . Ocimum Sanctum as a radioprotector in head and neck cancer patients undergoing radiation therapy. Free Radical Biology and Medicine2010;49 Suppl:S64. ">Kumarchandra 2010</a>; <a href="./references#CD012744-bbs2-0061" title="Manoor MaiyaV , VaidN , BasuS , VatyamS , HegdeS , DeshmukhS , et al. The use of xylitol for the prevention of xerostomia in patients receiving intensity modulated radiation therapy for head and neck cancers. International Journal of Radiation Oncology, Biology, Physics2014;90(1 Suppl):S562. ">Manoor 2014</a>; <a href="./references#CD012744-bbs2-0063" title="MitineC , ChaltinM , SalembierC , MerloP , BeauduinM . Head and neck radiotherapy: does pilocarpine hydrochloride reduce radiation‐induced xerostomia?. Proceedings of the management of head and neck tumors: what are the challenges for the third millennium; 1999 Dec 3‐4; Brussels (Belgium). European Laryngological Society, 1999. ">Mitine 2000</a>; <a href="./references#CD012744-bbs2-0064" title="MixMD , JamesonM , TillsM , DibajS , GromanA , JaggernauthW , et al. Randomized double‐blind, placebo‐controlled, multicenter phase 2 trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in locally‐advanced squamous cell carcinoma of the head and neck. International Journal of Radiation Oncology, Biology, Physics2013;87(2 Suppl):S466‐7. ">Mix 2013</a>; <a href="./references#CD012744-bbs2-0066" title="Norberg‐SpaakLE , LundquistPG , BerndtsonM , KlintenbergC . Can pilocarpine treatment during irradiation prevent salivary gland damage?. Swedish Dental Journal1996;20:234. ">Norberg‐Spaak 1996</a>; <a href="./references#CD012744-bbs2-0067" title="Norberg‐SpaakLE . Can pilocarpine treatment during irradiation prevent salivary gland damage. Clinical Otolaryngology and Allied Sciences1997;22:88. ">Norberg‐Spaak 1997</a>; <a href="./references#CD012744-bbs2-0069" title="ParkJ , McGuireDB , KangH . Effects of cold sterile normal saline (CSNS) mouth care in head and neck cancer (HNC) patients undergoing concurrent chemoradiotherapy (CCRT). Supportive Care in Cancer2012;20(1 Suppl):S246‐7. [Abs No 1028] ">Park 2012</a>; <a href="./references#CD012744-bbs2-0070" title="ParkK‐N , SonY‐I , BaekCH . Protection of radiotherapy‐induced xerostomia with vitamin E+C complex. Otolaryngology ‐ Head and Neck Surgery2012;147(2 Suppl):P174. ">Park 2012a</a>; <a href="./references#CD012744-bbs2-0073" title="ResubalJR , CalaguasMJ . The effect of zilongjin(r) in patients with head and neck cancer needing radiotherapy with and without chemotherapy. Radiotherapy and Oncology2011;99(Suppl 1):S336. ">Resubal 2011</a>; <a href="./references#CD012744-bbs2-0076" title="RudatV , MünterM , RadesD , GrötzK , HaberkornU , BrennerW . The effect of amifostine or IMRT to preserve the parotid function after radiotherapy of the head and neck region measured by quantitative salivary gland scintigraphy. Journal of Clinical Oncology2005;23(16 Suppl):5502. ">Rudat 2005</a>; <a href="./references#CD012744-bbs2-0079" title="StrnadV , SauerR , KrafftT , LerchS . Preliminary results of a randomised study using WR‐2721 in radiation therapy alone in patients with head and neck cancer. European Journal of Cancer1997;33(Suppl 8):S189. ">Strnad 1997</a>; <a href="./references#CD012744-bbs2-0084" title="ZaleM , ChambersMS , KhanZ . Pilocarpine effects on xerostomia associated with radiation therapy. Journal of Dental Research1993;72(Abs Spec Issue):375. [Abs No 2175] ">Zale 1993</a>. </p> <p>Other reasons for exclusion were: not a randomised controlled trial or unclear if a randomised controlled trial; prevention of salivary gland dysfunction not the aim of study/not reported; radioactive iodine used rather than radiotherapy; study did not include head and neck cancer patients; the intervention was not a pharmacological agent. </p> </section> </section> <section id="CD012744-sec-0085"> <h3 class="title">Risk of bias in included studies</h3> <section id="CD012744-sec-0086"> <h4 class="title">Allocation</h4> <section id="CD012744-sec-0087"> <h5 class="title">Random sequence generation</h5> <p>Twenty of the included studies described an adequate method of random sequence generation and were assessed as at low risk of bias for this domain (<a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a>; <a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>; <a href="./references#CD012744-bbs2-0009" title="BurlageFR , RoesinkJM , KampingaHH , CoppesRP , TerhaardC , LangendijkJA , et al. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double‐blind, randomized, placebo‐controlled study. International Journal of Radiation Oncology, Biology, Physics2008;70(1):14‐22. ">Burlage 2008</a>; <a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a>; <a href="./references#CD012744-bbs2-0014" title="HaddadP , KarimiM . A randomised, double‐blind, placebo‐controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation‐induced xerostomia. Radiotherapy and Oncology2002;64(1):29‐32. ">Haddad 2002</a>; <a href="./references#CD012744-bbs2-0015" title="HaddadR , SonisS , PosnerM , WirthL , CostelloR , BraschaykoP , et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer2009;115(19):4514‐23. ">Haddad 2009</a>; <a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a>; <a href="./references#CD012744-bbs2-0020" title="JaguarGC . A Prospective Study of Bethanechol in the Salivary Glands Physiology in Patients Following Head and Neck Radiotherapy [Estudo Prospectivo do Uso do Betanecol na Fisiologia de Glândulas Salivares em Pacientes Irradiados em Região de Cabeça e Pescoço] [Dissertation]. Sao Paulo (Brazil): Fundaçao Antonio Prudente, 2010. JaguarGC , CamposL , PellizzonAC , LimaEN , KowalskiLP , AlvesFA . Double‐blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in cancer patients. Supportive Care in Cancer2012;20(1 Suppl):S252. JaguarGC , LimaEN , KowalskiLP , PellizzonAC , CarvalhoAL , BoccalettiKW , et al. Double blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in head and neck cancer patients. Radiotherapy and Oncology2015;115(2):253‐6. ">Jaguar 2015</a>; <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>; <a href="./references#CD012744-bbs2-0022" title="JhamBC , ChenH , CarvalhoAL , FreireAR . A randomized phase III prospective trial of bethanechol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis. Journal of Oral Science2009;51(4):565‐72. JhamBC , TeixeiraIV , AboudCG , CarvalhoAL , Coelho MdeM , FreireAR . A randomized phase III prospective trial of bethanechol to prevent radiotherapy‐induced salivary gland damage in patients with head and neck cancer. Oral Oncology2007;43(2):137‐42. ">Jham 2007</a>; <a href="./references#CD012744-bbs2-0024" title="LanzósI , HerreraD , SantosS , O'ConnorA , PeñaC , LanzósE , et al. Mucositis in irradiated cancer patients: effects of an antiseptic mouthrinse. Medicina Oral, Patología Oral y Cirugía Bucal2010;15(5):e732‐8. ">Lanzós 2010</a>; <a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a>; <a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin 2014</a>; <a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a>; <a href="./references#CD012744-bbs2-0030" title="PimentelMJ , FilhoMM , AraújoM , GomesDQ , DaCostaLJ . Evaluation of radioprotective effect of pilocarpine ingestion on salivary glands. Anticancer Research2014;34(4):1993‐9. ">Pimentel 2014</a>; <a href="./references#CD012744-bbs2-0032" title="RodeM , SmidL , BudihnaM , SobaE , RodeM , GaspersicD . The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics1999;45(2):373‐8. ">Rode 1999</a>; <a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a>; <a href="./references#CD012744-bbs2-0035" title="ValdezIH , WolffA , AtkinsonJC , MacynskiAA , FoxPC . Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer1993;71(5):1848‐51. WolffA , AtkinsonJC , MacynskiAA , FoxPC . Oral complications of cancer therapies. Pretherapy interventions to modify salivary dysfunction. NCI Monographs1990;(9):87‐90. ">Valdez 1993</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>). The remaining 19 studies stated that allocation was random but did not describe their methods and were therefore assessed as at unclear risk of bias for this domain. </p> </section> <section id="CD012744-sec-0088"> <h5 class="title">Allocation concealment</h5> <p>Allocation concealment was clearly described in 16 of the included studies and they were assessed as being at low risk of bias for this domain (<a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a>; <a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>; <a href="./references#CD012744-bbs2-0009" title="BurlageFR , RoesinkJM , KampingaHH , CoppesRP , TerhaardC , LangendijkJA , et al. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double‐blind, randomized, placebo‐controlled study. International Journal of Radiation Oncology, Biology, Physics2008;70(1):14‐22. ">Burlage 2008</a>; <a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a>; <a href="./references#CD012744-bbs2-0014" title="HaddadP , KarimiM . A randomised, double‐blind, placebo‐controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation‐induced xerostomia. Radiotherapy and Oncology2002;64(1):29‐32. ">Haddad 2002</a>; <a href="./references#CD012744-bbs2-0015" title="HaddadR , SonisS , PosnerM , WirthL , CostelloR , BraschaykoP , et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer2009;115(19):4514‐23. ">Haddad 2009</a>; <a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a>; <a href="./references#CD012744-bbs2-0024" title="LanzósI , HerreraD , SantosS , O'ConnorA , PeñaC , LanzósE , et al. Mucositis in irradiated cancer patients: effects of an antiseptic mouthrinse. Medicina Oral, Patología Oral y Cirugía Bucal2010;15(5):e732‐8. ">Lanzós 2010</a>; <a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a>; <a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a>; <a href="./references#CD012744-bbs2-0030" title="PimentelMJ , FilhoMM , AraújoM , GomesDQ , DaCostaLJ . Evaluation of radioprotective effect of pilocarpine ingestion on salivary glands. Anticancer Research2014;34(4):1993‐9. ">Pimentel 2014</a>; <a href="./references#CD012744-bbs2-0032" title="RodeM , SmidL , BudihnaM , SobaE , RodeM , GaspersicD . The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics1999;45(2):373‐8. ">Rode 1999</a>; <a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a>; <a href="./references#CD012744-bbs2-0035" title="ValdezIH , WolffA , AtkinsonJC , MacynskiAA , FoxPC . Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer1993;71(5):1848‐51. WolffA , AtkinsonJC , MacynskiAA , FoxPC . Oral complications of cancer therapies. Pretherapy interventions to modify salivary dysfunction. NCI Monographs1990;(9):87‐90. ">Valdez 1993</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>). The remaining 23 did not describe any methods used to conceal the random sequence, and so were assessed as being at unclear risk of bias. </p> </section> </section> <section id="CD012744-sec-0089"> <h4 class="title">Blinding</h4> <section id="CD012744-sec-0090"> <h5 class="title">Blinding of participants and personnel (performance bias)</h5> <p>Twenty‐one studies were placebo‐controlled and double‐blind, and were assessed at low risk of performance bias. In the remaining 18 studies, blinding of the patients and their caregivers to the allocated treatment was not possible because the active and control treatments were administered differently, the control group had no intervention at all, or the personnel administering or patients were not blinded to the intervention (<a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a>; <a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a>; <a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a>; <a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a>; <a href="./references#CD012744-bbs2-0008" title="BuentzelJ , MickeO , GlatzelM , BrunsF , KistersK , MueckeR . Evaluation of the effect of selenium on radiation‐induced toxicities in head neck cancer patients. Journal of Clinical Oncology2009;27(15 Suppl):e20698. BüntzelJ , MickeO , GlatzelM , SchäferU , RiesenbeckD , KistersK , et al. Selenium substitution during radiotherapy in head and neck cancer. Trace Elements and Electrolytes2010;27:235‐9. BüntzelJ , RiesenbeckD , GlatzelM , Berndt‐SkorkaR , RiedelT , MückeR , et al. Limited effects of selenium substitution in the prevention of radiation‐associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Research2010;30(5):1829‐32. ">Büntzel 2010</a>; <a href="./references#CD012744-bbs2-0015" title="HaddadR , SonisS , PosnerM , WirthL , CostelloR , BraschaykoP , et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer2009;115(19):4514‐23. ">Haddad 2009</a>; <a href="./references#CD012744-bbs2-0016" title="HanF , ZhangJD , ShaoZY , LiuFJ . Effects of concurrent chemoradiotherapy combined with Jinlong capsules for patients with advanced nasopharyngeal squamous carcinoma. Chinese Journal of Cancer Prevention and Treatment2010;(2):138‐9. ">Han 2010</a>; <a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a>; <a href="./references#CD012744-bbs2-0019" title="HuYR , WuCQ , LiuYJ , WangY , LiX , ZhongH , et al. Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumour. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):623‐5. ">Hu 2005</a>; <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>; <a href="./references#CD012744-bbs2-0022" title="JhamBC , ChenH , CarvalhoAL , FreireAR . A randomized phase III prospective trial of bethanechol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis. Journal of Oral Science2009;51(4):565‐72. JhamBC , TeixeiraIV , AboudCG , CarvalhoAL , Coelho MdeM , FreireAR . A randomized phase III prospective trial of bethanechol to prevent radiotherapy‐induced salivary gland damage in patients with head and neck cancer. Oral Oncology2007;43(2):137‐42. ">Jham 2007</a>; <a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a>; <a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a>; <a href="./references#CD012744-bbs2-0032" title="RodeM , SmidL , BudihnaM , SobaE , RodeM , GaspersicD . The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics1999;45(2):373‐8. ">Rode 1999</a>; <a href="./references#CD012744-bbs2-0034" title="VachaP , FehlauerF , MahlmannB , MarxM , HinkeA , SommerK , et al. Randomized phase III trial of postoperative radiochemotherapy +/‐ amifostine in head and neck cancer. Is there evidence for radioprotection?. Strahlentherapie und Onkologie2003;179(6):385‐9. VachaP , MarxM , EngelA , RichterE , FeyerabendT . Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlentherapie und Onkologie1999;175 Suppl 4:18‐22. ">Vacha 2003</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>; <a href="./references#CD012744-bbs2-0039" title="WatanabeT , IshiharaM , MatsuuraK , MizutaK , ItohY . Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. International Journal of Cancer2010;127(8):1984‐90. ">Watanabe 2010</a>). </p> </section> <section id="CD012744-sec-0091"> <h5 class="title">Blinding of outcome assessment (detection bias)</h5> <p>Twenty‐one studies were assessing the effect of the intervention versus a placebo where the assessor was also blinded and these have been assessed as at low risk of bias. A further study which was not placebo‐controlled was assessed at low risk of bias because the outcome assessment for salivary gland dysfunction was objective (<a href="./references#CD012744-bbs2-0032" title="RodeM , SmidL , BudihnaM , SobaE , RodeM , GaspersicD . The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics1999;45(2):373‐8. ">Rode 1999</a>). The remaining 17 studies were assessed as being at high risk of detection bias, as the assessor was not blinded, the intervention was assessed against no intervention, the administration of the drug was different in the intervention and control groups or the assessment of xerostomia was subjective (<a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a>; <a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a>; <a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a>; <a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a>; <a href="./references#CD012744-bbs2-0008" title="BuentzelJ , MickeO , GlatzelM , BrunsF , KistersK , MueckeR . Evaluation of the effect of selenium on radiation‐induced toxicities in head neck cancer patients. Journal of Clinical Oncology2009;27(15 Suppl):e20698. BüntzelJ , MickeO , GlatzelM , SchäferU , RiesenbeckD , KistersK , et al. Selenium substitution during radiotherapy in head and neck cancer. Trace Elements and Electrolytes2010;27:235‐9. BüntzelJ , RiesenbeckD , GlatzelM , Berndt‐SkorkaR , RiedelT , MückeR , et al. Limited effects of selenium substitution in the prevention of radiation‐associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Research2010;30(5):1829‐32. ">Büntzel 2010</a>; <a href="./references#CD012744-bbs2-0015" title="HaddadR , SonisS , PosnerM , WirthL , CostelloR , BraschaykoP , et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer2009;115(19):4514‐23. ">Haddad 2009</a>; <a href="./references#CD012744-bbs2-0016" title="HanF , ZhangJD , ShaoZY , LiuFJ . Effects of concurrent chemoradiotherapy combined with Jinlong capsules for patients with advanced nasopharyngeal squamous carcinoma. Chinese Journal of Cancer Prevention and Treatment2010;(2):138‐9. ">Han 2010</a>; <a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a>; <a href="./references#CD012744-bbs2-0019" title="HuYR , WuCQ , LiuYJ , WangY , LiX , ZhongH , et al. Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumour. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):623‐5. ">Hu 2005</a>; <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>; <a href="./references#CD012744-bbs2-0022" title="JhamBC , ChenH , CarvalhoAL , FreireAR . A randomized phase III prospective trial of bethanechol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis. Journal of Oral Science2009;51(4):565‐72. JhamBC , TeixeiraIV , AboudCG , CarvalhoAL , Coelho MdeM , FreireAR . A randomized phase III prospective trial of bethanechol to prevent radiotherapy‐induced salivary gland damage in patients with head and neck cancer. Oral Oncology2007;43(2):137‐42. ">Jham 2007</a>; <a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a>; <a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a>; <a href="./references#CD012744-bbs2-0034" title="VachaP , FehlauerF , MahlmannB , MarxM , HinkeA , SommerK , et al. Randomized phase III trial of postoperative radiochemotherapy +/‐ amifostine in head and neck cancer. Is there evidence for radioprotection?. Strahlentherapie und Onkologie2003;179(6):385‐9. VachaP , MarxM , EngelA , RichterE , FeyerabendT . Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlentherapie und Onkologie1999;175 Suppl 4:18‐22. ">Vacha 2003</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>; <a href="./references#CD012744-bbs2-0039" title="WatanabeT , IshiharaM , MatsuuraK , MizutaK , ItohY . Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. International Journal of Cancer2010;127(8):1984‐90. ">Watanabe 2010</a>). </p> </section> </section> <section id="CD012744-sec-0092"> <h4 class="title">Incomplete outcome data</h4> <p>Twenty‐one studies had no or negligible attrition and were assessed as being low risk. Twelve studies were assessed to be at high risk of attrition bias, due to high dropout rates, no reasons given for dropouts or differential attrition between the groups, which could be linked to the intervention (<a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a>; <a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a>; <a href="./references#CD012744-bbs2-0009" title="BurlageFR , RoesinkJM , KampingaHH , CoppesRP , TerhaardC , LangendijkJA , et al. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double‐blind, randomized, placebo‐controlled study. International Journal of Radiation Oncology, Biology, Physics2008;70(1):14‐22. ">Burlage 2008</a>; <a href="./references#CD012744-bbs2-0013" title="GrötzKA , Henneicke‐Von ZepelinHH , KohnenR , KutznerJ , BelzGG . Prophylaxis of mucositis and dry mouth after head and neck radiotherapy. A new treatment. Krankenhauspharmazie2002;23(5):193‐8. GrötzKA , Henneicke‐von ZepelinHH , KohnenR , al‐NawasB , BockischA , KutznerJ , et al. Prospective double‐blind study of prophylaxis of radioxerostomia with Coumarin/Troxerutine in patients with head and neck cancer [Prospektive, doppelblinde Therapiestudie zur Prophylaxe der Radioxerostomie durch Cumarin/Troxerutin bei Patienten mit Kopf‐Hals‐Karzinomen]. Strahlentherapie und Onkologie1999;175(8):397‐404. GrötzKA , WüstenbergP , KohnenR , Al‐NawasB , Henneicke‐von ZepelinH , BockischA , et al. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer ‐ a prospective, randomized, placebo‐controlled, double‐blind study. British Journal of Oral and Maxillofacial Surgery2001;39(1):34‐9. ">Grötz 2001</a>; <a href="./references#CD012744-bbs2-0014" title="HaddadP , KarimiM . A randomised, double‐blind, placebo‐controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation‐induced xerostomia. Radiotherapy and Oncology2002;64(1):29‐32. ">Haddad 2002</a>; <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>; <a href="./references#CD012744-bbs2-0022" title="JhamBC , ChenH , CarvalhoAL , FreireAR . A randomized phase III prospective trial of bethanechol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis. Journal of Oral Science2009;51(4):565‐72. JhamBC , TeixeiraIV , AboudCG , CarvalhoAL , Coelho MdeM , FreireAR . A randomized phase III prospective trial of bethanechol to prevent radiotherapy‐induced salivary gland damage in patients with head and neck cancer. Oral Oncology2007;43(2):137‐42. ">Jham 2007</a>; <a href="./references#CD012744-bbs2-0024" title="LanzósI , HerreraD , SantosS , O'ConnorA , PeñaC , LanzósE , et al. Mucositis in irradiated cancer patients: effects of an antiseptic mouthrinse. Medicina Oral, Patología Oral y Cirugía Bucal2010;15(5):e732‐8. ">Lanzós 2010</a>; <a href="./references#CD012744-bbs2-0030" title="PimentelMJ , FilhoMM , AraújoM , GomesDQ , DaCostaLJ . Evaluation of radioprotective effect of pilocarpine ingestion on salivary glands. Anticancer Research2014;34(4):1993‐9. ">Pimentel 2014</a>; <a href="./references#CD012744-bbs2-0034" title="VachaP , FehlauerF , MahlmannB , MarxM , HinkeA , SommerK , et al. Randomized phase III trial of postoperative radiochemotherapy +/‐ amifostine in head and neck cancer. Is there evidence for radioprotection?. Strahlentherapie und Onkologie2003;179(6):385‐9. VachaP , MarxM , EngelA , RichterE , FeyerabendT . Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlentherapie und Onkologie1999;175 Suppl 4:18‐22. ">Vacha 2003</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>; <a href="./references#CD012744-bbs2-0038" title="WardeP , O'SullivanB , AslanidisJ , KrollB , LockwoodG , MathM , et al. A phase III placebo‐controlled trial of oral pilocarpine in patients undergoing radiotherapy for head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;54(1):9‐13. ">Warde 2002</a>). For the six remaining studies, there was insufficient information to determine risk of attrition bias (<a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a>; <a href="./references#CD012744-bbs2-0015" title="HaddadR , SonisS , PosnerM , WirthL , CostelloR , BraschaykoP , et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer2009;115(19):4514‐23. ">Haddad 2009</a>; <a href="./references#CD012744-bbs2-0023" title="LajtmanZ , KrajinaZ , KrpanD , VinceljJ , BorcicV , Popovic‐KovacicJ . Pilocarpine in the prevention of postirradiation xerostomia. Acta Medica Croatica2000;54(2):65‐7. ">Lajtman 2000</a>; <a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a>; <a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a>; <a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a>). </p> </section> <section id="CD012744-sec-0093"> <h4 class="title">Selective reporting</h4> <p>Nineteen of the included studies reported the outcomes specified in the methods section in full, including information about xerostomia and adverse effects (<a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a>; <a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a>; <a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a>; <a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a>; <a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>; <a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a>; <a href="./references#CD012744-bbs2-0014" title="HaddadP , KarimiM . A randomised, double‐blind, placebo‐controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation‐induced xerostomia. Radiotherapy and Oncology2002;64(1):29‐32. ">Haddad 2002</a>; <a href="./references#CD012744-bbs2-0016" title="HanF , ZhangJD , ShaoZY , LiuFJ . Effects of concurrent chemoradiotherapy combined with Jinlong capsules for patients with advanced nasopharyngeal squamous carcinoma. Chinese Journal of Cancer Prevention and Treatment2010;(2):138‐9. ">Han 2010</a>; <a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a>; <a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a>; <a href="./references#CD012744-bbs2-0019" title="HuYR , WuCQ , LiuYJ , WangY , LiX , ZhongH , et al. Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumour. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):623‐5. ">Hu 2005</a>; <a href="./references#CD012744-bbs2-0020" title="JaguarGC . A Prospective Study of Bethanechol in the Salivary Glands Physiology in Patients Following Head and Neck Radiotherapy [Estudo Prospectivo do Uso do Betanecol na Fisiologia de Glândulas Salivares em Pacientes Irradiados em Região de Cabeça e Pescoço] [Dissertation]. Sao Paulo (Brazil): Fundaçao Antonio Prudente, 2010. JaguarGC , CamposL , PellizzonAC , LimaEN , KowalskiLP , AlvesFA . Double‐blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in cancer patients. Supportive Care in Cancer2012;20(1 Suppl):S252. JaguarGC , LimaEN , KowalskiLP , PellizzonAC , CarvalhoAL , BoccalettiKW , et al. Double blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in head and neck cancer patients. Radiotherapy and Oncology2015;115(2):253‐6. ">Jaguar 2015</a>; <a href="./references#CD012744-bbs2-0022" title="JhamBC , ChenH , CarvalhoAL , FreireAR . A randomized phase III prospective trial of bethanechol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis. Journal of Oral Science2009;51(4):565‐72. JhamBC , TeixeiraIV , AboudCG , CarvalhoAL , Coelho MdeM , FreireAR . A randomized phase III prospective trial of bethanechol to prevent radiotherapy‐induced salivary gland damage in patients with head and neck cancer. Oral Oncology2007;43(2):137‐42. ">Jham 2007</a>; <a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a>; <a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin 2014</a>; <a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>; <a href="./references#CD012744-bbs2-0038" title="WardeP , O'SullivanB , AslanidisJ , KrollB , LockwoodG , MathM , et al. A phase III placebo‐controlled trial of oral pilocarpine in patients undergoing radiotherapy for head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;54(1):9‐13. ">Warde 2002</a>). One study was assessed to be at unclear risk of reporting bias (<a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a>). The remaining 19 studies were assessed as at high risk of reporting bias as they did not report on adverse effects or xerostomia, did not report on all outcomes, only significant data were reported or data on individuals were not reported, and grouped data did not have the standard deviations. </p> </section> <section id="CD012744-sec-0094"> <h4 class="title">Other potential sources of bias</h4> <p>We did not consider there to be any other issues arising from other potential sources in any of the studies and we therefore assessed them all as being at low risk of bias for this domain. </p> <section id="CD012744-sec-0095"> <h5 class="title">Overall risk of bias</h5> <p>Overall, three of the included studies (8%) were assessed as at low risk of bias for all domains (<a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>; <a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a>; <a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a>), and four studies (10%) were assessed as being at unclear risk of bias for at least one domain (<a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a>; <a href="./references#CD012744-bbs2-0020" title="JaguarGC . A Prospective Study of Bethanechol in the Salivary Glands Physiology in Patients Following Head and Neck Radiotherapy [Estudo Prospectivo do Uso do Betanecol na Fisiologia de Glândulas Salivares em Pacientes Irradiados em Região de Cabeça e Pescoço] [Dissertation]. Sao Paulo (Brazil): Fundaçao Antonio Prudente, 2010. JaguarGC , CamposL , PellizzonAC , LimaEN , KowalskiLP , AlvesFA . Double‐blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in cancer patients. Supportive Care in Cancer2012;20(1 Suppl):S252. JaguarGC , LimaEN , KowalskiLP , PellizzonAC , CarvalhoAL , BoccalettiKW , et al. Double blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in head and neck cancer patients. Radiotherapy and Oncology2015;115(2):253‐6. ">Jaguar 2015</a>; <a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin 2014</a>; <a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a>). The remaining 32 studies (82%) were at high risk of bias for at least one domain. Risk of bias can be viewed graphically in <a href="#CD012744-fig-0002">Figure 2</a> and <a href="#CD012744-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012744-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012744-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD012744-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012744-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> </section> </section> </section> <section id="CD012744-sec-0096"> <h3 class="title" id="CD012744-sec-0096">Effects of interventions</h3> <p>See: <a href="./full#CD012744-tbl-0001"><b>Summary of findings for the main comparison</b> Pilocarpine compared to no treatment/placebo for preventing salivary gland dysfunction following radiotherapy</a>; <a href="./full#CD012744-tbl-0002"><b>Summary of findings 2</b> Amifostine compared to no treatment/placebo for preventing salivary gland dysfunction following radiotherapy</a>; <a href="./full#CD012744-tbl-0003"><b>Summary of findings 3</b> Palifermin compared to placebo for preventing salivary gland dysfunction following radiotherapy</a> </p> <section id="CD012744-sec-0097"> <h4 class="title">Pilocarpine versus no treatment/placebo</h4> <p>Pilocarpine hydrochloride, at various dosages, was assessed in 12 trials: <a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a>; <a href="./references#CD012744-bbs2-0009" title="BurlageFR , RoesinkJM , KampingaHH , CoppesRP , TerhaardC , LangendijkJA , et al. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double‐blind, randomized, placebo‐controlled study. International Journal of Radiation Oncology, Biology, Physics2008;70(1):14‐22. ">Burlage 2008</a>; <a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a>; <a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a>; <a href="./references#CD012744-bbs2-0014" title="HaddadP , KarimiM . A randomised, double‐blind, placebo‐controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation‐induced xerostomia. Radiotherapy and Oncology2002;64(1):29‐32. ">Haddad 2002</a>; <a href="./references#CD012744-bbs2-0023" title="LajtmanZ , KrajinaZ , KrpanD , VinceljJ , BorcicV , Popovic‐KovacicJ . Pilocarpine in the prevention of postirradiation xerostomia. Acta Medica Croatica2000;54(2):65‐7. ">Lajtman 2000</a>; <a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a>; <a href="./references#CD012744-bbs2-0030" title="PimentelMJ , FilhoMM , AraújoM , GomesDQ , DaCostaLJ . Evaluation of radioprotective effect of pilocarpine ingestion on salivary glands. Anticancer Research2014;34(4):1993‐9. ">Pimentel 2014</a>; <a href="./references#CD012744-bbs2-0032" title="RodeM , SmidL , BudihnaM , SobaE , RodeM , GaspersicD . The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics1999;45(2):373‐8. ">Rode 1999</a>; <a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a>; <a href="./references#CD012744-bbs2-0035" title="ValdezIH , WolffA , AtkinsonJC , MacynskiAA , FoxPC . Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer1993;71(5):1848‐51. WolffA , AtkinsonJC , MacynskiAA , FoxPC . Oral complications of cancer therapies. Pretherapy interventions to modify salivary dysfunction. NCI Monographs1990;(9):87‐90. ">Valdez 1993</a>; <a href="./references#CD012744-bbs2-0038" title="WardeP , O'SullivanB , AslanidisJ , KrollB , LockwoodG , MathM , et al. A phase III placebo‐controlled trial of oral pilocarpine in patients undergoing radiotherapy for head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;54(1):9‐13. ">Warde 2002</a>. Over 900 participants were randomised to either pilocarpine or no treatment/placebo; 698 were evaluated (although number varied by outcome/timing of assessment). Eleven of the trials were judged to be at high risk of bias; one was at unclear risk (<a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a>). </p> <section id="CD012744-sec-0098"> <h5 class="title">Xerostomia</h5> <p>Nine trials evaluated xerostomia, however, the method of assessment varied across studies. </p> <p>Seven trials presented continuous data on xerostomia obtained by simple VAS or a composite based on a number of xerostomia‐focused questions (<a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a>; <a href="./references#CD012744-bbs2-0009" title="BurlageFR , RoesinkJM , KampingaHH , CoppesRP , TerhaardC , LangendijkJA , et al. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double‐blind, randomized, placebo‐controlled study. International Journal of Radiation Oncology, Biology, Physics2008;70(1):14‐22. ">Burlage 2008</a>; <a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a>; <a href="./references#CD012744-bbs2-0014" title="HaddadP , KarimiM . A randomised, double‐blind, placebo‐controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation‐induced xerostomia. Radiotherapy and Oncology2002;64(1):29‐32. ">Haddad 2002</a>; <a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a>; <a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a>; <a href="./references#CD012744-bbs2-0038" title="WardeP , O'SullivanB , AslanidisJ , KrollB , LockwoodG , MathM , et al. A phase III placebo‐controlled trial of oral pilocarpine in patients undergoing radiotherapy for head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;54(1):9‐13. ">Warde 2002</a>). The trial by <a href="./references#CD012744-bbs2-0009" title="BurlageFR , RoesinkJM , KampingaHH , CoppesRP , TerhaardC , LangendijkJA , et al. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double‐blind, randomized, placebo‐controlled study. International Journal of Radiation Oncology, Biology, Physics2008;70(1):14‐22. ">Burlage 2008</a> was unable to be included in any statistical pooling as data were presented by Gy dose, but the number receiving each dose is unclear. There was no evidence of a difference between treatment groups at end of radiotherapy (standardised mean difference (SMD) 0.20, 95% confidence interval (CI) ‐0.16 to 0.56; P = 0.27; 122 participants), up to three months postradiotherapy (SMD 0.02, 95% CI ‐0.33 to 0.37; P = 0.92; 125 participants), or up to six months postradiotherapy (SMD ‐0.35, 95% CI ‐1.04 to 0.33; P = 0.31; 126 participants) (<a href="./references#CD012744-fig-0004" title="">Analysis 1.1</a>). There was substantial statistical heterogeneity present for the six‐month data (I<sup>2</sup> = 68%, P = 0.08). </p> <p>One trial used the LENT‐SOMA scale to provide an objective assessment of xerostomia (<a href="./references#CD012744-bbs2-0014" title="HaddadP , KarimiM . A randomised, double‐blind, placebo‐controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation‐induced xerostomia. Radiotherapy and Oncology2002;64(1):29‐32. ">Haddad 2002</a>). This single trial showed a statistically significant difference in favour of pilocarpine (mean difference (MD) ‐0.40, 95% CI ‐0.69 to ‐0.11; P = 0.006; 39 participants) at six months postradiotherapy (<a href="./references#CD012744-fig-0005" title="">Analysis 1.2</a>). </p> <p>Two trials presented binary data on the number of participants with/without xerostomia (<a href="./references#CD012744-bbs2-0023" title="LajtmanZ , KrajinaZ , KrpanD , VinceljJ , BorcicV , Popovic‐KovacicJ . Pilocarpine in the prevention of postirradiation xerostomia. Acta Medica Croatica2000;54(2):65‐7. ">Lajtman 2000</a>; <a href="./references#CD012744-bbs2-0030" title="PimentelMJ , FilhoMM , AraújoM , GomesDQ , DaCostaLJ . Evaluation of radioprotective effect of pilocarpine ingestion on salivary glands. Anticancer Research2014;34(4):1993‐9. ">Pimentel 2014</a>). There was no evidence of a difference between treatment groups at the end of radiotherapy (risk ratio (RR) 0.60, 95% CI 0.18 to 2.02; P = 0.41; 11 participants) or at three months postradiotherapy (RR 1.00, 95% CI 0.92 to 1.08; P = 1.00; 48 participants) (<a href="./references#CD012744-fig-0006" title="">Analysis 1.3</a>). </p> </section> <section id="CD012744-sec-0099"> <h5 class="title">Salivary flow rates</h5> <p>Eight studies presented continuous data for either stimulated or unstimulated salivary flow (e.g. ml/min or g) (<a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a>; <a href="./references#CD012744-bbs2-0009" title="BurlageFR , RoesinkJM , KampingaHH , CoppesRP , TerhaardC , LangendijkJA , et al. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double‐blind, randomized, placebo‐controlled study. International Journal of Radiation Oncology, Biology, Physics2008;70(1):14‐22. ">Burlage 2008</a>; <a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a>; <a href="./references#CD012744-bbs2-0023" title="LajtmanZ , KrajinaZ , KrpanD , VinceljJ , BorcicV , Popovic‐KovacicJ . Pilocarpine in the prevention of postirradiation xerostomia. Acta Medica Croatica2000;54(2):65‐7. ">Lajtman 2000</a>; <a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a>; <a href="./references#CD012744-bbs2-0030" title="PimentelMJ , FilhoMM , AraújoM , GomesDQ , DaCostaLJ . Evaluation of radioprotective effect of pilocarpine ingestion on salivary glands. Anticancer Research2014;34(4):1993‐9. ">Pimentel 2014</a>; <a href="./references#CD012744-bbs2-0032" title="RodeM , SmidL , BudihnaM , SobaE , RodeM , GaspersicD . The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics1999;45(2):373‐8. ">Rode 1999</a>; <a href="./references#CD012744-bbs2-0035" title="ValdezIH , WolffA , AtkinsonJC , MacynskiAA , FoxPC . Use of pilocarpine during head and neck radiation therapy to reduce xerostomia and salivary dysfunction. Cancer1993;71(5):1848‐51. WolffA , AtkinsonJC , MacynskiAA , FoxPC . Oral complications of cancer therapies. Pretherapy interventions to modify salivary dysfunction. NCI Monographs1990;(9):87‐90. ">Valdez 1993</a>). The studies by <a href="./references#CD012744-bbs2-0009" title="BurlageFR , RoesinkJM , KampingaHH , CoppesRP , TerhaardC , LangendijkJA , et al. Protection of salivary function by concomitant pilocarpine during radiotherapy: a double‐blind, randomized, placebo‐controlled study. International Journal of Radiation Oncology, Biology, Physics2008;70(1):14‐22. ">Burlage 2008</a>; <a href="./references#CD012744-bbs2-0023" title="LajtmanZ , KrajinaZ , KrpanD , VinceljJ , BorcicV , Popovic‐KovacicJ . Pilocarpine in the prevention of postirradiation xerostomia. Acta Medica Croatica2000;54(2):65‐7. ">Lajtman 2000</a>; <a href="./references#CD012744-bbs2-0030" title="PimentelMJ , FilhoMM , AraújoM , GomesDQ , DaCostaLJ . Evaluation of radioprotective effect of pilocarpine ingestion on salivary glands. Anticancer Research2014;34(4):1993‐9. ">Pimentel 2014</a> and <a href="./references#CD012744-bbs2-0032" title="RodeM , SmidL , BudihnaM , SobaE , RodeM , GaspersicD . The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics1999;45(2):373‐8. ">Rode 1999</a> were unable to be included in any statistical pooling due to insufficient reporting of data. There was no evidence of a difference between treatment groups for unstimulated or stimulated flow rates at any time point (<a href="./references#CD012744-fig-0007" title="">Analysis 1.4</a>; <a href="./references#CD012744-fig-0008" title="">Analysis 1.5</a>). </p> <p>One study presented binary data on whether stimulated or unstimulated salivary flow was &gt; 0 g (<a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a>). There is insufficient evidence to determine whether pilocarpine is beneficial for this outcome at any time point (<a href="./references#CD012744-fig-0009" title="">Analysis 1.6</a>; <a href="./references#CD012744-fig-0010" title="">Analysis 1.7</a>). </p> </section> <section id="CD012744-sec-0100"> <h5 class="title">Survival</h5> <p>Only one trial reported on overall survival within the trial period (six months) (<a href="./references#CD012744-bbs2-0014" title="HaddadP , KarimiM . A randomised, double‐blind, placebo‐controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation‐induced xerostomia. Radiotherapy and Oncology2002;64(1):29‐32. ">Haddad 2002</a>). There was no evidence of a difference between treatment groups (RR 1.07, 95% CI 0.80 to 1.43; P = 0.66; 60 participants) (<a href="./references#CD012744-fig-0011" title="">Analysis 1.8</a>). </p> </section> <section id="CD012744-sec-0101"> <h5 class="title">Quality of life and other oral related symptoms</h5> <p>There was insufficient evidence to determine whether or not pilocarpine improved quality of life measurements for global quality of life, quality of life (HNRQ), oral discomfort, eating difficulties and sleeping problems at the end of radiotherapy (<a href="./references#CD012744-fig-0012" title="">Analysis 1.9</a>; Additional <a href="#CD012744-tbl-0004">Table 1</a>). One trial (<a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a>) found an increased risk in speech difficulties at the end of radiotherapy in the pilocarpine group (MD 20.20, 95% CI 1.93 to 38.47; P = 0.03; 34 participants) when assessed using a VAS scale (0 to 100 mm) (Additional <a href="#CD012744-tbl-0004">Table 1</a>). </p> <div class="table" id="CD012744-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Pilocarpine versus no treatment/placebo (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pilocarpine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral related symptoms (other than salivary gland dysfunction/xerostomia)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 38.7 (SD 31.6)</p> <p>n = 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 56.7 (SD 26.7)</p> <p>n = 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference ‐18.00 (95% CI ‐37.41 to 1.41), P = 0.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Speech difficulties</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 57.5 (SD 26.8)</p> <p>n = 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 37.3 (SD 27.5)</p> <p>n = 18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference 20.20 (95% CI 1.93 to 38.47), P = 0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eating difficulties</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 47.4 (SD 33.9)</p> <p>n = 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 61.8 (SD 25.4)</p> <p>n = 17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference ‐14.40 (95% CI ‐35.38 to 6.58), P = 0.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mucosal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 38.8 (SD 33.9)</p> <p>n = 17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 53.6 (SD 34.2)</p> <p>n = 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference ‐14.80 (95% CI ‐37.07 to 7.47), P = 0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0030" title="PimentelMJ , FilhoMM , AraújoM , GomesDQ , DaCostaLJ . Evaluation of radioprotective effect of pilocarpine ingestion on salivary glands. Anticancer Research2014;34(4):1993‐9. ">Pimentel 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.30 (95% CI 0.05 to 1.89), P = 0.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Sweating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Random‐effects meta‐analysis of 5 studies: RR 2.98 (95% CI 1.43 to 6.22), P = 0.004</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.52 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chilling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.00 (95% CI 0.13 to 67.06), P = 0.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Random‐effects meta‐analysis of 3 studies: RR 1.39 (95% CI 0.63 to 3.05), P = 0.41</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.93 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0014" title="HaddadP , KarimiM . A randomised, double‐blind, placebo‐controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation‐induced xerostomia. Radiotherapy and Oncology2002;64(1):29‐32. ">Haddad 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Random‐effects meta‐analysis of 3 studies: RR 1.28 (95% CI 0.70 to 2.35), P = 0.43</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.92 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.67 (95% CI 0.12 to 3.69), P = 0.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Excessive lacrimation (tears)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Random‐effects meta‐analysis of 3 studies: RR 2.54 (95% CI 0.70 to 9.17), P = 0.15</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.71 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0014" title="HaddadP , KarimiM . A randomised, double‐blind, placebo‐controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation‐induced xerostomia. Radiotherapy and Oncology2002;64(1):29‐32. ">Haddad 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dysphasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.50 (95% CI 0.30 to 7.43), P = 0.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weakness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.45 (95% CI 0.25 to 8.51), P = 0.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Nervous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Random‐effects meta‐analysis of 2 studies: RR 1.02 (95% CI 0.11 to 9.33), P = 0.99</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.33 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Random‐effects meta‐analysis of 3 studies: RR 0.87 (95% CI 0.41 to 1.86), P = 0.72</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.53 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.00 (95% CI 0.13 to 67.06), P = 0.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Urinary frequency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Random‐effects meta‐analysis of 2 studies: RR 0.87 (95% CI 0.43 to 1.75), P = 0.70</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.32 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Random‐effects meta‐analysis of 2 studies: RR 0.80 (95% CI 0.18 to 3.45), P = 0.76</p> <p>Heterogeneity: I<sup>2</sup> = 13%, P = 0.28 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Palpitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.10 (95% CI 0.01 to 1.73), P = 0.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.90 (95% CI 0.12 to 70.44), P = 0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Motor tremors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.93 (95% CI 0.18 to 21.02), P = 0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 37.3 (SD 36.4)</p> <p>n = 17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 49.6 (SD 36.9)</p> <p>n = 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference ‐12.30 (95% CI ‐36.27 to 11.67), P = 0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RTOG (grade 3; mucous membrane, pharynx and larynx)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0038" title="WardeP , O'SullivanB , AslanidisJ , KrollB , LockwoodG , MathM , et al. A phase III placebo‐controlled trial of oral pilocarpine in patients undergoing radiotherapy for head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;54(1):9‐13. ">Warde 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistically significant difference between treatment groups</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI = confidence interval; RR = risk ratio; RTOG = Radiation Therapy Oncology Group; SD = standard deviation. </p> </div> </div> <p>There was insufficient evidence from one study (<a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a>) to determine whether or not pilocarpine improved oral mucosal pain at the end of radiotherapy (MD ‐14.80, 95% CI ‐37.07 to 7.47; P = 0.19; 36 participants) (Additional <a href="#CD012744-tbl-0004">Table 1</a>). The effect of pilocarpine on the treatment and prevention of mucositis has been assessed in more detail in separate Cochrane Reviews (<a href="./references#CD012744-bbs2-0093" title="ClarksonJE , WorthingtonHV , FurnessS , McCabeM , KhalidT , MeyerS . Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews2010, Issue 8. [DOI: 10.1002/14651858.CD001973.pub4] ">Clarkson 2010</a>; <a href="./references#CD012744-bbs2-0113" title="WorthingtonHV , ClarksonJE , BryanG , FurnessS , GlennyA‐M , LittlewoodA , et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews2011, Issue 4. [DOI: 10.1002/14651858.CD000978.pub5] ">Worthington 2011</a>). </p> </section> <section id="CD012744-sec-0102"> <h5 class="title">Side effects</h5> <p>No evidence of a difference was found between treatment groups for any reported adverse event, apart from for sweating where data from five studies showed an increased risk associated with pilocarpine (RR 2.98, 95% CI 1.43 to 6.22; P = 0.004; 389 participants) (Additional <a href="#CD012744-tbl-0004">Table 1</a>). There was no observed statistical heterogeneity (I<sup>2</sup> = 0%, P = 0.52). </p> </section> <section id="CD012744-sec-0103"> <h5 class="title">Cost</h5> <p>None of the included studies evaluating the effectiveness of pilocarpine reported cost data. </p> </section> </section> <section id="CD012744-sec-0104"> <h4 class="title">Biperiden plus pilocarpine versus no treatment</h4> <p>One trial, assessed at high risk of bias, compared biperiden and pilocarpine with no treatment (<a href="./references#CD012744-bbs2-0032" title="RodeM , SmidL , BudihnaM , SobaE , RodeM , GaspersicD . The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics1999;45(2):373‐8. ">Rode 1999</a>). </p> <section id="CD012744-sec-0105"> <h5 class="title">Xerostomia</h5> <p>No xerostomia data related to the effectiveness of biperiden and pilocarpine were reported. </p> </section> <section id="CD012744-sec-0106"> <h5 class="title">Salivary flow rates</h5> <p>There was insufficient evidence, from a single trial of 60 participants (<a href="./references#CD012744-bbs2-0032" title="RodeM , SmidL , BudihnaM , SobaE , RodeM , GaspersicD . The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics1999;45(2):373‐8. ">Rode 1999</a>), to determine whether or not biperiden and pilocarpine reduced the unstimulated salivary flow rate between patients at the end of radiotherapy (<a href="./references#CD012744-fig-0013" title="">Analysis 2.1</a>). </p> </section> <section id="CD012744-sec-0107"> <h5 class="title">Survival</h5> <p>Not reported.</p> </section> <section id="CD012744-sec-0108"> <h5 class="title">Quality of life and other oral related symptoms</h5> <p>There was insufficient evidence to determine whether or not biperiden and pilocarpine reduces the risk of WHO grade 3+ dysphagia up to one year after radiotherapy (Additional <a href="#CD012744-tbl-0005">Table 2</a>). No further data on quality of life or other oral related symptoms were reported. </p> <div class="table" id="CD012744-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Biperiden plus pilocarpine versus no treatment/placebo (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pilocarpine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dysphagia (WHO grade 3+)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0032" title="RodeM , SmidL , BudihnaM , SobaE , RodeM , GaspersicD . The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics1999;45(2):373‐8. ">Rode 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.25 (95% CI 0.03 to 2.11), P = 0.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI = confidence interval; RR = risk ratio; RT = radiotherapy; WHO = World Health Organization.</p> </div> </div> </section> <section id="CD012744-sec-0109"> <h5 class="title">Side effects</h5> <p>No data were reported on side effects.</p> </section> <section id="CD012744-sec-0110"> <h5 class="title">Cost</h5> <p>No cost data related to the effectiveness of biperiden and pilocarpine were reported.</p> </section> </section> <section id="CD012744-sec-0111"> <h4 class="title">Amifostine versus no treatment/placebo</h4> <p>Eleven trials, one at low risk of bias (<a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>) and ten at high risk of bias (<a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a>; <a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a>; <a href="./references#CD012744-bbs2-0015" title="HaddadR , SonisS , PosnerM , WirthL , CostelloR , BraschaykoP , et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer2009;115(19):4514‐23. ">Haddad 2009</a>; <a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a>; <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>; <a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a>; <a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a>; <a href="./references#CD012744-bbs2-0034" title="VachaP , FehlauerF , MahlmannB , MarxM , HinkeA , SommerK , et al. Randomized phase III trial of postoperative radiochemotherapy +/‐ amifostine in head and neck cancer. Is there evidence for radioprotection?. Strahlentherapie und Onkologie2003;179(6):385‐9. VachaP , MarxM , EngelA , RichterE , FeyerabendT . Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlentherapie und Onkologie1999;175 Suppl 4:18‐22. ">Vacha 2003</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>), randomised 1036 participants (887 analysed, although the number varied by outcome/timing of assessment) to amifostine or no treatment group/placebo. The trial by <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a> had three comparison groups: two different doses of amifostine and a 'no treatment' group. For the purpose of this comparison, the two amifostine groups were combined. </p> <section id="CD012744-sec-0112"> <h5 class="title">Xerostomia</h5> <p>Three studies (<a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a>; <a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>) were combined in a meta‐analysis showing that amifostine reduced the risk of developing grade ≥ 2 xerostomia (on a 0 to 4 scale) at the end of radiotherapy (RR 0.35, 95% CI 0.19 to 0.67; P = 0.001; 119 participants) (<a href="./references#CD012744-fig-0015" title="">Analysis 3.1</a>). </p> <p>Up to and including three months postradiotherapy, a smaller effect was observed in favour of amifostine in a meta‐analysis of five studies (<a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a>; <a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>; <a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>) (RR 0.66, 95% CI 0.48 to 0.92; P = 0.01; 687 participants) (<a href="./references#CD012744-fig-0015" title="">Analysis 3.1</a>). However, there was substantial heterogeneity present (I<sup>2</sup> = 63%). </p> <p>At 12 months postradiotherapy, there was insufficient evidence of a difference in the risk of grade ≥ 2 xerostomia (RR 0.70, 95% CI 0.40 to 1.23; P = 0.21; 682 participants analysed) (<a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a>; <a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>; <a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a>; <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>; <a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>) (<a href="./references#CD012744-fig-0015" title="">Analysis 3.1</a>). There was considerable heterogeneity present (I<sup>2</sup> = 83%). </p> <p>Three further studies had no usable data: one failed to report the data by study group and reported that "For the end point xerostomia we are not able to demonstrate that amifostine had a positive effect, and there was no difference detected between the arms in terms of xerostomia, with 41% of patients reporting xerostomia of grade ≥ 2" (<a href="./references#CD012744-bbs2-0015" title="HaddadR , SonisS , PosnerM , WirthL , CostelloR , BraschaykoP , et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer2009;115(19):4514‐23. ">Haddad 2009</a>); one failed to report the timing of assessment (<a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a>); and one only reported xerostomia during radiotherapy (i.e. not at any of the time points we were interested in) (<a href="./references#CD012744-bbs2-0034" title="VachaP , FehlauerF , MahlmannB , MarxM , HinkeA , SommerK , et al. Randomized phase III trial of postoperative radiochemotherapy +/‐ amifostine in head and neck cancer. Is there evidence for radioprotection?. Strahlentherapie und Onkologie2003;179(6):385‐9. VachaP , MarxM , EngelA , RichterE , FeyerabendT . Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlentherapie und Onkologie1999;175 Suppl 4:18‐22. ">Vacha 2003</a>). </p> </section> <section id="CD012744-sec-0113"> <h5 class="title">Salivary flow rates</h5> <section id="CD012744-sec-0114"> <h6 class="title">Unstimulated</h6> <p>There was inconsistent evidence regarding the effect of amifostine of unstimulated salivary flow rate. A greater salivary flow rate for those receiving amifostine was shown at the end of radiotherapy (MD 0.34, 95% CI 0.07 to 0.61; P = 0.01; 83 participants) (<a href="./references#CD012744-fig-0016" title="">Analysis 3.2</a>). </p> <p>There was insufficient evidence of a difference from one study (<a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>) up to and including three months postradiotherapy (MD 0.13, 95% CI ‐0.90 to 1.16; P = 0.8; 41 participants), but the same study showed a slight benefit in favour of amifostine at 12 months postradiotherapy (MD 0.32, 95% CI 0.09 to 0.55; P = 0.006; 27 participants) (<a href="./references#CD012744-fig-0016" title="">Analysis 3.2</a>). A further study (<a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>) showed a benefit at 12 months postradiotherapy in favour of amifostine when looking at incidence of producing &gt; 0.1 g of saliva over 5 minutes (RR 1.45, 95% CI 1.13 to 1.86; P = 0.004; 175 participants) (<a href="./references#CD012744-fig-0017" title="">Analysis 3.3</a>). </p> <p><a href="./references#CD012744-bbs2-0015" title="HaddadR , SonisS , PosnerM , WirthL , CostelloR , BraschaykoP , et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer2009;115(19):4514‐23. ">Haddad 2009</a> failed to report the salivary flow data by study group and simply reported that "No difference was observed between the 2 treatment arms." </p> </section> <section id="CD012744-sec-0115"> <h6 class="title">Stimulated</h6> <p>There was insufficient evidence of a difference from one study (<a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>) at the end of radiotherapy (MD ‐0.09, 95% CI ‐1.48 to 1.30; P = 0.90; 47 participants), up to and including three months postradiotherapy (MD 0.38, 95% CI ‐1.43 to 2.19; P = 0.68; 41 participants), or 12 months postradiotherapy (MD 0.82, 95% CI ‐0.47 to 2.11; P = 0.21; 27 participants) (<a href="./references#CD012744-fig-0018" title="">Analysis 3.4</a>). There was also insufficient evidence of a difference from one study (<a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>), analysing 173 participants, when looking at incidence of producing &gt; 0.1 g of saliva over 5 minutes at 12 months postradiotherapy (RR 1.12, 95% CI 0.89 to 1.41; P = 0.32) (<a href="./references#CD012744-fig-0019" title="">Analysis 3.5</a>). </p> <p><a href="./references#CD012744-bbs2-0015" title="HaddadR , SonisS , PosnerM , WirthL , CostelloR , BraschaykoP , et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer2009;115(19):4514‐23. ">Haddad 2009</a> failed to report the salivary flow data by study group and simply reported that "No difference was observed between the 2 treatment arms." </p> </section> </section> <section id="CD012744-sec-0116"> <h5 class="title">Survival</h5> <p>There was insufficient evidence to determine whether or not amifostine reduces overall survival, progression‐free survival, disease‐free survival or locoregional tumour control up to 24 months postradiotherapy. </p> <section id="CD012744-sec-0117"> <h6 class="title">Overall survival</h6> <p>There was insufficient evidence from a meta‐analysis of two studies (<a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>) to determine whether or not amifostine reduces overall survival at 12 to 24 months postradiotherapy (hazard ratio (HR) 1.18, 95% CI 0.85 to 1.66; P = 0.33; 271 participants) (<a href="./references#CD012744-fig-0020" title="">Analysis 3.6</a>). Two further studies found no difference in overall survival at two years or more postradiotherapy (<a href="./references#CD012744-bbs2-0015" title="HaddadR , SonisS , PosnerM , WirthL , CostelloR , BraschaykoP , et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer2009;115(19):4514‐23. ">Haddad 2009</a>; <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>) (<a href="./references#CD012744-fig-0021" title="">Analysis 3.7</a>). </p> </section> <section id="CD012744-sec-0118"> <h6 class="title">Progression‐free survival</h6> <p>There was insufficient evidence from a meta‐analysis of two studies (<a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>) to determine whether or not amifostine reduces progression‐free survival at 12 to 24 months postradiotherapy (HR 0.94, 95% CI 0.70 to 1.27; P = 0.70; 247 participants) (<a href="./references#CD012744-fig-0022" title="">Analysis 3.8</a>). A further study (<a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a>) found no difference at 18 months postradiotherapy (RR 1.11, 95% CI 0.81 to 1.51; P = 0.52; 45 participants) (<a href="./references#CD012744-fig-0023" title="">Analysis 3.9</a>). This was supported by <a href="./references#CD012744-bbs2-0015" title="HaddadR , SonisS , PosnerM , WirthL , CostelloR , BraschaykoP , et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer2009;115(19):4514‐23. ">Haddad 2009</a> who reported "no differences noted" (<a href="./references#CD012744-fig-0024" title="">Analysis 3.10</a>). </p> </section> <section id="CD012744-sec-0119"> <h6 class="title">Locoregional tumour control</h6> <p>There was insufficient evidence from a meta‐analysis of two studies (<a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>) to determine whether or not amifostine reduces locoregional tumour control at 12 to 24 months postradiotherapy (HR 0.90, 95% CI 0.74 to 1.11; P = 0.33; 279 participants) (<a href="./references#CD012744-fig-0025" title="">Analysis 3.11</a>). Three further studies reported narrative evidence to support this result (<a href="./references#CD012744-bbs2-0015" title="HaddadR , SonisS , PosnerM , WirthL , CostelloR , BraschaykoP , et al. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Cancer2009;115(19):4514‐23. ">Haddad 2009</a>; <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>; <a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a>) (<a href="./references#CD012744-fig-0026" title="">Analysis 3.12</a>). </p> </section> <section id="CD012744-sec-0120"> <h6 class="title">Disease‐free survival</h6> <p>There was insufficient evidence from one study (<a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a>) to determine whether or not amifostine reduces disease‐free survival at 24 months postradiotherapy (RR 0.94, 95% CI 0.73 to 1.21; P = 0.64; 170 participants) (<a href="./references#CD012744-fig-0027" title="">Analysis 3.13</a>). Two studies reported narrative evidence to support this result (<a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>) (<a href="./references#CD012744-fig-0028" title="">Analysis 3.14</a>). </p> </section> </section> <section id="CD012744-sec-0121"> <h5 class="title">Quality of life and other oral related symptoms</h5> <p>There was insufficient evidence of a difference in quality of life from one study (<a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>), both at the end of radiotherapy (MD 0.38, 95% CI ‐0.07 to 0.83; P = 0.1; 298 participants), and up to and including three months postradiotherapy (MD 0.52, 95% CI ‐0.02 to 1.06; P = 0.06; 233 participants). The same study showed a benefit in favour of amifostine at 12 months postradiotherapy (MD 0.70, 95% CI 0.20 to 1.20; P = 0.006; 180 participants) (<a href="./references#CD012744-fig-0029" title="">Analysis 3.15</a>). A further study reported no differences in quality of life but did not present data (<a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>) (Additional <a href="#CD012744-tbl-0006">Table 3</a>). </p> <div class="table" id="CD012744-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Amifostine versus no treatment/placebo (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Amifostine</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assessed at end of RT and 6, 12, 18 and 24 months after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No significant differences between the 3 treatment arms"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Dysphagia (difficulty in swallowing) (0‐4 scale): grade 3 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Random‐effects meta‐analysis of 2 studies: RR 0.50 (95% CI 0.17 to 1.48); P = 0.21</p> <p>Heterogeneity: I<sup>2</sup> = 40%, P = 0.20 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.70 (95% CI 0.13 to 3.78); P = 0.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>By 8 weeks after RT, no participants had grade 3 or above dysphagia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dysgeusia (taste disturbance) (0‐4 scale): grade 2 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.24 (95% CI 0.10 to 0.61); P = 0.003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cost data (mean per patient supportive care costs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USD 4401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USD 5873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Random‐effects meta‐analysis of 5 studies: RR 4.90 (95% CI 2.87 to 8.38); P &lt; 0.00001</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.96 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"1 patient left due to gastrointestinal tract reaction/side effect, all other patients completed the treatment" </p> <p>"At the beginning of treatment, nausea and vomiting was obvious for amifostine group, but after treating with metoclopramide, there was no significant difference between 2 groups in gastrointestinal tract reaction/side effect" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Random‐effects meta‐analysis of 3 studies: RR 9.20 (95% CI 2.84 to 29.83); P = 0.0002</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.88 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Random‐effects meta‐analysis of 4 studies: RR 2.60 (95% CI 1.81 to 3.74); P &lt; 0.00001</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.45 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"1 patient left due to gastrointestinal tract reaction/side effect, all other patients completed the treatment" </p> <p>"At the beginning of treatment, nausea and vomiting was obvious for amifostine group, but after treating with metoclopramide, there was no significant difference between 2 groups in gastrointestinal tract reaction/side effect" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Allergic response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Random‐effects meta‐analysis of 3 studies: RR 7.51 (95% CI 1.40 to 40.39); P = 0.02</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.77 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthenia (weakness or lack of energy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.91 (95% CI 0.31 to 27.24); P = 0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alopecia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0034" title="VachaP , FehlauerF , MahlmannB , MarxM , HinkeA , SommerK , et al. Randomized phase III trial of postoperative radiochemotherapy +/‐ amifostine in head and neck cancer. Is there evidence for radioprotection?. Strahlentherapie und Onkologie2003;179(6):385‐9. VachaP , MarxM , EngelA , RichterE , FeyerabendT . Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlentherapie und Onkologie1999;175 Suppl 4:18‐22. ">Vacha 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Similar in both groups and increased continuously during the treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0034" title="VachaP , FehlauerF , MahlmannB , MarxM , HinkeA , SommerK , et al. Randomized phase III trial of postoperative radiochemotherapy +/‐ amifostine in head and neck cancer. Is there evidence for radioprotection?. Strahlentherapie und Onkologie2003;179(6):385‐9. VachaP , MarxM , EngelA , RichterE , FeyerabendT . Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlentherapie und Onkologie1999;175 Suppl 4:18‐22. ">Vacha 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Similar in both groups and increased continuously during the treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Hot flush</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"..dizziness, fatigue, hiccup, sneezing, facial flush all in less than 5% of the patients"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence (drowsiness)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Sneezing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"..dizziness, fatigue, hiccup, sneezing, facial flush all in less than 5% of the patients"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Hiccup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"..dizziness, fatigue, hiccup, sneezing, facial flush all in less than 5% of the patients"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"...dizziness, fatigue, hiccup, sneezing, facial flush all in less than 5% of the patients" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"..dizziness, fatigue, hiccup, sneezing, facial flush all in less than 5% of the patients"</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI = confidence interval; RR = risk ratio; RT = radiotherapy; USD = US dollars.</p> </div> </div> <p>Two of the 11 studies presented data on dysphagia (<a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a>; <a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a>). There was insufficient evidence of a difference in the risk of developing grade ≥ 3 dysphagia (on a 0 to 4 scale) at the end of radiotherapy (RR 0.50, 95% CI 0.17 to 1.48; P = 0.21; 73 participants) and up to and including three months postradiotherapy (four weeks after) (RR 0.70, 95% CI 0.13 to 3.78; P = 0.68; 45 participants) (Additional <a href="#CD012744-tbl-0006">Table 3</a>). In <a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a>, no participants had grade 3 or above dysphagia by eight weeks after radiotherapy. </p> <p>One study presented data on dysgeusia (<a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a>). The study showed that amifostine reduced the risk of developing grade ≥ 2 dysgeusia (on a 0 to 4 scale) at the end of radiotherapy (RR 0.24, 95% CI 0.10 to 0.61; P = 0.003; 28 participants) (Additional <a href="#CD012744-tbl-0006">Table 3</a>). </p> </section> <section id="CD012744-sec-0122"> <h5 class="title">Side effects</h5> <p>Adverse events were reported inconsistently across the 11 included trials. There was a higher risk of vomiting in the amifostine group (RR 4.90, 95% CI 2.87 to 8.38; P &lt; 0.00001; five studies; 601 participants) (<a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a>; <a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>; <a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a>; <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>). Two further studies reported high rates of vomiting in the amifostine group but did not mention vomiting in the control group (<a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>). The risk of hypotension was higher in the amifostine group (RR 9.20, 95% CI 2.84 to 29.83; P = 0.0002; three studies; 376 participants) (<a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a>; <a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a>). Another study reported hypotension only in the amifostine group (<a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>). The risk of nausea was higher in the amifostine group (RR 2.60, 95% CI 1.81 to 3.74; P &lt; 0.00001; four studies; 556 participants) (<a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>; <a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a>; <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>). Two further studies reported high rates of nausea in the amifostine group but did not mention nausea in the control group (<a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a>; <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a>). The risk of allergic response was higher in the amifostine group (RR 7.51, 95% CI 1.40 to 40.39; P = 0.02; three studies; 524 participants) (<a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a>; <a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>; <a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>). There was insufficient evidence of a difference in asthenia (weakness/lack of energy) from one study (RR 2.91, 95% CI 0.31 to 27.24; P = 0.35; 130 participants) (<a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a>). Other side effects (alopecia, skin toxicity, hot flush, drowsiness, sneezing, hiccupping, dizziness and fatigue) were reported either narratively or only for the amifostine group (Additional <a href="#CD012744-tbl-0006">Table 3</a>). </p> </section> <section id="CD012744-sec-0123"> <h5 class="title">Cost</h5> <p>One study (<a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a>), analysing 28 participants, reported economic cost data in a separate paper (<a href="./references#CD012744-bbs2-0090" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigations2001;19(2):107‐13. ">Bennett 2001</a>). In 2001, the mean per patient supportive care costs were lower in the amifostine group (USD 4401) than the control group (USD 5873) (P = 0.02) (Additional <a href="#CD012744-tbl-0006">Table 3</a>). </p> </section> </section> <section id="CD012744-sec-0124"> <h4 class="title">Amifostine (comparison of dosages)</h4> <p>One trial, at high risk of bias, compared two different amifostine regimens of 200 mg/m² either five or three times a week (<a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a>) (a third 'no treatment' group was not considered in this comparison). </p> <section id="CD012744-sec-0125"> <h5 class="title">Xerostomia</h5> <p>There was insufficient evidence to determine whether or not different amifostine dosages reduced the risk of developing grade ≥ 2 xerostomia (on a 0 to 4 scale) at 12 months postradiotherapy (RR 0.94, 95% CI 0.58 to 1.53; P = 0.80; 49 participants) (<a href="./references#CD012744-fig-0030" title="">Analysis 4.1</a>). </p> </section> <section id="CD012744-sec-0126"> <h5 class="title">Salivary flow rates</h5> <p>No salivary flow rate data, related to the effectiveness of different doses of amifostine, were reported. </p> </section> <section id="CD012744-sec-0127"> <h5 class="title">Survival</h5> <p>There is insufficient evidence reported on overall survival or locoregional tumour control (<a href="./references#CD012744-fig-0031" title="">Analysis 4.2</a>; <a href="./references#CD012744-fig-0032" title="">Analysis 4.3</a>). </p> </section> <section id="CD012744-sec-0128"> <h5 class="title">Quality of life and other oral related symptoms</h5> <p>The paper reported "no significant differences between the three treatment arms" in quality of life assessed at the end of radiotherapy and 6, 12, 18 and 24 months after radiotherapy (Additional <a href="#CD012744-tbl-0007">Table 4</a>). </p> <div class="table" id="CD012744-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Amifostine: comparison of different doses (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amifostine 3 times weekly</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amifostine 5 times weekly</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assessed at end of RT and 6, 12, 18 and 24 months after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No significant differences between the 3 treatment arms"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.64 (95% CI 0.33 to 1.25); P = 0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.25 (95% CI 0.06 to 1.08); P = 0.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allergic response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.00 (95% CI 0.15 to 6.64); P = 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI = confidence interval; RR = risk ratio; RT = radiotherapy.</p> </div> </div> </section> <section id="CD012744-sec-0129"> <h5 class="title">Side effects</h5> <p>There was insufficient evidence of a difference in nausea (RR 0.64, 95% CI 0.33 to 1.25; P = 0.19; 60 participants), vomiting (RR 0.25, 95% CI 0.06 to 1.08; P = 0.06; 60 participants), or allergic response (RR 1.00, 95% CI 0.15 to 6.64; P = 1; 60 participants) (Additional <a href="#CD012744-tbl-0007">Table 4</a>). </p> </section> <section id="CD012744-sec-0130"> <h5 class="title">Cost</h5> <p>No cost data related to the effectiveness of different doses of amifostine were reported.</p> </section> </section> <section id="CD012744-sec-0131"> <h4 class="title">Amifostine (intravenous versus subcutaneous)</h4> <p>One study, at high risk of bias, compared intravenous and subcutaneous delivery of amifostine (<a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a>). </p> <section id="CD012744-sec-0132"> <h5 class="title">Xerostomia</h5> <p>There was insufficient evidence to determine whether or not different methods of amifostine delivery reduced the risk of developing grade ≥ 2 xerostomia (on a 0 to 4 scale) up to and including three months postradiotherapy (RR 1.03, 95% CI 0.76 to 1.40; P = 0.86; 263 participants). There was a benefit in favour of amifostine at 12 months postradiotherapy (RR 0.61, 95% CI 0.42 to 0.88; P = 0.008; 127 participants) (<a href="./references#CD012744-fig-0033" title="">Analysis 5.1</a>). </p> </section> <section id="CD012744-sec-0133"> <h5 class="title">Salivary flow rates</h5> <p>No salivary flow rate data, related to the effectiveness of different routes of administration of amifostine, were reported. </p> </section> <section id="CD012744-sec-0134"> <h5 class="title">Survival</h5> <p>There was insufficient evidence of a difference in overall survival (HR 1.36, 95% CI 0.89 to 2.10; P = 0.16; <a href="./references#CD012744-fig-0034" title="">Analysis 5.2</a>) or locoregional tumour control (HR 1.34, 95% CI 0.76 to 2.36; P = 0.32; <a href="./references#CD012744-fig-0035" title="">Analysis 5.3</a>), both at 48 months postradiotherapy. </p> </section> <section id="CD012744-sec-0135"> <h5 class="title">Quality of life and other oral related symptoms</h5> <p>No data on either quality of life or other oral related symptoms were reported.</p> </section> <section id="CD012744-sec-0136"> <h5 class="title">Side effects</h5> <p>The single trial comparing intravenous and subcutaneous delivery of amifostine reported increased incidence of hypotension for intravenous delivery. Skin rash and local pain at injection site were worse for subcutaneous delivery (Additional <a href="#CD012744-tbl-0008">Table 5</a>). Results were inconclusive with regard to nausea/vomiting, fever, and asthenia (weakness/lack of energy). </p> <div class="table" id="CD012744-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Amifostine: different routes of administration (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intravenous</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Subcutaneous</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Local pain at injection site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthenia (weakness or lack of energy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </section> <section id="CD012744-sec-0137"> <h5 class="title">Cost</h5> <p>No cost data related to the effectiveness of different routes of administration of amifostine were reported. </p> </section> </section> <section id="CD012744-sec-0138"> <h4 class="title">Chinese medicine versus no treatment/placebo</h4> <p>Five studies compared some form of Chinese medicine with no treatment/placebo. Four studies were assessed as being at high risk of bias (<a href="./references#CD012744-bbs2-0016" title="HanF , ZhangJD , ShaoZY , LiuFJ . Effects of concurrent chemoradiotherapy combined with Jinlong capsules for patients with advanced nasopharyngeal squamous carcinoma. Chinese Journal of Cancer Prevention and Treatment2010;(2):138‐9. ">Han 2010</a>; <a href="./references#CD012744-bbs2-0019" title="HuYR , WuCQ , LiuYJ , WangY , LiX , ZhongH , et al. Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumour. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):623‐5. ">Hu 2005</a>; <a href="./references#CD012744-bbs2-0031" title="ReshmaK , KamalakshS , BinduYS , PramodK , AsfaA , AmrithaD , et al. Tulasi (Ocimum Sanctum) as radioprotector in head and neck cancer patients undergoing radiation therapy. Biomedicine2012;32:39‐44. ">Reshma 2012</a>; <a href="./references#CD012744-bbs2-0037" title="WangQ , LiuH , QiaoN . Effects of traditional Chinese medicine on salivary glands in the patients with head and neck cancer during radiotherapy. Zhongguo Zhong Xi Yi Jie He Za Zhi1998;18(11):662‐4. ">Wang 1998</a>); one study was assessed as being at unclear risk of bias (<a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin 2014</a>). </p> <section id="CD012744-sec-0139"> <h5 class="title">Xerostomia</h5> <p><a href="./references#CD012744-bbs2-0019" title="HuYR , WuCQ , LiuYJ , WangY , LiX , ZhongH , et al. Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumour. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):623‐5. ">Hu 2005</a> found that patients who received Shenqi Fanghon recipe had a reduced risk of xerostomia at the end of radiotherapy compared to those in the no treatment control group (RR 0.39, 95% CI 0.28 to 0.55; P &lt; 0.00001; 140 participants) (<a href="./references#CD012744-fig-0036" title="">Analysis 6.1</a>). The paper was translated from Chinese, the methods were unclear. </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin 2014</a>, a trial of 71 participants, however, found no evidence of a difference for Tianwang Buxin Mini‐pills when compared with placebo when xerostomia was evaluated using both dichotomous data (<a href="./references#CD012744-fig-0036" title="">Analysis 6.1</a>) or continuous data (<a href="./references#CD012744-fig-0037" title="">Analysis 6.2</a>). Similarly, <a href="./references#CD012744-bbs2-0016" title="HanF , ZhangJD , ShaoZY , LiuFJ . Effects of concurrent chemoradiotherapy combined with Jinlong capsules for patients with advanced nasopharyngeal squamous carcinoma. Chinese Journal of Cancer Prevention and Treatment2010;(2):138‐9. ">Han 2010</a>, a trial of 95 participants, found no evidence of a difference for Jinlong capsules when compared with no intervention (<a href="./references#CD012744-fig-0036" title="">Analysis 6.1</a>). </p> <p><a href="./references#CD012744-bbs2-0037" title="WangQ , LiuH , QiaoN . Effects of traditional Chinese medicine on salivary glands in the patients with head and neck cancer during radiotherapy. Zhongguo Zhong Xi Yi Jie He Za Zhi1998;18(11):662‐4. ">Wang 1998</a>, a trial of 50 participants, found a difference in favour of Chinese medicine in an assessment of xerostomia (VAS) against a no treatment group at the end of radiotherapy (P &lt; 0.05). The results were graphically represented and the standard deviations were not available from the paper. </p> </section> <section id="CD012744-sec-0140"> <h5 class="title">Salivary flow rates</h5> <p>One study showed an increase in stimulated salivary flow rate in favour of Chinese medicine when compared with no treatment at the end of radiotherapy (MD 0.09, 95% CI 0.03 to 0.15; P = 0.001; 50 participants) (<a href="./references#CD012744-fig-0038" title="">Analysis 6.3</a>). The paper was translated from Chinese, with the standard deviations being estimated (<a href="./references#CD012744-bbs2-0037" title="WangQ , LiuH , QiaoN . Effects of traditional Chinese medicine on salivary glands in the patients with head and neck cancer during radiotherapy. Zhongguo Zhong Xi Yi Jie He Za Zhi1998;18(11):662‐4. ">Wang 1998</a>). <a href="./references#CD012744-bbs2-0031" title="ReshmaK , KamalakshS , BinduYS , PramodK , AsfaA , AmrithaD , et al. Tulasi (Ocimum Sanctum) as radioprotector in head and neck cancer patients undergoing radiation therapy. Biomedicine2012;32:39‐44. ">Reshma 2012</a> mentioned salivary status but provided no data. </p> </section> <section id="CD012744-sec-0141"> <h5 class="title">Survival</h5> <p><a href="./references#CD012744-bbs2-0019" title="HuYR , WuCQ , LiuYJ , WangY , LiX , ZhongH , et al. Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumour. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):623‐5. ">Hu 2005</a> evaluated overall survival (12 months postradiotherapy) but there was insufficient evidence to determine any effect (<a href="./references#CD012744-fig-0039" title="">Analysis 6.4</a>). </p> </section> <section id="CD012744-sec-0142"> <h5 class="title">Quality of life and other oral related symptoms</h5> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin 2014</a> evaluated quality of life (at end of intervention and up to and including three months postradiotherapy) but there was insufficient evidence to determine any effect (<a href="./references#CD012744-fig-0040" title="">Analysis 6.5</a>). The same study showed insufficient evidence of a difference for other oral related symptoms (both at end of radiotherapy and one month after) (Additional <a href="#CD012744-tbl-0009">Table 6</a>). In <a href="./references#CD012744-bbs2-0019" title="HuYR , WuCQ , LiuYJ , WangY , LiX , ZhongH , et al. Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumour. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):623‐5. ">Hu 2005</a> difficulty in mouth opening was worse in the control group (Additional <a href="#CD012744-tbl-0009">Table 6</a>). </p> <div class="table" id="CD012744-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Chinese medicine (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Dysphasia (difficulty in swallowing)</p> <p>(score for EORTC‐H&amp;N35 questionnaire: mean (SD))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.2 (26.3); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.9 (25.9); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.2 (29.8); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.7 (24.8); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dysgeusia (taste disturbance) (0 to 3 scale): grade 1 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.96 (95% CI 0.79 to 1.16); P = 0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Speech difficulty</p> <p>(mean (SD) score for EORTC‐H&amp;N35 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.3 (26.7); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.6 (26.2); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.4 (28.6); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.7 (19.5); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Difficulty in mouth opening</p> <p>(mean (SD) score for EORTC‐H&amp;N35 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.6 (28.2); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.4 (27.7); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.2 (31.5); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.3 (24.1); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty in mouth opening</p> <p>(0 to 2 scale): grade 1 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0019" title="HuYR , WuCQ , LiuYJ , WangY , LiX , ZhongH , et al. Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumour. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):623‐5. ">Hu 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (Shenqi Fanghou recipe)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"During the treatment"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52/70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.42 (95% CI 0.29 to 0.61); P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin toxicity (0 to 3 scale): grade 1 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.01 (95% CI 0.88 to 1.17); P = 0.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin toxicity (0 to 4 scale): grade 1 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0019" title="HuYR , WuCQ , LiuYJ , WangY , LiX , ZhongH , et al. Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumour. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):623‐5. ">Hu 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (Shenqi Fanghou recipe)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"During the treatment"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57/70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68/70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.84 (95% CI 0.74 to 0.94); P = 0.002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin toxicity (prevalence according to RTOG standards)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0016" title="HanF , ZhangJD , ShaoZY , LiuFJ . Effects of concurrent chemoradiotherapy combined with Jinlong capsules for patients with advanced nasopharyngeal squamous carcinoma. Chinese Journal of Cancer Prevention and Treatment2010;(2):138‐9. ">Han 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (Jinlong capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.82%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.32%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quote: "toxicities during and after treatment were assessed"</p> <p>Comment: time point for assessment unclear; minor discrepancies in presented data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting (0 to 3 scale): grade 1 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.61 (95% CI 0.93 to 7.30); P = 0.183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hoarseness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.29 (95% CI 0.03 to 2.65); P = 0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Fatigue</p> <p>(mean (SD) score for EORTC‐C30 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.2 (26.2); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.4 (23.0); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.2 (28.3); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.4 (25.0); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Pain</p> <p>(mean (SD) score for EORTC‐C30 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.8 (23.2); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.7 (27.4); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.9 (27.0); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.9 (29.9); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Pain</p> <p>(mean (SD) score for EORTC‐H&amp;N35 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.4 (25.1); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.4 (20.5); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.6 (24.2); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.8 (23.3); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Dyspnea</p> <p>(mean (SD) score for EORTC‐C30 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.1 (23.1); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.7 (20.7); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.5 (21.2); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6 (22.2); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Insomnia</p> <p>(mean (SD) score for EORTC‐C30 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.5 (25.0); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.2 (25.3); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.8 (24.8); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.8 (28.1); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Appetite loss</p> <p>(mean (SD) score for EORTC‐C30 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.0 (30.7); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.8 (29.0); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.2 (26.1); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.9 (30.0); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Constipation</p> <p>(mean (SD) score for EORTC‐C30 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.8 (27.4); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.2 (20.3); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.5 (30.3); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.7 (20.4); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Diarrhoea</p> <p>(mean (SD) score for EORTC‐C30 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.0 (15.0); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.2 (13.2); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.0 (15.1); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.1 (16.7); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0016" title="HanF , ZhangJD , ShaoZY , LiuFJ . Effects of concurrent chemoradiotherapy combined with Jinlong capsules for patients with advanced nasopharyngeal squamous carcinoma. Chinese Journal of Cancer Prevention and Treatment2010;(2):138‐9. ">Han 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (Jinlong capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leukopenia, nausea, vomiting, 1 participant had dizziness and blood pressure drop, 1 participant had skin rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0019" title="HuYR , WuCQ , LiuYJ , WangY , LiX , ZhongH , et al. Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumour. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):623‐5. ">Hu 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (Shenqi Fanghou recipe)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"During the treatment"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI = confidence interval; EORTC = European Organisation for Research and Treatment of Cancer; H&amp;N = head and neck; RR = risk ratio; RT = radiotherapy; RTOG = Radiation Therapy Oncology Group; SD = standard deviation; TWBXM = Tianwang Buxin Mini‐pills. </p> </div> </div> </section> <section id="CD012744-sec-0143"> <h5 class="title">Side effects</h5> <p>There was insufficient evidence of a difference for any side effects (at end of intervention and one month after) (Additional <a href="#CD012744-tbl-0009">Table 6</a>). </p> </section> <section id="CD012744-sec-0144"> <h5 class="title">Cost</h5> <p>No cost data related to the effectiveness of Chinese medicine were reported.</p> </section> </section> <section id="CD012744-sec-0145"> <h4 class="title">Palifermin versus placebo</h4> <p>Three trials, two at low (<a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a>; <a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a>) and one at unclear risk of bias (<a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a>), evaluated palifermin versus placebo. </p> <section id="CD012744-sec-0146"> <h5 class="title">Xerostomia</h5> <p>In a meta‐analysis of all three trials, there was insufficient evidence of a difference in the incidence of &gt; grade 2 xerostomia up to three months postradiotherapy (RR 0.97, 95% CI 0.77 to 1.22; P = 0.78; 471 participants). There was considerable heterogeneity present (I<sup>2</sup> = 76%, P = 0.02) (<a href="./references#CD012744-fig-0041" title="">Analysis 7.1</a>). It should be noted that a large proportion of participants in <a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> did not have assessments for xerostomia, but the intention‐to‐treat (ITT) rules stated that such participants would be assumed to have the outcome, and this may have had a substantial effect on the meta‐analysis result. </p> <p>Xerostomia was measured up to 12 months in two studies but no data were reported (<a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a>; <a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a>). </p> </section> <section id="CD012744-sec-0147"> <h5 class="title">Salivary flow rates</h5> <p>None of the trials evaluating palifermin provided data on salivary flow rates.</p> </section> <section id="CD012744-sec-0148"> <h5 class="title">Survival</h5> <p>All three trials reported data on overall and progression‐free survival at 42 to 72 months from baseline. There was insufficient evidence of a difference in both overall survival (HR 1.00, 95% CI 0.72 to 1.39; P = 0.99; <a href="./references#CD012744-fig-0042" title="">Analysis 7.2</a>) and progression‐free survival (HR 1.06, 95% CI 0.80 to 1.42; P = 0.67; <a href="./references#CD012744-fig-0043" title="">Analysis 7.3</a>). </p> </section> <section id="CD012744-sec-0149"> <h5 class="title">Quality of life and other oral related symptoms</h5> <p>All three trials provided data for a meta‐analysis of dysphagia at three months postradiotherapy, with insufficient evidence of a difference (RR 1.32, 95% CI 0.55 to 3.13; P = 0.54) (Additional <a href="#CD012744-tbl-0010">Table 7</a>). There was also insufficient evidence of a difference in mouth and throat soreness at three months postradiotherapy in a meta‐analysis of two trials (MD ‐0.12, 95% CI ‐0.27 to 0.02; P = 0.10) (Additional <a href="#CD012744-tbl-0010">Table 7</a>). </p> <div class="table" id="CD012744-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Palifermin versus placebo (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Palifermin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Oral related symptoms (other than salivary gland dysfunction/xerostomia)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Dysphagia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>3 months postRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Random‐effects meta‐analysis of 3 studies: RR 1.32 (95% CI 0.55 to 3.13); P = 0.54</p> <p>Heterogeneity: I<sup>2</sup> = 94%, P &lt; 0.00001 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61/64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Mouth and throat soreness ‐ 0 (no soreness) to 4 (extreme soreness) OMWQ‐HN scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3 months postRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 94, mean = 1.66, SD = 0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 94, mean = 1.86, SD = 0.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Random‐effects meta‐analysis of 2 studies: mean difference ‐0.12 (95% CI ‐0.27 to 0.02); P = 0.10 </p> <p>Heterogeneity: I<sup>2</sup> = 13%, P = 0.28 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 92, mean = 1.52, SD = 0.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 94, mean = 1.57, SD = 0.63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 0.96 (95% CI 0.77 to 1.19); P = 0.69</p> <p>Heterogeneity: I<sup>2</sup> = 28%, P = 0.24 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10 (95% CI 0.67 to 1.81); P = 0.70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 1.15 (95% CI 0.82 to 1.60); P = 0.42</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.57 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 1.28 (95% CI 0.49 to 3.36); P = 0.61</p> <p>Heterogeneity: I<sup>2</sup> = 57%, P = 0.13 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 0.77 (95% CI 0.23 to 2.55); P = 0.67</p> <p>Heterogeneity: I<sup>2</sup> = 63%, P = 0.10 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dyspnea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10 (95% CI 0.67 to 1.81); P = 0.70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.76 (95% CI 0.27 to 2.15); P = 0.61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 2.13 (95% CI 0.86 to 5.28); P = 0.10</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.86 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Decreased weight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 1.01 (95% CI 0.67 to 1.52); P = 0.96</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.73 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.60 (95% CI 0.17 to 2.07); P = 0.42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.38 (95% CI 0.11 to 1.33); P = 0.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypomagnesemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.48 (95% CI 0.13 to 1.79); P = 0.27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 0.98 (95% CI 0.72 to 1.33); P = 0.89</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.96 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radiation skin injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10 (95%CI 0.67 to 1.81); P = 0.70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 0.83 (95% CI 0.33 to 2.05); P = 0.68</p> <p>Heterogeneity: I<sup>2</sup> = 54%, P = 0.14 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Random‐effects meta‐analysis of 3 studies: RR 0.88 (95% CI 0.60 to 1.30); P = 0.52</p> <p>Heterogeneity: I<sup>2</sup> = 2%, P = 0.36 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 1.01 (95% CI 0.37 to 2.78); P = 0.98</p> <p>Heterogeneity: I<sup>2</sup> = 79%, P = 0.03 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Granulocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.59 (95% CI 0.47 to 5.39); P = 0.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharyngolaryngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.84 (95% CI 0.50 to 1.42); P = 0.52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypokalemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.04 (95% CI 0.98 to 4.28); P = 0.06</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.82 (95% CI 0.45 to 1.48); P = 0.50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mucosal inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.40 (95% CI 0.13 to 1.24); P = 0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.88 (95% CI 0.78 to 4.49); P = 0.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.54 (95% CI 0.75 to 16.58); P = 0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 6.07 (95% CI 0.74 to 49.40); P = 0.09</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Febrile neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/92</p> <p>Considered "serious adverse event"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.03 (95% CI 0.13 to 73.48); P = 0.50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Dehydration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Random‐effects meta‐analysis of 3 studies: RR 0.75 (95% CI 0.45 to 1.25); P = 0.27</p> <p>Heterogeneity: I<sup>2</sup> = 30%, P = 0.24 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/32</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI = confidence interval; OMWQ‐HN = Oral Mucositis Weekly Questionnaire ‐ Head and Neck Cancer; RR = risk ratio; RT = radiotherapy; SD = standard deviation. </p> </div> </div> </section> <section id="CD012744-sec-0150"> <h5 class="title">Side effects</h5> <p>All three trials provided information on possible adverse events, sometimes reporting the same adverse event (Additional <a href="#CD012744-tbl-0010">Table 7</a>). There was no evidence of patients in either group experiencing more or less of these adverse events. </p> </section> <section id="CD012744-sec-0151"> <h5 class="title">Cost</h5> <p>No cost data related to the effectiveness of palifermin were reported.</p> </section> </section> <section id="CD012744-sec-0152"> <h4 class="title">Bethanechol versus placebo</h4> <p>One study, at unclear risk of bias, compared bethanechol with placebo (<a href="./references#CD012744-bbs2-0020" title="JaguarGC . A Prospective Study of Bethanechol in the Salivary Glands Physiology in Patients Following Head and Neck Radiotherapy [Estudo Prospectivo do Uso do Betanecol na Fisiologia de Glândulas Salivares em Pacientes Irradiados em Região de Cabeça e Pescoço] [Dissertation]. Sao Paulo (Brazil): Fundaçao Antonio Prudente, 2010. JaguarGC , CamposL , PellizzonAC , LimaEN , KowalskiLP , AlvesFA . Double‐blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in cancer patients. Supportive Care in Cancer2012;20(1 Suppl):S252. JaguarGC , LimaEN , KowalskiLP , PellizzonAC , CarvalhoAL , BoccalettiKW , et al. Double blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in head and neck cancer patients. Radiotherapy and Oncology2015;115(2):253‐6. ">Jaguar 2015</a>). </p> <section id="CD012744-sec-0153"> <h5 class="title">Xerostomia</h5> <p>Bethanechol reduced the risk of developing grade ≥ 2 xerostomia (on a 0 to 3 scale) at the end of radiotherapy (RR 0.43, 95% CI 0.28 to 0.66; P = 0.0001; 84 participants). However, there was insufficient evidence of a difference up to and including three months postradiotherapy (RR 0.81, 95% CI 0.65 to 1.01; P = 0.06; 84 participants) (<a href="./references#CD012744-fig-0044" title="">Analysis 8.1</a>). </p> </section> <section id="CD012744-sec-0154"> <h5 class="title">Salivary flow rates</h5> <p>Bethanechol increased unstimulated saliva flow (ml/min) at two months postradiotherapy (MD 0.19, 95% CI 0.06 to 0.32; P = 0.004; 97 participants) (<a href="./references#CD012744-fig-0045" title="">Analysis 8.2</a>). </p> <p>There was insufficient evidence of a difference in stimulated saliva flow (ml/min) at two months postradiotherapy (MD 0.15, 95% CI ‐0.03 to 0.33; P = 0.11; 97 participants; <a href="./references#CD012744-fig-0046" title="">Analysis 8.3</a>). </p> </section> <section id="CD012744-sec-0155"> <h5 class="title">Survival</h5> <p>No survival data were reported.</p> </section> <section id="CD012744-sec-0156"> <h5 class="title">Quality of life and other oral related symptoms</h5> <p>No data on either quality of life or other oral related symptoms were reported.</p> </section> <section id="CD012744-sec-0157"> <h5 class="title">Side effects</h5> <p>The study reported narratively that there were no statistical differences between the groups in bethanechol‐related toxicity and that "no patient experienced severe (grade 3) toxicity and no one dropped out of the study due to adverse effects" (Additional <a href="#CD012744-tbl-0011">Table 8</a>). </p> <div class="table" id="CD012744-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Bethanechol versus placebo (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0020" title="JaguarGC . A Prospective Study of Bethanechol in the Salivary Glands Physiology in Patients Following Head and Neck Radiotherapy [Estudo Prospectivo do Uso do Betanecol na Fisiologia de Glândulas Salivares em Pacientes Irradiados em Região de Cabeça e Pescoço] [Dissertation]. Sao Paulo (Brazil): Fundaçao Antonio Prudente, 2010. JaguarGC , CamposL , PellizzonAC , LimaEN , KowalskiLP , AlvesFA . Double‐blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in cancer patients. Supportive Care in Cancer2012;20(1 Suppl):S252. JaguarGC , LimaEN , KowalskiLP , PellizzonAC , CarvalhoAL , BoccalettiKW , et al. Double blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in head and neck cancer patients. Radiotherapy and Oncology2015;115(2):253‐6. ">Jaguar 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistical difference between the groups in bethanechol‐related toxicity. Quote: "No patient experienced severe (grade 3) toxicity and no one dropped out of the study due to adverse effects" </p> </td> </tr> </tbody> </table> </div> </section> <section id="CD012744-sec-0158"> <h5 class="title">Cost</h5> <p>No cost data related to the effectiveness of bethanecol versus placebo were reported.</p> </section> </section> <section id="CD012744-sec-0159"> <h4 class="title">Bethanechol versus artificial saliva</h4> <p>One study, at high risk of bias, compared bethanechol with artificial saliva (<a href="./references#CD012744-bbs2-0022" title="JhamBC , ChenH , CarvalhoAL , FreireAR . A randomized phase III prospective trial of bethanechol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis. Journal of Oral Science2009;51(4):565‐72. JhamBC , TeixeiraIV , AboudCG , CarvalhoAL , Coelho MdeM , FreireAR . A randomized phase III prospective trial of bethanechol to prevent radiotherapy‐induced salivary gland damage in patients with head and neck cancer. Oral Oncology2007;43(2):137‐42. ">Jham 2007</a>). </p> <section id="CD012744-sec-0160"> <h5 class="title">Xerostomia</h5> <p>There was insufficient evidence of a difference in having a dry mouth (yes/no) either at the end of radiotherapy (RR 0.63, 95% CI 0.30 to 1.29; P = 0.2; 36 participants) or at 8 to 40 weeks postradiotherapy (RR 0.56, 95% CI 0.30 to 1.05; P = 0.07; 30 participants) (<a href="./references#CD012744-fig-0047" title="">Analysis 9.1</a>). </p> </section> <section id="CD012744-sec-0161"> <h5 class="title">Salivary flow rates</h5> <p>Bethanechol increased unstimulated saliva flow (ml/min) at the end of radiotherapy (MD 0.12, 95% CI 0.01 to 0.23; P = 0.03; 36 participants), but there was insufficient evidence of a difference at 8 to 40 weeks postradiotherapy (MD 0.07, 95% CI ‐0.02 to 0.16; P = 0.13; 33 participants) (<a href="./references#CD012744-fig-0048" title="">Analysis 9.2</a>). </p> <p>There was insufficient evidence of a difference in stimulated saliva flow (ml/min) at the end of radiotherapy (MD 0.13, 95% CI ‐0.03 to 0.29; P = 0.12; 32 participants), but there was a benefit in favour of bethanechol at 8 to 40 weeks postradiotherapy (MD 0.21, 95% CI 0.01 to 0.41; P = 0.04; 29 participants) (<a href="./references#CD012744-fig-0049" title="">Analysis 9.3</a>). </p> </section> <section id="CD012744-sec-0162"> <h5 class="title">Survival</h5> <p>There was insufficient evidence of a difference in overall survival at 40 weeks postradiotherapy (RR 1.59, 95% CI 0.43 to 5.84; P = 0.48; 43 participants; <a href="./references#CD012744-fig-0050" title="">Analysis 9.4</a>). </p> </section> <section id="CD012744-sec-0163"> <h5 class="title">Quality of life and other oral related symptoms</h5> <p>No data on either quality of life or other oral related symptoms were reported.</p> </section> <section id="CD012744-sec-0164"> <h5 class="title">Side effects</h5> <p>There were low rates of adverse effects (watering eyes, nervousness, frequent urination, sweating, warm face, cramps, diarrhoea, nausea) with insufficient evidence of any differences (Additional <a href="#CD012744-tbl-0012">Table 9</a>). </p> <div class="table" id="CD012744-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Bethanechol versus artificial saliva (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bethanechol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Artificial saliva</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lacrimation (watering eyes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><a href="./references#CD012744-bbs2-0022" title="JhamBC , ChenH , CarvalhoAL , FreireAR . A randomized phase III prospective trial of bethanechol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis. Journal of Oral Science2009;51(4):565‐72. JhamBC , TeixeiraIV , AboudCG , CarvalhoAL , Coelho MdeM , FreireAR . A randomized phase III prospective trial of bethanechol to prevent radiotherapy‐induced salivary gland damage in patients with head and neck cancer. Oral Oncology2007;43(2):137‐42. ">Jham 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 6.70 (95% CI 0.37 to 122.29); P = 0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 6.70 (95% CI 0.37 to 122.29); P = 0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Frequent urination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 6.70 (95% CI 0.37 to 122.29); P = 0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sweating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 4.78 (95% CI 0.24 to 94.12); P = 0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"1 patient using bethanechol dropped out of the study due to excessive sweating (Grade 2 severity; National Cancer Institute Common Terminology Criteria for Adverse Events – NCI CTCAE, v 3" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warm face</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 4.78 (95% CI 0.24 to 94.12); P = 0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cramps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.87 (95% CI 0.12 to 66.75); P = 0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.87 (95% CI 0.12 to 66.75); P = 0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.48 (95% CI 0.05 to 4.88); P = 0.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI = confidence interval; RR = risk ratio; RT = radiotherapy.</p> </div> </div> </section> <section id="CD012744-sec-0165"> <h5 class="title">Cost</h5> <p>No cost data related to the effectiveness of bethanechol versus artifical saliva were reported. </p> </section> </section> <section id="CD012744-sec-0166"> <h4 class="title">Selenium versus no intervention</h4> <p>Selenium was compared to no intervention in one trial assessed as at high risk of bias (<a href="./references#CD012744-bbs2-0008" title="BuentzelJ , MickeO , GlatzelM , BrunsF , KistersK , MueckeR . Evaluation of the effect of selenium on radiation‐induced toxicities in head neck cancer patients. Journal of Clinical Oncology2009;27(15 Suppl):e20698. BüntzelJ , MickeO , GlatzelM , SchäferU , RiesenbeckD , KistersK , et al. Selenium substitution during radiotherapy in head and neck cancer. Trace Elements and Electrolytes2010;27:235‐9. BüntzelJ , RiesenbeckD , GlatzelM , Berndt‐SkorkaR , RiedelT , MückeR , et al. Limited effects of selenium substitution in the prevention of radiation‐associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Research2010;30(5):1829‐32. ">Büntzel 2010</a>). </p> <section id="CD012744-sec-0167"> <h5 class="title">Xerostomia</h5> <p>We were unable to use any of the data as bar charts of mean scores (baseline to postradiotherapy) were presented with no standard deviations. The results reported in the text indicated that there was no evidence that selenium reduced xerostomia (<a href="./references#CD012744-fig-0051" title="">Analysis 10.1</a>). </p> </section> <section id="CD012744-sec-0168"> <h5 class="title">Salivary flow rates</h5> <p>No data on salivary flow rates were reported.</p> </section> <section id="CD012744-sec-0169"> <h5 class="title">Survival</h5> <p>No survival data were reported.</p> </section> <section id="CD012744-sec-0170"> <h5 class="title">Quality of life and other oral related symptoms</h5> <p>We were unable to use any of the data for loss of taste or dysphagia as bar charts of mean scores were presented with no standard deviations, but some information was reported in the text (Additional <a href="#CD012744-tbl-0013">Table 10</a>). There was insufficient evidence of any differences. </p> <div class="table" id="CD012744-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Selenium versus no intervention (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reported in text</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss of taste</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0008" title="BuentzelJ , MickeO , GlatzelM , BrunsF , KistersK , MueckeR . Evaluation of the effect of selenium on radiation‐induced toxicities in head neck cancer patients. Journal of Clinical Oncology2009;27(15 Suppl):e20698. BüntzelJ , MickeO , GlatzelM , SchäferU , RiesenbeckD , KistersK , et al. Selenium substitution during radiotherapy in head and neck cancer. Trace Elements and Electrolytes2010;27:235‐9. BüntzelJ , RiesenbeckD , GlatzelM , Berndt‐SkorkaR , RiedelT , MückeR , et al. Limited effects of selenium substitution in the prevention of radiation‐associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Research2010;30(5):1829‐32. ">Büntzel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks after end RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Ageusia was milder in the selenium group. But the difference was not significant"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dysphagia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0008" title="BuentzelJ , MickeO , GlatzelM , BrunsF , KistersK , MueckeR . Evaluation of the effect of selenium on radiation‐induced toxicities in head neck cancer patients. Journal of Clinical Oncology2009;27(15 Suppl):e20698. BüntzelJ , MickeO , GlatzelM , SchäferU , RiesenbeckD , KistersK , et al. Selenium substitution during radiotherapy in head and neck cancer. Trace Elements and Electrolytes2010;27:235‐9. BüntzelJ , RiesenbeckD , GlatzelM , Berndt‐SkorkaR , RiedelT , MückeR , et al. Limited effects of selenium substitution in the prevention of radiation‐associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Research2010;30(5):1829‐32. ">Büntzel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks after end RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The only significant difference was observed at week 7, when the selenium group had developed a mean value of 1.533 versus 2.167 in the control group (P = 0.05)" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0008" title="BuentzelJ , MickeO , GlatzelM , BrunsF , KistersK , MueckeR . Evaluation of the effect of selenium on radiation‐induced toxicities in head neck cancer patients. Journal of Clinical Oncology2009;27(15 Suppl):e20698. BüntzelJ , MickeO , GlatzelM , SchäferU , RiesenbeckD , KistersK , et al. Selenium substitution during radiotherapy in head and neck cancer. Trace Elements and Electrolytes2010;27:235‐9. BüntzelJ , RiesenbeckD , GlatzelM , Berndt‐SkorkaR , RiedelT , MückeR , et al. Limited effects of selenium substitution in the prevention of radiation‐associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Research2010;30(5):1829‐32. ">Büntzel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks after end RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"23 serious adverse events (SAEs) were seen in the selenium group, compared to 22 in the control group (P = 0.476). No statistically significant differences in toxicities were found using the 2‐tailed Fisher's exact test" </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>RT = radiotherapy.</p> </div> </div> </section> <section id="CD012744-sec-0171"> <h5 class="title">Side effects</h5> <p>The text around adverse events implied that there was no evidence that selenium caused a higher number of events. We were unable to analyse the data as they were clustered (Additional <a href="#CD012744-tbl-0013">Table 10</a>). </p> </section> <section id="CD012744-sec-0172"> <h5 class="title">Cost</h5> <p>No cost data related to the effectiveness of selenium were reported.</p> </section> </section> <section id="CD012744-sec-0173"> <h4 class="title">Antiseptic mouthrinse versus placebo</h4> <p>Antiseptic mouthrinse was assessed in one small trial at high risk of bias (<a href="./references#CD012744-bbs2-0024" title="LanzósI , HerreraD , SantosS , O'ConnorA , PeñaC , LanzósE , et al. Mucositis in irradiated cancer patients: effects of an antiseptic mouthrinse. Medicina Oral, Patología Oral y Cirugía Bucal2010;15(5):e732‐8. ">Lanzós 2010</a>). </p> <section id="CD012744-sec-0174"> <h5 class="title">Xerostomia</h5> <p>No data on xerostomia were reported.</p> </section> <section id="CD012744-sec-0175"> <h5 class="title">Salivary flow rates</h5> <p>This outcome was only reported during radiotherapy (i.e. not at any of the time points we were interested in). </p> </section> <section id="CD012744-sec-0176"> <h5 class="title">Survival</h5> <p>No survival data were reported.</p> </section> <section id="CD012744-sec-0177"> <h5 class="title">Quality of life and other oral related symptoms</h5> <p>No quality of life data were reported, however, data on hyposialosis (drooling) were reported; there was insufficient evidence to determine whether or not antiseptic mouthrinse reduced or increased drooling in patients after four weeks (Additional <a href="#CD012744-tbl-0014">Table 11</a>). </p> <div class="table" id="CD012744-tbl-0014"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Antiseptic mouthrinse versus placebo (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antiseptic rinse</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drooling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0024" title="LanzósI , HerreraD , SantosS , O'ConnorA , PeñaC , LanzósE , et al. Mucositis in irradiated cancer patients: effects of an antiseptic mouthrinse. Medicina Oral, Patología Oral y Cirugía Bucal2010;15(5):e732‐8. ">Lanzós 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased 6</p> <p>No change or decreased 8</p> <p>6/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased 3</p> <p>No change or decreased 7</p> <p>3/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.43 (95% CI 0.46 to 4.39); P = 0.53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0024" title="LanzósI , HerreraD , SantosS , O'ConnorA , PeñaC , LanzósE , et al. Mucositis in irradiated cancer patients: effects of an antiseptic mouthrinse. Medicina Oral, Patología Oral y Cirugía Bucal2010;15(5):e732‐8. ">Lanzós 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No relevant adverse events were reported in any group"</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI = confidence interval; RR = risk ratio.</p> </div> </div> </section> <section id="CD012744-sec-0178"> <h5 class="title">Side effects</h5> <p>The study reported "no relevant adverse events were reported in any group" (Additional <a href="#CD012744-tbl-0014">Table 11</a>). </p> </section> <section id="CD012744-sec-0179"> <h5 class="title">Cost</h5> <p>No cost data related to the effectiveness of antiseptic mouthrinses were reported.</p> </section> </section> <section id="CD012744-sec-0180"> <h4 class="title">Antimicrobial lozenge versus placebo</h4> <p>Antimicrobial lozenge was assessed in one trial assessed as at high risk of bias (<a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a>). </p> <section id="CD012744-sec-0181"> <h5 class="title">Xerostomia</h5> <p>There was insufficient evidence that the antimicrobial lozenges reduced xerostomia up to and including three months postradiotherapy (RR 1.16, 95% CI 0.97 to 1.40; P = 0.11; 133 participants) (<a href="./references#CD012744-fig-0052" title="">Analysis 11.1</a>). </p> </section> <section id="CD012744-sec-0182"> <h5 class="title">Salivary flow rates</h5> <p>No data on salivary flow rates were reported.</p> </section> <section id="CD012744-sec-0183"> <h5 class="title">Survival</h5> <p>No survival data were reported.</p> </section> <section id="CD012744-sec-0184"> <h5 class="title">Quality of life and other oral related symptoms</h5> <p>There was insufficient evidence of a difference between the groups for global quality of life (<a href="./references#CD012744-fig-0053" title="">Analysis 11.2</a>), mouth pain, sore/burning mouth, or throat pain (Additional <a href="#CD012744-tbl-0015">Table 12</a>). </p> <div class="table" id="CD012744-tbl-0015"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Antimicrobial lozenge versus placebo (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antimicrobial lozenge</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mouth pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse over 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.94 (95% CI 0.66 to 1.33); P=0.72</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sore/burning mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse over 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95 (95% CI 0.68 to 1.35); P=0.79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Throat pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse over 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.79 (95% CI 0.56 to 1.12); P=0.19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dryness in mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse over 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.18 (95% CI 0.97 to 1.42); P=0.09</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse over 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.90 (95% CI 1.10 to 3.28); P=0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse over 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.97 (95% CI 0.51 to 7.54); P=0.32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse over 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.91 (95% CI 0.59 to 1.42); P=0.67</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI = confidence interval; RR = risk ratio.</p> </div> </div> </section> <section id="CD012744-sec-0185"> <h5 class="title">Side effects</h5> <p>There is weak evidence that the antimicrobial lozenge may cause nausea, but insufficient evidence of a difference in dryness in the mouth, diarrhoea, or constipation (Additional <a href="#CD012744-tbl-0015">Table 12</a>). </p> </section> <section id="CD012744-sec-0186"> <h5 class="title">Cost</h5> <p>No cost data related to the effectiveness of antimicrobial lozenges were reported.</p> </section> </section> <section id="CD012744-sec-0187"> <h4 class="title">Polaprezinc versus azulene oral rinse</h4> <p>One study at high risk of bias compared polaprezinc with azulene oral rinse (<a href="./references#CD012744-bbs2-0039" title="WatanabeT , IshiharaM , MatsuuraK , MizutaK , ItohY . Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. International Journal of Cancer2010;127(8):1984‐90. ">Watanabe 2010</a>). </p> <section id="CD012744-sec-0188"> <h5 class="title">Xerostomia</h5> <p>There is some weak evidence that polaprezinc reduced severe xerostomia at the end of radiotherapy when compared with azulene rinse (RR 0.17, 95% CI 0.04 to 0.65; P = 0.009; 31 participants) (<a href="./references#CD012744-fig-0054" title="">Analysis 12.1</a>). </p> </section> <section id="CD012744-sec-0189"> <h5 class="title">Salivary flow rates</h5> <p>No data on salivary flow rates were reported.</p> </section> <section id="CD012744-sec-0190"> <h5 class="title">Survival</h5> <p>The study reported tumour response by RECIST (Response Evaluation Criteria In Solid Tumors) criteria for a specific group of patients only. </p> </section> <section id="CD012744-sec-0191"> <h5 class="title">Quality of life and other oral related symptoms</h5> <p>There is some weak evidence that polaprezinc reduces severe oral pain and severe taste disturbance, however there is no evidence that polaprezinc helps patients to eat more when compared with azulene oral rinse (Additional <a href="#CD012744-tbl-0016">Table 13</a>). </p> <div class="table" id="CD012744-tbl-0016"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Polaprezinc versus azulene rinse (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Polaprezinc</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Azulene rinse</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain &gt; 2 (0‐3 scale)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0039" title="WatanabeT , IshiharaM , MatsuuraK , MizutaK , ItohY . Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. International Journal of Cancer2010;127(8):1984‐90. ">Watanabe 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Over RT period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.36 (95% CI 0.17 to 0.77); P = 0.008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taste disturbance &gt; 2 (0‐3 scale)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0039" title="WatanabeT , IshiharaM , MatsuuraK , MizutaK , ItohY . Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. International Journal of Cancer2010;127(8):1984‐90. ">Watanabe 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Over RT period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.12 (95% CI 0.02 to 0.83); P = 0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disability of oral intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0039" title="WatanabeT , IshiharaM , MatsuuraK , MizutaK , ItohY . Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. International Journal of Cancer2010;127(8):1984‐90. ">Watanabe 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Over RT period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.31 (95% CI 0.07 to 1.31); P = 0.11</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI = confidence interval; RR = risk ratio; RT = radiotherapy.</p> </div> </div> </section> <section id="CD012744-sec-0192"> <h5 class="title">Side effects</h5> <p>No data on adverse events were reported.</p> </section> <section id="CD012744-sec-0193"> <h5 class="title">Cost</h5> <p>No cost data related to the effectiveness of polaprezinc or azulene were reported.</p> </section> </section> <section id="CD012744-sec-0194"> <h4 class="title">Venalot Depot (coumarin/troxerutin) versus placebo</h4> <p>One small trial, assessed as at high risk of bias, compared Venalot Depot with placebo (<a href="./references#CD012744-bbs2-0013" title="GrötzKA , Henneicke‐Von ZepelinHH , KohnenR , KutznerJ , BelzGG . Prophylaxis of mucositis and dry mouth after head and neck radiotherapy. A new treatment. Krankenhauspharmazie2002;23(5):193‐8. GrötzKA , Henneicke‐von ZepelinHH , KohnenR , al‐NawasB , BockischA , KutznerJ , et al. Prospective double‐blind study of prophylaxis of radioxerostomia with Coumarin/Troxerutine in patients with head and neck cancer [Prospektive, doppelblinde Therapiestudie zur Prophylaxe der Radioxerostomie durch Cumarin/Troxerutin bei Patienten mit Kopf‐Hals‐Karzinomen]. Strahlentherapie und Onkologie1999;175(8):397‐404. GrötzKA , WüstenbergP , KohnenR , Al‐NawasB , Henneicke‐von ZepelinH , BockischA , et al. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer ‐ a prospective, randomized, placebo‐controlled, double‐blind study. British Journal of Oral and Maxillofacial Surgery2001;39(1):34‐9. ">Grötz 2001</a>). </p> <section id="CD012744-sec-0195"> <h5 class="title">Xerostomia</h5> <p>RTOG scores are reported however these scores were a composite of radiation side effects on different sites, so could not be used for assessing xerostomia. </p> </section> <section id="CD012744-sec-0196"> <h5 class="title">Salivary flow rates</h5> <p>The sialometric data showed the reading dropped to an unmeasurable level in both groups so this was abandoned as a primary marker of efficacy and the protocol changed. </p> </section> <section id="CD012744-sec-0197"> <h5 class="title">Survival</h5> <p>We were unable to use the data on locoregional control.</p> </section> <section id="CD012744-sec-0198"> <h5 class="title">Quality of life and other oral related symptoms</h5> <p>No data on either quality of life or other oral related symptoms were reported.</p> </section> <section id="CD012744-sec-0199"> <h5 class="title">Side effects</h5> <p>The study reported that "no adverse events could be attributed to the experimental medication" (Additional <a href="#CD012744-tbl-0017">Table 14</a>). </p> <div class="table" id="CD012744-tbl-0017"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Venalot Depot (coumarin/troxerutin) versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0013" title="GrötzKA , Henneicke‐Von ZepelinHH , KohnenR , KutznerJ , BelzGG . Prophylaxis of mucositis and dry mouth after head and neck radiotherapy. A new treatment. Krankenhauspharmazie2002;23(5):193‐8. GrötzKA , Henneicke‐von ZepelinHH , KohnenR , al‐NawasB , BockischA , KutznerJ , et al. Prospective double‐blind study of prophylaxis of radioxerostomia with Coumarin/Troxerutine in patients with head and neck cancer [Prospektive, doppelblinde Therapiestudie zur Prophylaxe der Radioxerostomie durch Cumarin/Troxerutin bei Patienten mit Kopf‐Hals‐Karzinomen]. Strahlentherapie und Onkologie1999;175(8):397‐404. GrötzKA , WüstenbergP , KohnenR , Al‐NawasB , Henneicke‐von ZepelinH , BockischA , et al. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer ‐ a prospective, randomized, placebo‐controlled, double‐blind study. British Journal of Oral and Maxillofacial Surgery2001;39(1):34‐9. ">Grötz 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No adverse events could be attributed to the experimental medication"</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD012744-sec-0200"> <h5 class="title">Cost</h5> <p>No cost data related to the effectiveness of Venalot Depot were reported.</p> </section> </section> <section id="CD012744-sec-0201"> <h4 class="title">Sensitivity analysis</h4> <section id="CD012744-sec-0202"> <h5 class="title">Risk of bias</h5> <p>There were too few studies at low risk of bias to carry out sensitivity analyses based on this factor. </p> </section> <section id="CD012744-sec-0203"> <h5 class="title">Publication status</h5> <p>Four of the 39 studies were unpublished; <a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a> was a dissertation, <a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a>, <a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a> and <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> were conference abstracts. The authors of these papers were contacted and their data were provided. Sensitivity analysis was undertaken to assess whether the inclusion of unpublished information had an effect on the results of the review. </p> <section id="CD012744-sec-0204"> <h6 class="title">Pilocarpine</h6> <p><a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a> and <a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a> assessed pilocarpine. Removing these unpublished trials from the results did not alter the findings of the review i.e. xerostomia and salivary flow rates at the end of radiotherapy and three months postradiotherapy were still not significant. </p> </section> <section id="CD012744-sec-0205"> <h6 class="title">Amifostine</h6> <p><a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a> and <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> assessed amifostine. </p> <section id="CD012744-sec-0206"> <p><b>Xerostomia</b></p> <p>Removing <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> from the analysis of xerostomia at the end of radiotherapy increases the effect estimate from RR 0.35 (95% CI 0.19 to 0.67; P = 0.001; 119 participants) to RR 0.22 (95% CI 0.09 to 0.53; P = 0.0008; 60 participants). </p> <p>Removing <a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a> and <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> from the analysis of xerostomia at three months postradiotherapy does not change the result but increases the uncertainty around the effect estimate from RR 0.66 (95% CI 0.48 to 0.92; P = 0.01; 687 participants) to RR 0.66 (95% CI 0.40 to 1.09; P = 0.1; 473 participants), thus including the possibility of harm associated with amifostine. </p> <p>Removing <a href="./references#CD012744-bbs2-0028" title="PatniN , PatniS , BapnaA , SomaniN , GuptaA , RatnamBV . The role of amifostine in prophylaxis of radiotherapy induced mucositis and xerostomia in head and neck cancer. Journal of Clinical Oncology2004;22(14 Suppl):5568. ">Patni 2004</a> and <a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> from the analysis of xerostomia at 12 months postradiotherapy does not affect the result i.e. from RR 0.70 (95% CI 0.40 to 1.23; P = 0.21; 682 participants analysed) to RR 0.64 (95% CI 0.38 to 1.08; P = 0.09; 479 participants analysed). </p> </section> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012744-sec-0207" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012744-sec-0207"></div> <section id="CD012744-sec-0208"> <h3 class="title" id="CD012744-sec-0208">Summary of main results</h3> <p>A total of 39 trials were included in this review. We assessed the quality of the body of evidence for each outcome within a comparison (providing there was more than one study) using GRADE methodology (<a href="./references#CD012744-bbs2-0098" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490. ">GRADE 2004</a>). </p> <p><b>Pilocarpine</b> (<a href="./full#CD012744-tbl-0001">summary of findings Table for the main comparison</a>), compared with no treatment/placebo, was evaluated in 12 trials. There was no evidence of a difference in xerostomia between treatment groups at end of radiotherapy, three or six months. Similarly, there was also no evidence of a difference between treatment groups for salivary flow rates (stimulated or unstimulated) at any time point. There was insufficient evidence to determine the benefit of pilocarpine with regard to improving quality of life or increasing survival. There was no difference in reported adverse events, apart from sweating, where data from five studies showed an increased risk with pilocarpine. The body of evidence for each outcome was rated as very low quality, except for the adverse event of sweating which was low quality. </p> <p><b>Amifostine</b> (<a href="./full#CD012744-tbl-0002">summary of findings Table 2</a>), compared with no treatment/placebo, was evaluated in 11 studies. There is some (low‐quality) evidence that amifostine reduced the risk of developing grade ≥ 2 xerostomia (0 to 4 scale) at end of radiotherapy and, to a lesser extent, up to and including three months postradiotherapy. At 12 months postradiotherapy, there was insufficient evidence of a difference in the risk of grade ≥ 2 xerostomia. There was inconsistent (very low‐quality) evidence regarding the effect of amifostine on salivary flow rate. There was insufficient (very low‐quality) evidence to determine whether or not amifostine reduced overall survival, progression‐free survival, disease‐free survival or locoregional tumour control. Similarly, there was insufficient (very low‐quality) evidence to determine the benefit of amifostine in terms of quality of life. In general, adverse effects were poorly reported but there was (low‐quality) evidence that amifostine was associated with an increased risk of vomiting, hypotension, nausea and allergic response. </p> <p><b>Palifermin</b> (<a href="./full#CD012744-tbl-0003">summary of findings Table 3</a>), compared with placebo, was evaluated in three trials. There is insufficient (low‐quality) evidence to determine whether or not palifermin reduced the incidence of grade ≥ 2 xerostomia (0 to 4 scale) up to three months postradiotherapy. There was insufficient (moderate‐quality) evidence to determine the effect of palifermin on overall or progression‐free survival. There was no evidence of a difference in reported adverse effects. </p> <p>All evidence from any remaining comparisons did not undergo formal GRADE assessment but was considered to be of very low quality. </p> <p>Five trials (four at high risk of bias and one at unclear risk of bias) evaluated different forms of Chinese medicine. There is some evidence to suggest a benefit from Shenqi Fanghon recipe and an unspecified Chinese medicine at reducing xerostomia. Similarly, the unspecified Chinese medicine improved salivary flow rates. However, these findings were from single studies at high risk of bias. There was insufficient evidence to determine if any of the Chinese medicines had any effect on quality of life and survival. </p> <p>Other interventions evaluated, for which there is currently insufficient evidence to draw conclusions were: </p> <p> <ul id="CD012744-list-0010"> <li> <p>amifostine ‐ comparison of doses (single trial, at high risk of bias);</p> </li> <li> <p>amifostine ‐ different routes of administration (single trial, at high risk of bias);</p> </li> <li> <p>biperiden (single trial, at high risk of bias);</p> </li> <li> <p>bethanechol (single trial, at unclear risk of bias);</p> </li> <li> <p>bethanecol versus artificial saliva (single trial, at high risk of bias);</p> </li> <li> <p>selenium (single trial, at high risk of bias);</p> </li> <li> <p>antiseptic mouthrinse verus placebo (single trial, at high risk of bias);</p> </li> <li> <p>antimicrobial lozenge versus placebo (single trial, at high risk of bias);</p> </li> <li> <p>polaprezinc versus azulene oral rinse (single trial, at high risk of bias);</p> </li> <li> <p>Venalot Depot versus placebo (single trial, at high risk of bias).</p> </li> </ul> </p> </section> <section id="CD012744-sec-0209"> <h3 class="title" id="CD012744-sec-0209">Overall completeness and applicability of evidence</h3> <p>Although we found 39 eligible studies that covered a wide range of interventions, the evidence found is not sufficient to highlight much promise in terms of effective preventative treatments for salivary gland dysfunction. This is because, despite there being a reasonable number of studies for three of the interventions (amifostine: 12; pilocarpine: 12; palifermin: 3), there was inconsistency in the way outcomes were reported and in the timing of outcome measurement. Most comparisons included only a single small study, the large majority being at high risk of bias. The most complete body of evidence was for amifostine and the outcome of incidence of moderate to severe xerostomia. Guideline statements point out the lack of an established pharmacological prophylaxis for salivary gland dysfunction and highlight the potential of radiotherapeutic techniques/precautions in reducing damage to the salivary glands (for example parotid‐sparing plans) (<a href="./references#CD012744-bbs2-0092" title="BuglioneM , CavagniniR , DiRosarioF , MaddaloM , VassalliL , GrisantiS , et al. Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. Critical Reviews in Oncology/Hematology2016;102:47‐54. ">Buglione 2016</a>). Therefore, for completeness, it may be sensible to also carry out a Cochrane Review of non‐pharmacological interventions, although we are not aware of many randomised controlled trials. </p> <p>As mentioned, a wide range of interventions were assessed, but the studies were also conducted in both middle‐income and high‐income countries with no exclusion criteria in terms of the population included. Unfortunately, many studies did not include an objective measure of saliva flow to go with the more subjective measure of xerostomia. Furthermore, xerostomia was often measured differently between comparisons making it difficult to get an overall picture of the comparative effectiveness of the different interventions. </p> <p>It was interesting that two of the three interventions for which we were able to carry out meta‐analyses (amifostine and palifermin) have shown promise in a Cochrane Review on the prevention of oral mucositis, another major side effect of cancer treatment (<a href="./references#CD012744-bbs2-0113" title="WorthingtonHV , ClarksonJE , BryanG , FurnessS , GlennyA‐M , LittlewoodA , et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews2011, Issue 4. [DOI: 10.1002/14651858.CD000978.pub5] ">Worthington 2011</a>). As the evidence for amifostine in the prevention of salivary gland dysfunction is promising, this could be beneficial for patients as they may require fewer medications. However, amifostine is not currently recommended in clinical practice guidelines due to high costs and its side effects (<a href="./references#CD012744-bbs2-0092" title="BuglioneM , CavagniniR , DiRosarioF , MaddaloM , VassalliL , GrisantiS , et al. Oral toxicity management in head and neck cancer patients treated with chemotherapy and radiation: Xerostomia and trismus (Part 2). Literature review and consensus statement. Critical Reviews in Oncology/Hematology2016;102:47‐54. ">Buglione 2016</a>). Furthermore, the evidence for its long‐term benefit is weak. There was insufficient evidence to support the use of palifermin in this review, but it is possible that the intention‐to‐treat rules in one of the three studies in the xerostomia meta‐analysis may have influenced the result (<a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a>). Therefore, further studies assessing palifermin may be of interest. <a href="./references#CD012744-bbs2-0113" title="WorthingtonHV , ClarksonJE , BryanG , FurnessS , GlennyA‐M , LittlewoodA , et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database of Systematic Reviews2011, Issue 4. [DOI: 10.1002/14651858.CD000978.pub5] ">Worthington 2011</a> reported that there was no evidence that pilocarpine prevents oral mucositis. </p> </section> <section id="CD012744-sec-0210"> <h3 class="title" id="CD012744-sec-0210">Quality of the evidence</h3> <p>We included 39 studies that randomised 3520 participants; the number of participants analysed varied by outcome and time point. </p> <section id="CD012744-sec-0211"> <h4 class="title">Pilocarpine</h4> <p>We have very little confidence in the effect estimates for the outcomes of xerostomia, salivary flow rate, survival and quality of life (none of which showed a difference), mainly due to concerns regarding the risk of bias of the studies and imprecision of the results, but also due to inconsistency in the case of xerostomia. Further studies are likely to change the results. We had a little more confidence (although still limited) in the effect estimate for the adverse effect of sweating, which occurred more frequently in those receiving pilocarpine. Again it was risk of bias and imprecision which limited our confidence, and further studies would probably change the effect estimate. For more details see <a href="./full#CD012744-tbl-0001">summary of findings Table for the main comparison</a>. </p> </section> <section id="CD012744-sec-0212"> <h4 class="title">Amifostine</h4> <p>Our confidence in the effect estimates for xerostomia was limited by concerns regarding the risk of bias and inconsistency in the results of the individual studies. New studies could change the results. We had a similar level of confidence in the results for the adverse effects of vomiting, hypotension, nausea and allergic response, which were all more frequent in those receiving amifostine. Risk of bias and imprecision were the factors affecting our confidence. We had very little confidence in the effect estimates for salivary flow rate, survival and quality of life due to risk of bias and imprecision. For more details see <a href="./full#CD012744-tbl-0002">summary of findings Table 2</a>. </p> </section> <section id="CD012744-sec-0213"> <h4 class="title">Palifermin</h4> <p>Our confidence in the effect estimate for xerostomia was limited by concerns regarding imprecision and inconsistency in the results of the individual studies. We were moderately confident that palifermin did not compromise survival. For more details see <a href="./full#CD012744-tbl-0003">summary of findings Table 3</a>. </p> <p>We did not formally assess the quality of the evidence for all other comparisons in this review, but it is all considered to be very low quality due to single small studies that are mostly at high risk of bias. Further studies would very likely change the effect estimates for all outcomes and time points within these comparisons. </p> </section> </section> <section id="CD012744-sec-0214"> <h3 class="title" id="CD012744-sec-0214">Potential biases in the review process</h3> <p>Standard Cochrane methods were followed to avoid biases in the review process. However, we acknowledge that the decision to exclude data measured and reported during radiotherapy may be considered by some readers to be an arbitrary one. These data are potentially of interest and their exclusion may be thought of as a bias. </p> </section> <section id="CD012744-sec-0215"> <h3 class="title" id="CD012744-sec-0215">Agreements and disagreements with other studies or reviews</h3> <p>Although there are some systematic reviews on the treatment of salivary gland dysfunction caused by radiotherapy (<a href="./references#CD012744-bbs2-0094" title="DaviesAN , ThompsonJ . Parasympathomimetic drugs for the treatment of salivary gland dysfunction due to radiotherapy. Cochrane Database of Systematic Reviews2015, Issue 10. [DOI: 10.1002/14651858.CD003782.pub3] ">Davies 2015</a>; <a href="./references#CD012744-bbs2-0103" title="MercadanteV , Al HamadA , LodiG , PorterS , FedeleS . Interventions for the management of radiotherapy‐induced xerostomia and hyposalivation: A systematic review and meta‐analysis. Oral Oncology2017;66:64‐74. ">Mercadante 2017</a>), we are not aware of any high quality systematic reviews on prevention. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012744-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012744-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012744-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012744-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 1 Xerostomia." data-id="CD012744-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 1 Xerostomia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 2 Xerostomia (LENT‐SOMA scale)." data-id="CD012744-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 2 Xerostomia (LENT‐SOMA scale). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 3 Xerostomia." data-id="CD012744-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 3 Xerostomia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 4 Salivary flow rate (unstimulated)." data-id="CD012744-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 4 Salivary flow rate (unstimulated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 5 Salivary flow rate (stimulated)." data-id="CD012744-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 5 Salivary flow rate (stimulated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 6 Salivary flow rate (&gt; 0 g) unstimulated." data-id="CD012744-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 6 Salivary flow rate (&gt; 0 g) unstimulated. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 7 Salivary flow rate (&gt; 0 g) stimulated." data-id="CD012744-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 7 Salivary flow rate (&gt; 0 g) stimulated. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 8 Overall survival." data-id="CD012744-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 8 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 9 Quality of life." data-id="CD012744-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Pilocarpine versus no treatment/placebo, Outcome 9 Quality of life.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Biperiden plus pilocarpine versus no treatment, Outcome 1 Salivary flow rate (unstimulated)." data-id="CD012744-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Biperiden plus pilocarpine versus no treatment, Outcome 1 Salivary flow rate (unstimulated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Biperiden plus pilocarpine versus no treatment, Outcome 2 Salivary flow rate (&gt; 0 g) unstimulated." data-id="CD012744-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Biperiden plus pilocarpine versus no treatment, Outcome 2 Salivary flow rate (&gt; 0 g) unstimulated. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amifostine versus no treatment/placebo, Outcome 1 Xerostomia (0 to 4 scale ‐ grade 2 or above)." data-id="CD012744-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Amifostine versus no treatment/placebo, Outcome 1 Xerostomia (0 to 4 scale ‐ grade 2 or above). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amifostine versus no treatment/placebo, Outcome 2 Salivary flow rate (unstimulated)." data-id="CD012744-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Amifostine versus no treatment/placebo, Outcome 2 Salivary flow rate (unstimulated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amifostine versus no treatment/placebo, Outcome 3 Salivary flow rate (unstimulated) ‐ incidence of &gt; 0.1 g in 5 min." data-id="CD012744-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Amifostine versus no treatment/placebo, Outcome 3 Salivary flow rate (unstimulated) ‐ incidence of &gt; 0.1 g in 5 min. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amifostine versus no treatment/placebo, Outcome 4 Salivary flow rate (stimulated)." data-id="CD012744-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Amifostine versus no treatment/placebo, Outcome 4 Salivary flow rate (stimulated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amifostine versus no treatment/placebo, Outcome 5 Salivary flow rate (stimulated) ‐ incidence of &gt; 0.1 g in 5 min." data-id="CD012744-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Amifostine versus no treatment/placebo, Outcome 5 Salivary flow rate (stimulated) ‐ incidence of &gt; 0.1 g in 5 min. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amifostine versus no treatment/placebo, Outcome 6 Overall survival at 12 to 24 months postradiotherapy." data-id="CD012744-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Amifostine versus no treatment/placebo, Outcome 6 Overall survival at 12 to 24 months postradiotherapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0021"> <p> <div class="table" id="CD012744-tblf-0001"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amifostine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haddad 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median follow‐up 34 months after radiotherapy, minimum 26 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No differences noted"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jellema 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 times weekly = 84%</p> <p>5 times weekly = 58%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported narratively rather than as a risk ratio due to differing results in the amifostine arms </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Amifostine versus no treatment/placebo, Outcome 7 Overall survival ‐ narrative data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0021">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012744-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amifostine versus no treatment/placebo, Outcome 8 Progression‐free survival at 12 to 24 months postradiotherapy." data-id="CD012744-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Amifostine versus no treatment/placebo, Outcome 8 Progression‐free survival at 12 to 24 months postradiotherapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amifostine versus no treatment/placebo, Outcome 9 Progression‐free survival." data-id="CD012744-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Amifostine versus no treatment/placebo, Outcome 9 Progression‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0024"> <p> <div class="table" id="CD012744-tblf-0002"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amifostine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haddad 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median follow‐up 34 months after radiotherapy, minimum 26 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No differences noted"</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Amifostine versus no treatment/placebo, Outcome 10 Progression‐free survival ‐ narrative data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0024">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012744-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amifostine versus no treatment/placebo, Outcome 11 Locoregional tumour control at 12 to 24 months postradiotherapy." data-id="CD012744-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Amifostine versus no treatment/placebo, Outcome 11 Locoregional tumour control at 12 to 24 months postradiotherapy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0026"> <p> <div class="table" id="CD012744-tblf-0003"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amifostine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Haddad 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median follow‐up 34 months after radiotherapy, minimum 26 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No differences noted"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jellema 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 times weekly = 67%</p> <p>5 times weekly = 83%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Reported narratively rather than as a risk ratio due to differing results in the amifostine arms </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patni 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Amifostine does not alter the response or the survival"</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Amifostine versus no treatment/placebo, Outcome 12 Locoregional tumour control ‐ narrative data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0026">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012744-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amifostine versus no treatment/placebo, Outcome 13 Disease‐free survival." data-id="CD012744-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Amifostine versus no treatment/placebo, Outcome 13 Disease‐free survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0028"> <p> <div class="table" id="CD012744-tblf-0004"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amifostine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patni 2004</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"Amifostine does not alter the response or the survival"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Veerasarn 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"There was no statistical difference in 2‐year disease‐free survival"</p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Amifostine versus no treatment/placebo, Outcome 14 Disease‐free survival.</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0028">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012744-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Amifostine versus no treatment/placebo, Outcome 15 Quality of life (Patient Benefit Questionnaire)." data-id="CD012744-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 Amifostine versus no treatment/placebo, Outcome 15 Quality of life (Patient Benefit Questionnaire). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Amifostine (comparison of dosages), Outcome 1 Xerostomia (0 to 4 scale ‐ grade 2 or above)." data-id="CD012744-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Amifostine (comparison of dosages), Outcome 1 Xerostomia (0 to 4 scale ‐ grade 2 or above). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0031"> <p> <div class="table" id="CD012744-tblf-0005"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amifostine 3 times weekly</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amifostine 5 times weekly</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jellema 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Amifostine (comparison of dosages), Outcome 2 Overall survival ‐ narrative data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0031">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012744-fig-0032"> <p> <div class="table" id="CD012744-tblf-0006"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amifostine 3 times weekly</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amifostine 5 times weekly</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jellema 2006</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Amifostine (comparison of dosages), Outcome 3 Locoregional tumour control ‐ narrative data. </p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0032">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012744-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Amifostine (intravenous versus subcutaneous), Outcome 1 Xerostomia (0 to 4 scale ‐ grade 2 or above)." data-id="CD012744-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Amifostine (intravenous versus subcutaneous), Outcome 1 Xerostomia (0 to 4 scale ‐ grade 2 or above). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Amifostine (intravenous versus subcutaneous), Outcome 2 Overall survival." data-id="CD012744-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Amifostine (intravenous versus subcutaneous), Outcome 2 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Amifostine (intravenous versus subcutaneous), Outcome 3 Locoregional tumour control." data-id="CD012744-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Amifostine (intravenous versus subcutaneous), Outcome 3 Locoregional tumour control. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Chinese medicine versus no treatment/placebo, Outcome 1 Xerostomia." data-id="CD012744-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Chinese medicine versus no treatment/placebo, Outcome 1 Xerostomia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Chinese medicine versus no treatment/placebo, Outcome 2 Xerostomia." data-id="CD012744-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Chinese medicine versus no treatment/placebo, Outcome 2 Xerostomia.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Chinese medicine versus no treatment/placebo, Outcome 3 Salivary flow rate (stimulated)." data-id="CD012744-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Chinese medicine versus no treatment/placebo, Outcome 3 Salivary flow rate (stimulated). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Chinese medicine versus no treatment/placebo, Outcome 4 Overall survival (12 months postRT)." data-id="CD012744-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Chinese medicine versus no treatment/placebo, Outcome 4 Overall survival (12 months postRT). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-006-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-006-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Chinese medicine versus no treatment/placebo, Outcome 5 Quality of life (EORTC‐C30)." data-id="CD012744-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-006-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.5</div> <div class="figure-caption"> <p>Comparison 6 Chinese medicine versus no treatment/placebo, Outcome 5 Quality of life (EORTC‐C30). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-006-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Palifermin versus placebo, Outcome 1 Xerostomia (0 to 4 scale ‐ grade 2 or above)." data-id="CD012744-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Palifermin versus placebo, Outcome 1 Xerostomia (0 to 4 scale ‐ grade 2 or above). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Palifermin versus placebo, Outcome 2 Overall survival at 42 to 72 months from baseline." data-id="CD012744-fig-0042" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Palifermin versus placebo, Outcome 2 Overall survival at 42 to 72 months from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-007-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-007-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Palifermin versus placebo, Outcome 3 Progression‐free survival at 42 to 72 months from baseline." data-id="CD012744-fig-0043" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-007-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7 Palifermin versus placebo, Outcome 3 Progression‐free survival at 42 to 72 months from baseline. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-007-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Bethanechol versus placebo, Outcome 1 Xerostomia (0 to 3 scale ‐ grade 2 or above)." data-id="CD012744-fig-0044" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Bethanechol versus placebo, Outcome 1 Xerostomia (0 to 3 scale ‐ grade 2 or above). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Bethanechol versus placebo, Outcome 2 Salivary flow rate (unstimulated) ‐ ml/min." data-id="CD012744-fig-0045" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Bethanechol versus placebo, Outcome 2 Salivary flow rate (unstimulated) ‐ ml/min. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Bethanechol versus placebo, Outcome 3 Salivary flow rate (stimulated) ‐ ml/min." data-id="CD012744-fig-0046" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Bethanechol versus placebo, Outcome 3 Salivary flow rate (stimulated) ‐ ml/min. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Bethanechol versus artificial saliva, Outcome 1 Xerostomia (dry mouth? yes/no)." data-id="CD012744-fig-0047" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Bethanechol versus artificial saliva, Outcome 1 Xerostomia (dry mouth? yes/no). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Bethanechol versus artificial saliva, Outcome 2 Salivary flow rate (unstimulated) ‐ ml/min." data-id="CD012744-fig-0048" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Bethanechol versus artificial saliva, Outcome 2 Salivary flow rate (unstimulated) ‐ ml/min. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-009-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-009-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Bethanechol versus artificial saliva, Outcome 3 Salivary flow rate (stimulated) ‐ ml/min." data-id="CD012744-fig-0049" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-009-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9 Bethanechol versus artificial saliva, Outcome 3 Salivary flow rate (stimulated) ‐ ml/min. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-009-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-009-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-009-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Bethanechol versus artificial saliva, Outcome 4 Overall survival." data-id="CD012744-fig-0050" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-009-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.4</div> <div class="figure-caption"> <p>Comparison 9 Bethanechol versus artificial saliva, Outcome 4 Overall survival.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-009-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0051"> <p> <div class="table" id="CD012744-tblf-0007"> <table> <div class="table-heading"><span class="table-title"></span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Büntzel 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"comparing the mean value of xerostomia, no statistically significant difference can be seen between the groups" </p> </td> </tr> </tbody> </table> </div> </p> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Selenium versus no selenium, Outcome 1 Xerostomia.</p> </div> </div> <div class="tools"><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0051">Navigate to figure in review</a></div> </div> <div class="figure" id="CD012744-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Antimicrobial lozenge versus placebo, Outcome 1 Xerostomia (QoL response for dryness)." data-id="CD012744-fig-0052" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Antimicrobial lozenge versus placebo, Outcome 1 Xerostomia (QoL response for dryness). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Antimicrobial lozenge versus placebo, Outcome 2 Quality of life." data-id="CD012744-fig-0053" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Antimicrobial lozenge versus placebo, Outcome 2 Quality of life.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012744-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/urn:x-wiley:14651858:media:CD012744:CD012744-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_t/tCD012744-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Polaprezinc versus azulene oral rinse, Outcome 1 Xerostomia (grade 2 or above)." data-id="CD012744-fig-0054" src="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Polaprezinc versus azulene oral rinse, Outcome 1 Xerostomia (grade 2 or above). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012744/media/CDSR/CD012744/image_n/nCD012744-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012744-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Pilocarpine compared to no treatment/placebo for preventing salivary gland dysfunction following radiotherapy</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b> Pilocarpine compared to no treatment/placebo for preventing salivary gland dysfunction following radiotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region<br/> <b>Intervention:</b> pilocarpine<br/> <b>Comparison:</b> no treatment/placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment/placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with pilocarpine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xerostomia ‐ Up to and including 6 months postRT</p> <p>Studies used different ways of measuring the outcome and therefore we combined the studies using SMD </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.35 lower<br/> (1.04 lower to 0.33 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence of a difference at this time point and also at the end of RT and 3 months postRT </p> <p>1 of the 2 studies in this assessment showed inconsistent results when using an alternative way of measuring this outcome at the 6‐month time point. 2 further studies showed insufficient evidence of a difference, 1 at the end of RT and the other at 3 months postRT </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salivary flow rate (unstimulated) ‐ Up to and including 3 months postRT</p> <p>Studies used different ways of measuring the outcome and therefore we combined the studies using SMD </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.06 lower (0.23 lower to 0.11 higher)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence of a difference at this time point and also at the end of RT</p> <p>Same results for stimulated salivary flow rates at end of RT, and 3, 6 and 12 months postRT </p> <p>Same results for a further study at the end of RT and 3 months postRT looking at whether or not stimulated and unstimulated salivary flow was &gt; 0 g </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival ‐ Up to and including 6 months postRT</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>724 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>775 per 1000<br/> (579 to 1000) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.07<br/> (0.80 to 1.43) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence of a difference</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life ‐ Up to and including 6 months postRT</p> <p>McMaster University Head and Neck Questionnaire (HNRQ). Score 1‐7, lower score = poorer quality of life </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Control group mean was 5.3</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.20 higher<br/> (0.19 lower to 0.59 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence of a difference at this time point and also at the end of RT and 3 months postRT </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p>Insufficient evidence of a difference between groups for any reported adverse event, apart from for sweating where data from 5 studies showed an increased risk associated with pilocarpine (RR 2.98, 95% CI 1.43 to 6.22; P = 0.004; I<sup>2</sup> = 0%; 389 participants; ⊕⊕⊝⊝ LOW<sup>4</sup>) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)<br/> <br/> <b>CI:</b> confidence interval; <b>MD:</b> mean difference; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference; <b>RT:</b> radiotherapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 level for risk of bias, 1 level for imprecision (small sample size and 95% CIs include both possibility of benefit and harm), and 1 level for inconsistency (I<sup>2</sup> = 68%).<br/> <sup>2</sup>Downgraded by 1 level for risk of bias, and 2 levels for imprecision (single study with 12 participants per group and 95% CIs include both possibility of benefit and harm).<br/> <sup>3</sup>Downgraded by 1 level for risk of bias, and 2 levels for imprecision (single study and 95% CIs include both possibility of benefit and harm).<br/> <sup>4</sup>Downgraded by 1 level for risk of bias, and 1 level for imprecision (very wide 95% CIs). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Pilocarpine compared to no treatment/placebo for preventing salivary gland dysfunction following radiotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012744-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Amifostine compared to no treatment/placebo for preventing salivary gland dysfunction following radiotherapy</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b> Amifostine compared to no treatment/placebo for preventing salivary gland dysfunction following radiotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region<br/> <b>Intervention:</b> amifostine<br/> <b>Comparison:</b> no treatment/placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with no treatment/placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with amifostine</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xerostomia (0‐4 scale ‐ grade 2 or above) ‐ 12 months postRT</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>418 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>292 per 1000<br/> (167 to 514) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.70<br/> (0.40 to 1.23) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>682<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence of a difference at this time point. However, both at the end of RT (RR 0.35, 95% CI 0.19 to 0.67; 3 studies, 119 participants) and up to 3 months postRT (RR 0.66, 95% CI 0.48 to 0.92; 5 studies, 687 participants), amifostine reduced the risk of developing grade ≥ 2 xerostomia </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Salivary flow rate (mg/5 min) (unstimulated) ‐ 12 months postRT</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Control group mean was 0.16</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.32 higher<br/> (0.09 higher to 0.55 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amifostine led to increased unstimulated saliva flow both at 12 months postRT and at the end of RT, but there was insufficient evidence of a difference at 3 months postRT. This evidence was supported by a further study showing a benefit for amifostine at 12 months postRT when looking at incidence of producing &gt; 0.1 g of saliva over 5 minutes (RR 1.45, 95% CI 1.13 to 1.86; 175 participants). A further study narratively reported no difference </p> <p>Insufficient evidence of a difference in stimulated saliva flow at any time point</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival at 12 to 24 months postRT</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450 per 1000**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>531 per 1000<br/> (383 to 747) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.18<br/> (0.85 to 1.66) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>271<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to determine whether or not amifostine reduces overall survival, progression‐free survival, disease‐free survival or locoregional tumour control up to 24 months postRT </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Quality of life (Patient Benefit Questionnaire) ‐ 12 months postRT</p> <p>8 items each on a 10‐point scale where higher = better QoL</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Control group mean was 6.66</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>MD 0.7 higher<br/> (0.2 higher to 1.2 higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180<br/> (1 study) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> VERY LOW<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Amifostine led to a small improvement in quality of life at 12 months postRT, but there was insufficient evidence of a difference at the end of RT and 3 months postRT </p> <p>A further study narratively reported no difference at end of RT and 6, 12, 18, and 24 months postRT </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects</p> </td> <td align="" class="table-tint table-highlight" colspan="6" rowspan="1" valign=""> <p> <ul id="CD012744-list-0001"> <li> <p>Data from 5 studies showed an increased risk of vomiting associated with amifostine (RR 4.90, 95% CI 2.87 to 8.38; 601 participants; ⊕⊕⊝⊝ LOW<sup>4</sup>) </p> </li> <li> <p>Data from 3 studies showed an increased risk of hypotension associated with amifostine (RR 9.20, 95% CI 2.84 to 29.83; 376 participants; ⊕⊕⊝⊝ LOW<sup>4</sup>) </p> </li> <li> <p>Data from 4 studies showed an increased risk of nausea associated with amifostine (RR 2.60, 95% CI 1.81 to 3.74; 556 participants; ⊕⊕⊝⊝ LOW<sup>4</sup>) </p> </li> <li> <p>Data from 3 studies showed an increased risk of allergic response associated with amifostine (RR 7.51, 95% CI 1.40 to 40.39; 524 participants; ⊕⊕⊝⊝ LOW<sup>4</sup>) </p> </li> </ul> </p> <p>There was insufficient evidence of a difference between groups for any other adverse events </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)<br/> **2014 5‐year overall survival rate of patients with head and neck squamous cell carcinoma (<a href="http://www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf" target="_blank">www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf</a>)<br/> <br/> <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>MD:</b> mean difference; <b>QoL:</b> quality of life; <b>RR:</b> risk ratio; <b>RT:</b> radiotherapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 level for risk of bias, and 1 level for inconsistency (I<sup>2</sup> = 83%).<br/> <sup>2</sup>Downgraded by 1 level for risk of bias, and 2 levels for imprecision (single study and small sample size).<br/> <sup>3</sup>Downgraded by 1 level for risk of bias, and 2 levels for imprecision (small sample size and 95% CIs include both possibility of benefit and harm).<br/> <sup>4</sup>Downgraded by 1 level for risk of bias, and 1 level for imprecision (very wide 95% CIs). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Amifostine compared to no treatment/placebo for preventing salivary gland dysfunction following radiotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012744-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Palifermin compared to placebo for preventing salivary gland dysfunction following radiotherapy</span></div> <tbody> <tr class="table-header separated"> <td align="left" class="table-header" colspan="7" rowspan="1" valign="top"> <p><b> Palifermin compared to placebo for preventing salivary gland dysfunction following radiotherapy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region<br/> <b>Intervention:</b> palifermin<br/> <b>Comparison:</b> placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Number of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with palifermin</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xerostomia (0‐4 scale ‐ grade 2 or above) ‐ Up to and including 3 months postRT</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>727 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>705 per 1000<br/> (560 to 887) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.97<br/> (0.77 to 1.22) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>471<br/> (3 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW<sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence of a difference at this time point</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Overall survival at 42 to 72 months from baseline</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>450 per 1000**</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>450 per 1000<br/> (324 to 626) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.00<br/> (0.72 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(3 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE<sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient evidence to determine whether or not amifostine reduces overall survival and progression‐free survival up to 72 months </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse effects</p> </td> <td align="left" class="table-tint table-highlight" colspan="6" rowspan="1" valign="top"> <p>There was insufficient evidence of patients in either group experiencing more or less adverse events </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI) </p> <p>**2014 5‐year overall survival rate of patients with head and neck squamous cell carcinoma (<a href="http://www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf" target="_blank">www.who.int/selection_medicines/committees/expert/20/applications/HeadNeck.pdf</a>)<br/> <br/> <b>CI:</b> confidence interval; <b>HR:</b> hazard ratio; <b>RR:</b> risk ratio; <b>RT:</b> radiotherapy </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded by 1 level for imprecision (95% CIs include both possibility of benefit and harm), and 1 level for inconsistency (I<sup>2</sup> = 76%).<br/> <sup>2</sup>Downgraded by 1 level for imprecision (95% CIs include both possibility of benefit and harm). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Palifermin compared to placebo for preventing salivary gland dysfunction following radiotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012744-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Pilocarpine versus no treatment/placebo (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pilocarpine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Oral related symptoms (other than salivary gland dysfunction/xerostomia)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral discomfort</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 38.7 (SD 31.6)</p> <p>n = 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 56.7 (SD 26.7)</p> <p>n = 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference ‐18.00 (95% CI ‐37.41 to 1.41), P = 0.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Speech difficulties</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 57.5 (SD 26.8)</p> <p>n = 16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 37.3 (SD 27.5)</p> <p>n = 18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference 20.20 (95% CI 1.93 to 38.47), P = 0.03</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Eating difficulties</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 47.4 (SD 33.9)</p> <p>n = 15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 61.8 (SD 25.4)</p> <p>n = 17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference ‐14.40 (95% CI ‐35.38 to 6.58), P = 0.18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mucosal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 38.8 (SD 33.9)</p> <p>n = 17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 53.6 (SD 34.2)</p> <p>n = 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference ‐14.80 (95% CI ‐37.07 to 7.47), P = 0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Oral complications</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0030" title="PimentelMJ , FilhoMM , AraújoM , GomesDQ , DaCostaLJ . Evaluation of radioprotective effect of pilocarpine ingestion on salivary glands. Anticancer Research2014;34(4):1993‐9. ">Pimentel 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.30 (95% CI 0.05 to 1.89), P = 0.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Sweating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Random‐effects meta‐analysis of 5 studies: RR 2.98 (95% CI 1.43 to 6.22), P = 0.004</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.52 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chilling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0001" title="AbaciogluMU . Effect of Pilocarpine for the Prevention of Radiation‐Induced Xerostomia [Dissertation]. Marmara (Turkey): Marmara University Hospital, 1997. ">Abacioglu 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.00 (95% CI 0.13 to 67.06), P = 0.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Random‐effects meta‐analysis of 3 studies: RR 1.39 (95% CI 0.63 to 3.05), P = 0.41</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.93 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0014" title="HaddadP , KarimiM . A randomised, double‐blind, placebo‐controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation‐induced xerostomia. Radiotherapy and Oncology2002;64(1):29‐32. ">Haddad 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Random‐effects meta‐analysis of 3 studies: RR 1.28 (95% CI 0.70 to 2.35), P = 0.43</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.92 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.67 (95% CI 0.12 to 3.69), P = 0.64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Excessive lacrimation (tears)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Random‐effects meta‐analysis of 3 studies: RR 2.54 (95% CI 0.70 to 9.17), P = 0.15</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.71 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0014" title="HaddadP , KarimiM . A randomised, double‐blind, placebo‐controlled trial of concomitant pilocarpine with head and neck irradiation for prevention of radiation‐induced xerostomia. Radiotherapy and Oncology2002;64(1):29‐32. ">Haddad 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dysphasia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.50 (95% CI 0.30 to 7.43), P = 0.62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Weakness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.45 (95% CI 0.25 to 8.51), P = 0.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Nervous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Random‐effects meta‐analysis of 2 studies: RR 1.02 (95% CI 0.11 to 9.33), P = 0.99</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.33 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Rhinitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Random‐effects meta‐analysis of 3 studies: RR 0.87 (95% CI 0.41 to 1.86), P = 0.72</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.53 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Blurred vision</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0027" title="Lozada‐NurF , SchoelchM , FuK , MuscoplatC , TrivediM , SmithC , et al. A pilot study to evaluate the effect of pilocarpine tablets on salivary flow and mucositis in head and neck cancer patients during radiotherapy. Proceedings of the American Society of Clinical Oncology1998;17:399. [Abs No 1541] ">Lozada‐Nur 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.00 (95% CI 0.13 to 67.06), P = 0.49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Urinary frequency</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Random‐effects meta‐analysis of 2 studies: RR 0.87 (95% CI 0.43 to 1.75), P = 0.70</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.32 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Random‐effects meta‐analysis of 2 studies: RR 0.80 (95% CI 0.18 to 3.45), P = 0.76</p> <p>Heterogeneity: I<sup>2</sup> = 13%, P = 0.28 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Palpitation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0033" title="SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Journal of the Medical Association of Thailand2001;84(2):195‐203. SangthawanD , WatthanaarpornchaiS , PhungrassamiT . Randomized double blind, placebo‐controlled study of pilocarpine administered during head and neck irradiation to reduce xerostomia. Radiation Oncology Association of Thailand2002;7:242. ">Sangthawan 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.10 (95% CI 0.01 to 1.73), P = 0.11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin flushing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.90 (95% CI 0.12 to 70.44), P = 0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Motor tremors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0011" title="FisherJ , ScottC , ScarantinoCW , LevequeFG , WhiteRL , RotmanM , et al. Phase III quality‐of‐life study results: impact on patients' quality of life to reducing xerostomia after radiotherapy for head‐and‐neck cancer ‐ RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2003;56(3):832‐6. ScarantinoC , LeVequeF , SwannRS , WhiteR , SchulsingerA , HodsonI , et al. Effect of pilocarpine during radiation therapy: results of RTOG 97‐09, a phase III randomized study in head and neck cancer patients. Journal of Supportive Oncology2006;4(5):252‐8. ScarantinoCW , LevequeF , ScottC , WhiteRL , RotmanM , HodsonDI , et al. A phase III study on the concurrent use of oral pilocarpine to reduce hyposalivation and mucositis associated with radiation therapy in head and neck cancer patients. Final results of RTOG 97‐09. International Journal of Radiation Oncology, Biology, Physics2001;51(3 Suppl 1):85‐6. [Abs No 157] ScarantinoCW , LevequeFG , ScottCB , WhiteRL , RotmanM , HodsonDI . A phase III study of concomitant oral pilocarpine to reduce hypo‐salivation and mucositis associated with curative radiation therapy (RT) in head and neck (H&amp;N) cancer patients. RTOG 9709. Proceedings of the American Society of Clinical Oncology2001;20:225a. [Abs No 897] ">Fisher 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/118</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/114</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.93 (95% CI 0.18 to 21.02), P = 0.59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0012" title="GornitskyM , ShenoudaG , SultanemK , KatzH , HierM , BlackM , et al. Double‐blind randomized, placebo‐controlled study of pilocarpine to salvage salivary gland function during radiotherapy of patients with head and neck cancer. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics2004;98(1):45‐52. ">Gornitsky 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 37.3 (SD 36.4)</p> <p>n = 17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean 49.6 (SD 36.9)</p> <p>n = 19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mean difference ‐12.30 (95% CI ‐36.27 to 11.67), P = 0.31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RTOG (grade 3; mucous membrane, pharynx and larynx)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0038" title="WardeP , O'SullivanB , AslanidisJ , KrollB , LockwoodG , MathM , et al. A phase III placebo‐controlled trial of oral pilocarpine in patients undergoing radiotherapy for head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;54(1):9‐13. ">Warde 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistically significant difference between treatment groups</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI = confidence interval; RR = risk ratio; RTOG = Radiation Therapy Oncology Group; SD = standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Pilocarpine versus no treatment/placebo (other outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012744-tbl-0005"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Biperiden plus pilocarpine versus no treatment/placebo (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pilocarpine</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dysphagia (WHO grade 3+)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0032" title="RodeM , SmidL , BudihnaM , SobaE , RodeM , GaspersicD . The effect of pilocarpine and biperiden on salivary secretion during and after radiotherapy in head and neck cancer patients. International Journal of Radiation Oncology, Biology, Physics1999;45(2):373‐8. ">Rode 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.25 (95% CI 0.03 to 2.11), P = 0.20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI = confidence interval; RR = risk ratio; RT = radiotherapy; WHO = World Health Organization.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Biperiden plus pilocarpine versus no treatment/placebo (other outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012744-tbl-0006"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Amifostine versus no treatment/placebo (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Amifostine</b> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assessed at end of RT and 6, 12, 18 and 24 months after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No significant differences between the 3 treatment arms"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Dysphagia (difficulty in swallowing) (0‐4 scale): grade 3 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Random‐effects meta‐analysis of 2 studies: RR 0.50 (95% CI 0.17 to 1.48); P = 0.21</p> <p>Heterogeneity: I<sup>2</sup> = 40%, P = 0.20 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 weeks after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.70 (95% CI 0.13 to 3.78); P = 0.68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>By 8 weeks after RT, no participants had grade 3 or above dysphagia</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dysgeusia (taste disturbance) (0‐4 scale): grade 2 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.24 (95% CI 0.10 to 0.61); P = 0.003</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cost data (mean per patient supportive care costs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USD 4401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>USD 5873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="7" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="5" valign=""> <p>Random‐effects meta‐analysis of 5 studies: RR 4.90 (95% CI 2.87 to 8.38); P &lt; 0.00001</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.96 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"1 patient left due to gastrointestinal tract reaction/side effect, all other patients completed the treatment" </p> <p>"At the beginning of treatment, nausea and vomiting was obvious for amifostine group, but after treating with metoclopramide, there was no significant difference between 2 groups in gastrointestinal tract reaction/side effect" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0002" title="AntonadouD , PepelassiM , SynodinouM , PuglisiM , ThrouvalasN . Prophylactic use of amifostine to prevent radiochemotherapy‐induced mucositis and xerostomia in head‐and‐neck cancer. International Journal of Radiation Oncology, Biology, Physics2002;52(3):739‐47. ">Antonadou 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Random‐effects meta‐analysis of 3 studies: RR 9.20 (95% CI 2.84 to 29.83); P = 0.0002</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.88 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0007" title="BennettCL , LaneD , StinsonT , GlatzelM , BuntzelJ . Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany. Cancer Investigation2001;19(2):107‐13. BuntzelJ , GlatzelM , SchuthJ , FrohlichD , KuttnerK . Selective cytoprotection with amifostine: a new strategy in supportive care of head and neck malignancies. Oto‐Rhino‐Laryngologia Nova1997;7:276‐80. BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine (A) in the treatment of head and neck cancer with simultaneous radiochemotherapy (RCT). European Cancer Conference; 1997 Sep 14‐18; Hamburg (Germany). Hamburg (Germany): ECCO, 1997. [Abs No 852] BuntzelJ , KuttnerK , RussellL , OsterW , SchuthJ , GlatzelM . Selective cytoprotection by amifostine in the treatment of head and neck cancer with simultaneous radiochemotherapy. Proceedings of the American Society of Clinical Oncology1997;16:393. [Abs No 1400] BüntzelJ . Experiences with selenium in the treatment of acute and late toxicities due to radiochemotherapy of head and neck cancer [Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf‐Hals‐Karzinomen]. Medizinische Klinik1999;94 Suppl III:49‐53. BüntzelJ , GlatzelM , KuttnerK , SchuthJ , OsterW , FrohlichF . Selective cytoprotection with amifostine in simultaneous radiochemotherapy of head neck cancer. Annals of Oncology1996;7(81):381. BüntzelJ , GlatzelM , KuttnerK , WeinaugR , FröhlichD . Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer. Seminars in Radiation Oncology2002;12(1 Suppl 1):4‐13. BüntzelJ , Kuttner , FrohlichD , SchuthJ , GlatzelM . Amifostine in simultaneous radiochemotherapy for head and neck cancer. Oto‐Rhino‐Laryngologia Nova1997;7:204‐10. BüntzelJ , KüttnerK , FröhlichD , GlatzelM . Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer. Annals of Oncology1998;9(5):505‐9. BüntzelJ , SchuthJ , KüttnerK , GlatzelM . Radiochemotherapy with amifostine cytoprotection for head and neck cancer. Supportive Care in Cancer1998;6(2):155‐60. ">Büntzel 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25/153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign=""> <p>Random‐effects meta‐analysis of 4 studies: RR 2.60 (95% CI 1.81 to 3.74); P &lt; 0.00001</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.45 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0017" title="HeX , HuC , WuY . Radioprotective effect of amifostine in nasopharyngeal carcinoma. Fudan University Journal of Medical Sciences2004;31(1):53‐8. ">He 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"1 patient left due to gastrointestinal tract reaction/side effect, all other patients completed the treatment" </p> <p>"At the beginning of treatment, nausea and vomiting was obvious for amifostine group, but after treating with metoclopramide, there was no significant difference between 2 groups in gastrointestinal tract reaction/side effect" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Allergic response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0004" title="BrizelD , SauerR , WannenmacherM , HenkeM , EschwegeF , WassermanT . Randomized phase III trial of radiation amifostine in patients with head and neck cancer. 34th Annual Meeting of the American Society of Clinical Oncology; 1998 May 17‐19; Los Angeles (USA). Los Angeles (USA): American Society of Clinical Oncology, 1998. [Abs No 1487] BrizelDM , WassermanT . The influence of intravenous amifostine on xerostomia and survival during radiotherapy for head and neck cancer: two year follow‐up of a prospective randomized trial. Journal of Clinical Oncology2004;22(14 Suppl):5536. BrizelDM , WassermanTH , HenkeM , StrnadV , RudatV , MonnierA , et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. Journal of Clinical Oncology2000;18(19):3339‐45. RudatV , MeyerJ , MommF , BendelM , HenkeM , StrnadV , et al. Protective effect of amifostine on dental health after radiotherapy of the head and neck. International Journal of Radiation Oncology, Biology, Physics2000;48(5):1339‐43. StrnadV , SauerR . Radioprotection of head and neck tissue by amifostine. Frontiers of Radiation Therapy and Oncology2002;37:101‐11. WassermanT , MackowiakJI , BrizelDM , OsterW , ZhangJ , PeeplesPJ , et al. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer. International Journal of Radiation Oncology, Biology, Physics2000;48(4):1035‐9. WassermanTH , BrizelDM , HenkeM , MonnierA , EschwegeF , SauerR , et al. Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head‐and‐ neck cancer: 2‐year follow‐up of a prospective, randomized, phase III trial. International Journal of Radiation Oncology, Biology, Physics2005;63(4):985‐90. ">Brizel 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/153</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Random‐effects meta‐analysis of 3 studies: RR 7.51 (95% CI 1.40 to 40.39); P = 0.02</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.77 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthenia (weakness or lack of energy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0006" title="BuentzelJ , MickeO , AdamietzIA , MonnierA , GlatzelM , deVriesA . Intravenous amifostine during chemoradiotherapy for head‐and‐neck cancer: a randomized placebo‐controlled phase III study. International Journal of Radiation Oncology, Biology, Physics2006;64(3):684‐91. ">Buentzel 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.91 (95% CI 0.31 to 27.24); P = 0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Alopecia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0034" title="VachaP , FehlauerF , MahlmannB , MarxM , HinkeA , SommerK , et al. Randomized phase III trial of postoperative radiochemotherapy +/‐ amifostine in head and neck cancer. Is there evidence for radioprotection?. Strahlentherapie und Onkologie2003;179(6):385‐9. VachaP , MarxM , EngelA , RichterE , FeyerabendT . Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlentherapie und Onkologie1999;175 Suppl 4:18‐22. ">Vacha 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Similar in both groups and increased continuously during the treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0034" title="VachaP , FehlauerF , MahlmannB , MarxM , HinkeA , SommerK , et al. Randomized phase III trial of postoperative radiochemotherapy +/‐ amifostine in head and neck cancer. Is there evidence for radioprotection?. Strahlentherapie und Onkologie2003;179(6):385‐9. VachaP , MarxM , EngelA , RichterE , FeyerabendT . Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial. Strahlentherapie und Onkologie1999;175 Suppl 4:18‐22. ">Vacha 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Similar in both groups and increased continuously during the treatment</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Hot flush</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"..dizziness, fatigue, hiccup, sneezing, facial flush all in less than 5% of the patients"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Somnolence (drowsiness)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Sneezing</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"..dizziness, fatigue, hiccup, sneezing, facial flush all in less than 5% of the patients"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Hiccup</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"..dizziness, fatigue, hiccup, sneezing, facial flush all in less than 5% of the patients"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0036" title="VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , ChitapanaruxI , TesavibulC , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland dysfunction. European Journal of Cancer Supplements2003;1(5):S273. [Abs No 908] VeerasarnV , PhromratanapongseP , SuntornpongN , LorvidhayaV , SukthomyaV , ChitapanaruxI , et al. Effect of amifostine to prevent radiotherapy‐induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. Journal of the Medical Association of Thailand2006;89(12):2056‐67. ">Veerasarn 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Data not reported in control group. Unknown if this was due to 0 events</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"...dizziness, fatigue, hiccup, sneezing, facial flush all in less than 5% of the patients" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0029" title="PengLH , SunY , ZhangXL , ZhangQ , FuS . Efficacy of amifostine on patients with head and neck squamous cell carcinomas undergoing radiation therapy and chemotherapy and clinical observation on its hematologic toxicity. Journal of China Pharmacy2006;17(5):1166‐8. ">Peng 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"..dizziness, fatigue, hiccup, sneezing, facial flush all in less than 5% of the patients"</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI = confidence interval; RR = risk ratio; RT = radiotherapy; USD = US dollars.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Amifostine versus no treatment/placebo (other outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012744-tbl-0007"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Amifostine: comparison of different doses (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amifostine 3 times weekly</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Amifostine 5 times weekly</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quality of life</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Assessed at end of RT and 6, 12, 18 and 24 months after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No significant differences between the 3 treatment arms"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.64 (95% CI 0.33 to 1.25); P = 0.19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.25 (95% CI 0.06 to 1.08); P = 0.06</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Allergic response</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0021" title="JellemaAP , SlotmanBJ , MullerMJ , LeemansCR , SmeeleLE , HoekmanK , et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: a prospective randomized study in squamous cell head and neck cancer. Cancer2006;107(3):544‐53. ">Jellema 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.00 (95% CI 0.15 to 6.64); P = 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI = confidence interval; RR = risk ratio; RT = radiotherapy.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Amifostine: comparison of different doses (other outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012744-tbl-0008"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Amifostine: different routes of administration (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Intravenous</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Subcutaneous</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.267</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hypotension</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Local pain at injection site</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.256</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthenia (weakness or lack of energy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0003" title="BardetE , MartinL , CalaisG , AlfonsiM , FehamN E , TuchaisC , et al. Subcutaneous compared with intravenous administration of amifostine in patients with head and neck cancer receiving radiotherapy: final results of the GORTEC2000‐02 phase III randomized trial. Journal of Clinical Oncology2011;29(2):127‐33. BardetE , MartinL , CalaisG , TuchaisC , BourhisJ , RheinB , et al. Preliminary data of the GORTEC 2000‐02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Seminars in Oncology2002;29(6 Suppl 19):57‐60. ">Bardet 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.054</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Amifostine: different routes of administration (other outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012744-tbl-0009"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Chinese medicine (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Intervention</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Dysphasia (difficulty in swallowing)</p> <p>(score for EORTC‐H&amp;N35 questionnaire: mean (SD))</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50.2 (26.3); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38.9 (25.9); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.2 (29.8); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26.7 (24.8); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dysgeusia (taste disturbance) (0 to 3 scale): grade 1 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.96 (95% CI 0.79 to 1.16); P = 0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Speech difficulty</p> <p>(mean (SD) score for EORTC‐H&amp;N35 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.3 (26.7); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.6 (26.2); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.4 (28.6); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22.7 (19.5); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Difficulty in mouth opening</p> <p>(mean (SD) score for EORTC‐H&amp;N35 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.6 (28.2); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.4 (27.7); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32.2 (31.5); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33.3 (24.1); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Difficulty in mouth opening</p> <p>(0 to 2 scale): grade 1 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0019" title="HuYR , WuCQ , LiuYJ , WangY , LiX , ZhongH , et al. Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumour. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):623‐5. ">Hu 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (Shenqi Fanghou recipe)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"During the treatment"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22/70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52/70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.42 (95% CI 0.29 to 0.61); P &lt; 0.001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin toxicity (0 to 3 scale): grade 1 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.01 (95% CI 0.88 to 1.17); P = 0.82</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin toxicity (0 to 4 scale): grade 1 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0019" title="HuYR , WuCQ , LiuYJ , WangY , LiX , ZhongH , et al. Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumour. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):623‐5. ">Hu 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (Shenqi Fanghou recipe)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"During the treatment"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57/70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68/70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.84 (95% CI 0.74 to 0.94); P = 0.002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Skin toxicity (prevalence according to RTOG standards)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0016" title="HanF , ZhangJD , ShaoZY , LiuFJ . Effects of concurrent chemoradiotherapy combined with Jinlong capsules for patients with advanced nasopharyngeal squamous carcinoma. Chinese Journal of Cancer Prevention and Treatment2010;(2):138‐9. ">Han 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (Jinlong capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.82%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58.32%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Quote: "toxicities during and after treatment were assessed"</p> <p>Comment: time point for assessment unclear; minor discrepancies in presented data</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea/vomiting (0 to 3 scale): grade 1 and above</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.61 (95% CI 0.93 to 7.30); P = 0.183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hoarseness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.29 (95% CI 0.03 to 2.65); P = 0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Fatigue</p> <p>(mean (SD) score for EORTC‐C30 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43.2 (26.2); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.4 (23.0); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.2 (28.3); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36.4 (25.0); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Pain</p> <p>(mean (SD) score for EORTC‐C30 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46.8 (23.2); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41.7 (27.4); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35.9 (27.0); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.9 (29.9); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.54</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Pain</p> <p>(mean (SD) score for EORTC‐H&amp;N35 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.4 (25.1); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42.4 (20.5); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.02</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.6 (24.2); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.8 (23.3); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Dyspnea</p> <p>(mean (SD) score for EORTC‐C30 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17.1 (23.1); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16.7 (20.7); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20.5 (21.2); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.6 (22.2); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Insomnia</p> <p>(mean (SD) score for EORTC‐C30 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.5 (25.0); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.2 (25.3); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30.8 (24.8); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.8 (28.1); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Appetite loss</p> <p>(mean (SD) score for EORTC‐C30 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.0 (30.7); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45.8 (29.0); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28.2 (26.1); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34.9 (30.0); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Constipation</p> <p>(mean (SD) score for EORTC‐C30 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.8 (27.4); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.2 (20.3); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.5 (30.3); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.7 (20.4); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Diarrhoea</p> <p>(mean (SD) score for EORTC‐C30 questionnaire)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.0 (15.0); n = 35</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.2 (13.2); n = 33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">Lin</a> </p> <p><a href="./references#CD012744-bbs2-0026" title="LinKS , JenYM , ChaoTY , LinYS , WangLH , LinCJ , et al. Prevention of acute radiation‐associated toxicity by traditional chinese medicine Tianwang Buxin mini‐pills in patients with head and neck cancer. Journal of Medical Sciences (Taipei, Taiwan)2014;34:152‐60. ">2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (TWBXM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 month after RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9.0 (15.1); n = 23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6.1 (16.7); n = 21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P = 0.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0016" title="HanF , ZhangJD , ShaoZY , LiuFJ . Effects of concurrent chemoradiotherapy combined with Jinlong capsules for patients with advanced nasopharyngeal squamous carcinoma. Chinese Journal of Cancer Prevention and Treatment2010;(2):138‐9. ">Han 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (Jinlong capsule)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leukopenia, nausea, vomiting, 1 participant had dizziness and blood pressure drop, 1 participant had skin rash </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0019" title="HuYR , WuCQ , LiuYJ , WangY , LiX , ZhongH , et al. Clinical observation on effect of shenqi fanghou recipe in preventing and treating radiation injury in patients with head and neck tumour. Zhongguo Zhong Xi Yi Jie He Za Zhi2005;25(7):623‐5. ">Hu 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Chinese medicine (Shenqi Fanghou recipe)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"During the treatment"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No adverse event</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CI = confidence interval; EORTC = European Organisation for Research and Treatment of Cancer; H&amp;N = head and neck; RR = risk ratio; RT = radiotherapy; RTOG = Radiation Therapy Oncology Group; SD = standard deviation; TWBXM = Tianwang Buxin Mini‐pills. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Chinese medicine (other outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012744-tbl-0010"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Palifermin versus placebo (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Palifermin</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Oral related symptoms (other than salivary gland dysfunction/xerostomia)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Dysphagia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>3 months postRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p>Random‐effects meta‐analysis of 3 studies: RR 1.32 (95% CI 0.55 to 3.13); P = 0.54</p> <p>Heterogeneity: I<sup>2</sup> = 94%, P &lt; 0.00001 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61/64</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Mouth and throat soreness ‐ 0 (no soreness) to 4 (extreme soreness) OMWQ‐HN scale</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>3 months postRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 94, mean = 1.66, SD = 0.73</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 94, mean = 1.86, SD = 0.65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Random‐effects meta‐analysis of 2 studies: mean difference ‐0.12 (95% CI ‐0.27 to 0.02); P = 0.10 </p> <p>Heterogeneity: I<sup>2</sup> = 13%, P = 0.28 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 92, mean = 1.52, SD = 0.69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 94, mean = 1.57, SD = 0.63</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Adverse events</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 0.96 (95% CI 0.77 to 1.19); P = 0.69</p> <p>Heterogeneity: I<sup>2</sup> = 28%, P = 0.24 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fever</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10 (95% CI 0.67 to 1.81); P = 0.70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 1.15 (95% CI 0.82 to 1.60); P = 0.42</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.57 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 1.28 (95% CI 0.49 to 3.36); P = 0.61</p> <p>Heterogeneity: I<sup>2</sup> = 57%, P = 0.13 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Insomnia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 0.77 (95% CI 0.23 to 2.55); P = 0.67</p> <p>Heterogeneity: I<sup>2</sup> = 63%, P = 0.10 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dyspnea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10 (95% CI 0.67 to 1.81); P = 0.70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cough</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.76 (95% CI 0.27 to 2.15); P = 0.61</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 2.13 (95% CI 0.86 to 5.28); P = 0.10</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.86 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Decreased weight</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 1.01 (95% CI 0.67 to 1.52); P = 0.96</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.73 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.60 (95% CI 0.17 to 2.07); P = 0.42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.38 (95% CI 0.11 to 1.33); P = 0.13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypomagnesemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.48 (95% CI 0.13 to 1.79); P = 0.27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 0.98 (95% CI 0.72 to 1.33); P = 0.89</p> <p>Heterogeneity: I<sup>2</sup> = 0%, P = 0.96 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Radiation skin injury</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.10 (95%CI 0.67 to 1.81); P = 0.70</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Anaemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 0.83 (95% CI 0.33 to 2.05); P = 0.68</p> <p>Heterogeneity: I<sup>2</sup> = 54%, P = 0.14 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Random‐effects meta‐analysis of 3 studies: RR 0.88 (95% CI 0.60 to 1.30); P = 0.52</p> <p>Heterogeneity: I<sup>2</sup> = 2%, P = 0.36 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14/93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Random‐effects meta‐analysis of 2 studies: RR 1.01 (95% CI 0.37 to 2.78); P = 0.98</p> <p>Heterogeneity: I<sup>2</sup> = 79%, P = 0.03 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20/93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Granulocytopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.59 (95% CI 0.47 to 5.39); P = 0.45</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pharyngolaryngeal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.84 (95% CI 0.50 to 1.42); P = 0.52</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hypokalemia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.04 (95% CI 0.98 to 4.28); P = 0.06</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pyrexia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.82 (95% CI 0.45 to 1.48); P = 0.50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mucosal inflammation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.40 (95% CI 0.13 to 1.24); P = 0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Asthenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 1.88 (95% CI 0.78 to 4.49); P = 0.16</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.54 (95% CI 0.75 to 16.58); P = 0.11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Back pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 6.07 (95% CI 0.74 to 49.40); P = 0.09</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Febrile neutropenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/92</p> <p>Considered "serious adverse event"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 3.03 (95% CI 0.13 to 73.48); P = 0.50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Dehydration</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0025" title="LeQT , KimHE , SchneiderCJ , MurakozyG , SkladowskiK , ReinischS , et al. Palifermin reduces severe mucositis in definitive chemoradiotherapy of locally advanced head and neck cancer: a randomized, placebo‐controlled study. Journal of Clinical Oncology2011;29(20):2808‐14. ">Le 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>Random‐effects meta‐analysis of 3 studies: RR 0.75 (95% CI 0.45 to 1.25); P = 0.27</p> <p>Heterogeneity: I<sup>2</sup> = 30%, P = 0.24 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0018" title="HenkeM , AlfonsiM , FoaP , GiraltJ , BardetE , CerezoL , et al. Palifermin decreases severe oral mucositis of patients undergoing postoperative radiochemotherapy for head and neck cancer: a randomized, placebo‐controlled trial. Journal of Clinical Oncology2011;29(20):2815‐20. ">Henke 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13/93</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0005" title="BrizelDM , MurphyBA , RosenthalDI , PandyaKJ , GlückS , BrizelHE , et al. Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma. Journal of Clinical Oncology2008;26(15):2489‐96. ">Brizel 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/32</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI = confidence interval; OMWQ‐HN = Oral Mucositis Weekly Questionnaire ‐ Head and Neck Cancer; RR = risk ratio; RT = radiotherapy; SD = standard deviation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Palifermin versus placebo (other outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012744-tbl-0011"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Bethanechol versus placebo (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse effects</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0020" title="JaguarGC . A Prospective Study of Bethanechol in the Salivary Glands Physiology in Patients Following Head and Neck Radiotherapy [Estudo Prospectivo do Uso do Betanecol na Fisiologia de Glândulas Salivares em Pacientes Irradiados em Região de Cabeça e Pescoço] [Dissertation]. Sao Paulo (Brazil): Fundaçao Antonio Prudente, 2010. JaguarGC , CamposL , PellizzonAC , LimaEN , KowalskiLP , AlvesFA . Double‐blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in cancer patients. Supportive Care in Cancer2012;20(1 Suppl):S252. JaguarGC , LimaEN , KowalskiLP , PellizzonAC , CarvalhoAL , BoccalettiKW , et al. Double blind randomized prospective trial of bethanechol in the prevention of radiation‐induced salivary gland dysfunction in head and neck cancer patients. Radiotherapy and Oncology2015;115(2):253‐6. ">Jaguar 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No statistical difference between the groups in bethanechol‐related toxicity. Quote: "No patient experienced severe (grade 3) toxicity and no one dropped out of the study due to adverse effects" </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Bethanechol versus placebo (other outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012744-tbl-0012"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Bethanechol versus artificial saliva (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Bethanechol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Artificial saliva</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Comments</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lacrimation (watering eyes)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p><a href="./references#CD012744-bbs2-0022" title="JhamBC , ChenH , CarvalhoAL , FreireAR . A randomized phase III prospective trial of bethanechol to prevent mucositis, candidiasis, and taste loss in patients with head and neck cancer undergoing radiotherapy: a secondary analysis. Journal of Oral Science2009;51(4):565‐72. JhamBC , TeixeiraIV , AboudCG , CarvalhoAL , Coelho MdeM , FreireAR . A randomized phase III prospective trial of bethanechol to prevent radiotherapy‐induced salivary gland damage in patients with head and neck cancer. Oral Oncology2007;43(2):137‐42. ">Jham 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="8" valign=""> <p>End of RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 6.70 (95% CI 0.37 to 122.29); P = 0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 6.70 (95% CI 0.37 to 122.29); P = 0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Frequent urination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 6.70 (95% CI 0.37 to 122.29); P = 0.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sweating</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 4.78 (95% CI 0.24 to 94.12); P = 0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"1 patient using bethanechol dropped out of the study due to excessive sweating (Grade 2 severity; National Cancer Institute Common Terminology Criteria for Adverse Events – NCI CTCAE, v 3" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Warm face</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 4.78 (95% CI 0.24 to 94.12); P = 0.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cramps</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.87 (95% CI 0.12 to 66.75); P = 0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 2.87 (95% CI 0.12 to 66.75); P = 0.51</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2/21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RR 0.48 (95% CI 0.05 to 4.88); P = 0.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>CI = confidence interval; RR = risk ratio; RT = radiotherapy.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Bethanechol versus artificial saliva (other outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012744-tbl-0013"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Selenium versus no intervention (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Reported in text</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Loss of taste</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0008" title="BuentzelJ , MickeO , GlatzelM , BrunsF , KistersK , MueckeR . Evaluation of the effect of selenium on radiation‐induced toxicities in head neck cancer patients. Journal of Clinical Oncology2009;27(15 Suppl):e20698. BüntzelJ , MickeO , GlatzelM , SchäferU , RiesenbeckD , KistersK , et al. Selenium substitution during radiotherapy in head and neck cancer. Trace Elements and Electrolytes2010;27:235‐9. BüntzelJ , RiesenbeckD , GlatzelM , Berndt‐SkorkaR , RiedelT , MückeR , et al. Limited effects of selenium substitution in the prevention of radiation‐associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Research2010;30(5):1829‐32. ">Büntzel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks after end RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Ageusia was milder in the selenium group. But the difference was not significant"</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dysphagia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0008" title="BuentzelJ , MickeO , GlatzelM , BrunsF , KistersK , MueckeR . Evaluation of the effect of selenium on radiation‐induced toxicities in head neck cancer patients. Journal of Clinical Oncology2009;27(15 Suppl):e20698. BüntzelJ , MickeO , GlatzelM , SchäferU , RiesenbeckD , KistersK , et al. Selenium substitution during radiotherapy in head and neck cancer. Trace Elements and Electrolytes2010;27:235‐9. BüntzelJ , RiesenbeckD , GlatzelM , Berndt‐SkorkaR , RiedelT , MückeR , et al. Limited effects of selenium substitution in the prevention of radiation‐associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Research2010;30(5):1829‐32. ">Büntzel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks after end RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"The only significant difference was observed at week 7, when the selenium group had developed a mean value of 1.533 versus 2.167 in the control group (P = 0.05)" </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0008" title="BuentzelJ , MickeO , GlatzelM , BrunsF , KistersK , MueckeR . Evaluation of the effect of selenium on radiation‐induced toxicities in head neck cancer patients. Journal of Clinical Oncology2009;27(15 Suppl):e20698. BüntzelJ , MickeO , GlatzelM , SchäferU , RiesenbeckD , KistersK , et al. Selenium substitution during radiotherapy in head and neck cancer. Trace Elements and Electrolytes2010;27:235‐9. BüntzelJ , RiesenbeckD , GlatzelM , Berndt‐SkorkaR , RiedelT , MückeR , et al. Limited effects of selenium substitution in the prevention of radiation‐associated toxicities. Results of a randomized study in head and neck cancer patients. Anticancer Research2010;30(5):1829‐32. ">Büntzel 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 weeks after end RT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"23 serious adverse events (SAEs) were seen in the selenium group, compared to 22 in the control group (P = 0.476). No statistically significant differences in toxicities were found using the 2‐tailed Fisher's exact test" </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>RT = radiotherapy.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Selenium versus no intervention (other outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012744-tbl-0014"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Antiseptic mouthrinse versus placebo (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antiseptic rinse</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drooling</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0024" title="LanzósI , HerreraD , SantosS , O'ConnorA , PeñaC , LanzósE , et al. Mucositis in irradiated cancer patients: effects of an antiseptic mouthrinse. Medicina Oral, Patología Oral y Cirugía Bucal2010;15(5):e732‐8. ">Lanzós 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 weeks from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased 6</p> <p>No change or decreased 8</p> <p>6/14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased 3</p> <p>No change or decreased 7</p> <p>3/10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.43 (95% CI 0.46 to 4.39); P = 0.53</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0024" title="LanzósI , HerreraD , SantosS , O'ConnorA , PeñaC , LanzósE , et al. Mucositis in irradiated cancer patients: effects of an antiseptic mouthrinse. Medicina Oral, Patología Oral y Cirugía Bucal2010;15(5):e732‐8. ">Lanzós 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No relevant adverse events were reported in any group"</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI = confidence interval; RR = risk ratio.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Antiseptic mouthrinse versus placebo (other outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012744-tbl-0015"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Antimicrobial lozenge versus placebo (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Antimicrobial lozenge</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Placebo</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mouth pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse over 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.94 (95% CI 0.66 to 1.33); P=0.72</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sore/burning mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse over 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32/62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.95 (95% CI 0.68 to 1.35); P=0.79</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Throat pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse over 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.79 (95% CI 0.56 to 1.12); P=0.19</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dryness in mouth</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse over 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.18 (95% CI 0.97 to 1.42); P=0.09</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse over 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.90 (95% CI 1.10 to 3.28); P=0.02</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse over 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.97 (95% CI 0.51 to 7.54); P=0.32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Constipation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0010" title="DuncanGG , EpsteinJB , TuD , ElSayedS , BezjakA , OttawayJ , et al. Quality of life, mucositis, and xerostomia from radiotherapy for head and neck cancers: a report from the NCIC CTG HN2 randomized trial of an antimicrobial lozenge to prevent mucositis. Head &amp; Neck2005;27(5):421‐8. ">Duncan 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Worse over 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24/66</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26/65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.91 (95% CI 0.59 to 1.42); P=0.67</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI = confidence interval; RR = risk ratio.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Antimicrobial lozenge versus placebo (other outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012744-tbl-0016"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Polaprezinc versus azulene rinse (other outcomes)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time point</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Polaprezinc</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Azulene rinse</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain &gt; 2 (0‐3 scale)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0039" title="WatanabeT , IshiharaM , MatsuuraK , MizutaK , ItohY . Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. International Journal of Cancer2010;127(8):1984‐90. ">Watanabe 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Over RT period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.36 (95% CI 0.17 to 0.77); P = 0.008</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taste disturbance &gt; 2 (0‐3 scale)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0039" title="WatanabeT , IshiharaM , MatsuuraK , MizutaK , ItohY . Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. International Journal of Cancer2010;127(8):1984‐90. ">Watanabe 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Over RT period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.12 (95% CI 0.02 to 0.83); P = 0.03</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Disability of oral intake</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD012744-bbs2-0039" title="WatanabeT , IshiharaM , MatsuuraK , MizutaK , ItohY . Polaprezinc prevents oral mucositis associated with radiochemotherapy in patients with head and neck cancer. International Journal of Cancer2010;127(8):1984‐90. ">Watanabe 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Over RT period</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 0.31 (95% CI 0.07 to 1.31); P = 0.11</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>CI = confidence interval; RR = risk ratio; RT = radiotherapy.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Polaprezinc versus azulene rinse (other outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012744-tbl-0017"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Venalot Depot (coumarin/troxerutin) versus placebo</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study ID</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Adverse events</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD012744-bbs2-0013" title="GrötzKA , Henneicke‐Von ZepelinHH , KohnenR , KutznerJ , BelzGG . Prophylaxis of mucositis and dry mouth after head and neck radiotherapy. A new treatment. Krankenhauspharmazie2002;23(5):193‐8. GrötzKA , Henneicke‐von ZepelinHH , KohnenR , al‐NawasB , BockischA , KutznerJ , et al. Prospective double‐blind study of prophylaxis of radioxerostomia with Coumarin/Troxerutine in patients with head and neck cancer [Prospektive, doppelblinde Therapiestudie zur Prophylaxe der Radioxerostomie durch Cumarin/Troxerutin bei Patienten mit Kopf‐Hals‐Karzinomen]. Strahlentherapie und Onkologie1999;175(8):397‐404. GrötzKA , WüstenbergP , KohnenR , Al‐NawasB , Henneicke‐von ZepelinH , BockischA , et al. Prophylaxis of radiogenic sialadenitis and mucositis by coumarin/troxerutine in patients with head and neck cancer ‐ a prospective, randomized, placebo‐controlled, double‐blind study. British Journal of Oral and Maxillofacial Surgery2001;39(1):34‐9. ">Grötz 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>"No adverse events could be attributed to the experimental medication"</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Venalot Depot (coumarin/troxerutin) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/full#CD012744-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012744-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pilocarpine versus no treatment/placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Xerostomia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [‐0.16, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Up to and including 3 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.33, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Up to and including 6 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>126</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐1.04, 0.33]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Xerostomia (LENT‐SOMA scale) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Up to and including 6 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Xerostomia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Up to and including 3 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Salivary flow rate (unstimulated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>76</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [‐0.24, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Up to and including 3 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.27 [‐1.07, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Salivary flow rate (stimulated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.44, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Up to and including 3 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐0.41, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Up to and including 6 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [‐0.84, 1.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Up to and including 12 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.53 [‐0.83, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Salivary flow rate (&gt; 0 g) unstimulated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.90 [0.98, 3.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Up to and including 3 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.0 [0.86, 4.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Salivary flow rate (&gt; 0 g) stimulated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.87 [0.77, 4.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Up to and including 3 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.23, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Up to and including 3 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Up to and including 6 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Pilocarpine versus no treatment/placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012744-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Biperiden plus pilocarpine versus no treatment</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Salivary flow rate (unstimulated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.08, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Up to and including 3 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Salivary flow rate (&gt; 0 g) unstimulated <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.77, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Up to and including 3 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.50 [1.88, 29.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Up to and including 6 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>29.00 [1.81, 465.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4 Up to and including 12 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>35.00 [2.20, 556.71]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Biperiden plus pilocarpine versus no treatment</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012744-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Amifostine versus no treatment/placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Xerostomia (0 to 4 scale ‐ grade 2 or above) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.19, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Up to and including 3 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>687</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.48, 0.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 12 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>682</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.40, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Salivary flow rate (unstimulated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.07, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Up to and including 3 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.90, 1.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 12 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.32 [0.09, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Salivary flow rate (unstimulated) ‐ incidence of &gt; 0.1 g in 5 min <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 12 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [1.13, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Salivary flow rate (stimulated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐1.48, 1.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Up to and including 3 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [‐1.43, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 12 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [‐0.47, 2.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Salivary flow rate (stimulated) ‐ incidence of &gt; 0.1 g in 5 min <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 12 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.89, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Overall survival at 12 to 24 months postradiotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.18 [0.85, 1.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Overall survival ‐ narrative data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Progression‐free survival at 12 to 24 months postradiotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>247</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.70, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Progression‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 18 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.81, 1.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Progression‐free survival ‐ narrative data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Locoregional tumour control at 12 to 24 months postradiotherapy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>279</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.74, 1.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Locoregional tumour control ‐ narrative data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 24 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.73, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Disease‐free survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Quality of life (Patient Benefit Questionnaire) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>298</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [‐0.07, 0.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Up to and including 3 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.52 [‐0.02, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 12 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.20, 1.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Amifostine versus no treatment/placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012744-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Amifostine (comparison of dosages)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Xerostomia (0 to 4 scale ‐ grade 2 or above) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 12 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.58, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall survival ‐ narrative data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Locoregional tumour control ‐ narrative data <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Amifostine (comparison of dosages)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012744-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Amifostine (intravenous versus subcutaneous)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Xerostomia (0 to 4 scale ‐ grade 2 or above) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Up to and including 3 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>263</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.76, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 12 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>127</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.42, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 48 months after radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [0.89, 2.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Locoregional tumour control <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 48 months after radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [0.76, 2.36]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Amifostine (intravenous versus subcutaneous)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012744-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Chinese medicine versus no treatment/placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Xerostomia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 End of radiotherapy: Shenqi Fanghou recipe versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>140</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.28, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 End of radiotherapy: TWBXM versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.78, 1.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Up to and including 3 months postradiotherapy: Jinlong capsules versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>95</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.59, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Xerostomia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 End of radiotherapy: TWBXM versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.41 [‐16.19, 11.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Up to and including 3 months postradiotherapy: TWBXM versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐17.21, 17.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Salivary flow rate (stimulated) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 End of radiotherapy: Chinese medicine versus no intervention</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.03, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Overall survival (12 months postRT) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.05 [0.84, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Quality of life (EORTC‐C30) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 End of radiotherapy: TWBXM versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.39 [‐8.74, 13.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Up to and including 3 months postradiotherapy: TWBXM versus placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.93 [‐13.04, 16.90]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Chinese medicine versus no treatment/placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012744-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Palifermin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Xerostomia (0 to 4 scale ‐ grade 2 or above) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Up to and including 3 months postRT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>471</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.77, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Overall survival at 42 to 72 months from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.72, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Progression‐free survival at 42 to 72 months from baseline <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.80, 1.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Palifermin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012744-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Bethanechol versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Xerostomia (0 to 3 scale ‐ grade 2 or above) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.28, 0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Up to and including 3 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>84</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.65, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Salivary flow rate (unstimulated) ‐ ml/min <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 2 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.06, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Salivary flow rate (stimulated) ‐ ml/min <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 2 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [‐0.03, 0.33]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Bethanechol versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012744-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Bethanechol versus artificial saliva</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Xerostomia (dry mouth? yes/no) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.30, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 8 to 40 weeks postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.30, 1.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Salivary flow rate (unstimulated) ‐ ml/min <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [0.01, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 8 to 40 weeks postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.02, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Salivary flow rate (stimulated) ‐ ml/min <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.03, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 8 to 40 weeks postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [0.01, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Overall survival <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 40 weeks postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.59 [0.43, 5.84]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Bethanechol versus artificial saliva</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012744-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Selenium versus no selenium</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Xerostomia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Other data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>No numeric data</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Selenium versus no selenium</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012744-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Antimicrobial lozenge versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Xerostomia (QoL response for dryness) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Up to and including 3 months postradiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.16 [0.97, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Up to and including 3 months postradiotherapy (change score over 6 months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.65, 1.50]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Antimicrobial lozenge versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012744-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Polaprezinc versus azulene oral rinse</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Xerostomia (grade 2 or above) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 End of radiotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>31</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [0.04, 0.65]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Polaprezinc versus azulene oral rinse</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012744/references#CD012744-tbl-0029">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012744&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012744-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012744-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012744-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012744-note-0002">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD012744-note-0025">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012744-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012744-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012744\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012744\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012744\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012744"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012744\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012744\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012744\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012744\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012744\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012744"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012744\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012744\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012744\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012744"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012744\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012744\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012744\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012744"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=FKeXZrqu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012744&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012744';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012744/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012744/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012744%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727137942"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012744/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727137946"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012744/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea4b69cee9365',t:'MTc0MDcyNzEzOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 